P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
2.645e-08 | -17.45 | signal transduction | biological process | GO:0007165 | 4637 | 31 | 18204 | 49 |
GAB1,P2RY6,ZFP36L1,CSF3R,CD74,RASGRP2,HCK,UNC93B1,DOCK2,MLKL,DAPP1,PLXND1,ELMO1,RXRA,ITGAX,MARCO,ABR,PLEK,SNX17,THRB,SH2B3,MAP3K11,PREX1,ITGB2,RAC2,FYB1,PSAP,CYFIP1,INPP5D,CSF1R,PLXNC1 |
1.480e-07 | -15.73 | signaling | biological process | GO:0023052 | 4968 | 31 | 18204 | 49 |
CYFIP1,CSF1R,INPP5D,PLXNC1,SNX17,ABR,PLEK,THRB,RAC2,FYB1,PREX1,ITGB2,MAP3K11,SH2B3,PSAP,DOCK2,DAPP1,PLXND1,MLKL,RXRA,ELMO1,MARCO,ITGAX,CD74,ZFP36L1,CSF3R,P2RY6,GAB1,RASGRP2,UNC93B1,HCK |
1.605e-07 | -15.64 | plasma membrane | cellular component | GO:0005886 | 5538 | 31 | 19108 | 47 |
MARCO,P2RY6,RASGRP2,CSF1R,ITGAX,CD68,SMPD4,CMTM6,FYB1,PLXNC1,CSF3R,ITGB2,PLEK,HCK,PLXND1,MLKL,VMP1,PSAP,PREX1,RAC2,DAPP1,DOCK2,SH2B3,MYO1F,ELMO1,ITM2B,SLCO2B1,INPP5D,NCAM2,ENTPD1,CD74 |
1.821e-07 | -15.52 | cell communication | biological process | GO:0007154 | 5010 | 31 | 18204 | 49 |
PLXNC1,INPP5D,CSF1R,CYFIP1,PSAP,MAP3K11,SH2B3,FYB1,RAC2,PREX1,ITGB2,THRB,PLEK,ABR,SNX17,ITGAX,MARCO,ELMO1,RXRA,DAPP1,PLXND1,MLKL,DOCK2,UNC93B1,HCK,RASGRP2,CSF3R,ZFP36L1,GAB1,P2RY6,CD74 |
7.389e-07 | -14.12 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 34 | 18204 | 49 |
MARCO,SLCO2B1,ITGAX,ELMO1,RXRA,CD68,DAPP1,PLXND1,MLKL,DOCK2,HCK,UNC93B1,RASGRP2,CD74,ZFP36L1,CSF3R,P2RY6,GAB1,PLXNC1,CSF1R,INPP5D,SMPD4,CYFIP1,PSAP,RAC2,FYB1,PREX1,ITGB2,MAP3K11,SH2B3,THRB,SNX17,ABR,PLEK |
7.874e-07 | -14.05 | response to stimulus | biological process | GO:0050896 | 7803 | 38 | 18204 | 49 |
P2RY6,GAB1,CSF3R,ZFP36L1,CD74,TNFAIP8L2,UNC93B1,ENTPD1,HCK,RASGRP2,MLKL,PLXND1,DAPP1,CD68,DOCK2,SLCO2B1,ITGAX,MARCO,RXRA,ELMO1,MFNG,THRB,PLEK,ABR,SNX17,PSAP,SH2B3,MAP3K11,ITGB2,PREX1,FYB1,RAC2,CPN1,SMPD4,INPP5D,CSF1R,CYFIP1,PLXNC1 |
9.747e-07 | -13.84 | INPP5D (inositol polyphosphate-5-phosphatase D) | protein interactions | 3635 | 70 | 5 | 19454 | 50 |
HCK,CSF3R,CSF1R,INPP5D,GAB1 |
1.242e-06 | -13.60 | cell periphery | cellular component | GO:0071944 | 6020 | 31 | 19108 | 47 |
ITGAX,CSF1R,RASGRP2,MARCO,P2RY6,PSAP,PREX1,HCK,PLXND1,MLKL,VMP1,FYB1,ITGB2,CSF3R,PLXNC1,PLEK,CD68,SMPD4,CMTM6,INPP5D,ELMO1,ITM2B,SLCO2B1,DAPP1,SH2B3,MYO1F,DOCK2,RAC2,CD74,NCAM2,ENTPD1 |
1.899e-06 | -13.17 | regulation of cell shape | biological process | GO:0008360 | 139 | 6 | 18204 | 49 |
CYFIP1,ITGB2,PLXND1,PLXNC1,CSF1R,HCK |
3.248e-06 | -12.64 | Nef and signal transduction | REACTOME pathways | R-HSA-164944 | 8 | 3 | 10285 | 41 |
ELMO1,HCK,DOCK2 |
4.205e-06 | -12.38 | membrane | cellular component | GO:0016020 | 9220 | 38 | 19108 | 47 |
RASGRP2,P2RY6,MARCO,ITGAX,CSF1R,PLEK,MFNG,ITGB2,CSF3R,PLXNC1,FYB1,CMTM6,SMPD4,CD68,PREX1,PSAP,RMC1,VMP1,MLKL,HCK,PLXND1,ADAM33,MYO1F,DOCK2,SH2B3,MAP3K11,UNC93B1,DAPP1,RAC2,SNX17,ABR,INPP5D,SLCO2B1,ELMO1,ITM2B,ENTPD1,NCAM2,CD74 |
5.827e-06 | -12.05 | integrin-mediated signaling pathway | biological process | GO:0007229 | 96 | 5 | 18204 | 49 |
ITGB2,FYB1,PLEK,HCK,ITGAX |
5.922e-06 | -12.04 | integrin alphaX-beta2 complex | cellular component | GO:0034689 | 2 | 2 | 19108 | 47 |
ITGB2,ITGAX |
6.230e-06 | -11.99 | receptor complex | cellular component | GO:0043235 | 409 | 8 | 19108 | 47 |
CD74,RXRA,ITGAX,CSF1R,PLXND1,PLXNC1,CSF3R,ITGB2 |
6.866e-06 | -11.89 | PH_domain | interpro domains | IPR001849 | 266 | 7 | 18521 | 50 |
SH2B3,PLEK,DAPP1,ABR,ELMO1,GAB1,PREX1 |
7.098e-06 | -11.86 | positive regulation of thyroid hormone mediated signaling pathway | biological process | GO:0002157 | 2 | 2 | 18204 | 49 |
RXRA,THRB |
8.978e-06 | -11.62 | immune system process | biological process | GO:0002376 | 1991 | 17 | 18204 | 49 |
MARCO,DOCK2,INPP5D,CSF1R,CD68,SH2B3,PREX1,ITGB2,RAC2,FYB1,TNFAIP8L2,HCK,UNC93B1,ZFP36L1,CSF3R,CD74,MFNG |
1.204e-05 | -11.33 | hemopoiesis | biological process | GO:0030097 | 688 | 10 | 18204 | 49 |
CD74,DOCK2,ZFP36L1,PLEK,CSF1R,MFNG,PREX1,RAC2,SH2B3,RBM47 |
1.837e-05 | -10.90 | PH-like_dom_sf | interpro domains | IPR011993 | 431 | 8 | 18521 | 50 |
SH2B3,PLEK,DAPP1,ABR,SNX17,GAB1,ELMO1,PREX1 |
2.023e-05 | -10.81 | regulation of monocyte differentiation | biological process | GO:0045655 | 20 | 3 | 18204 | 49 |
INPP5D,CD74,ZFP36L1 |
3.047e-05 | -10.40 | cytoplasmic vesicle membrane | cellular component | GO:0030659 | 1230 | 12 | 19108 | 47 |
RAC2,MARCO,SNX17,ITM2B,ITGAX,ITGB2,CSF3R,CMTM6,CD68,CD74,PSAP,RMC1 |
3.199e-05 | -10.35 | cell adhesion | biological process | GO:0007155 | 942 | 11 | 18204 | 49 |
HCK,ENTPD1,ITGB2,RAC2,VMP1,CSF3R,ZFP36L1,PLEK,ITGAX,PLXNC1,NCAM2 |
3.570e-05 | -10.24 | vacuole | cellular component | GO:0005773 | 857 | 10 | 19108 | 47 |
CD68,CMTM6,UNC93B1,CSF3R,HCK,VMP1,TNFAIP8L2,RMC1,CD74,PSAP |
3.601e-05 | -10.23 | vesicle membrane | cellular component | GO:0012506 | 1251 | 12 | 19108 | 47 |
CSF3R,ITGB2,CD68,CMTM6,RMC1,PSAP,CD74,MARCO,RAC2,SNX17,ITGAX,ITM2B |
3.907e-05 | -10.15 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 16 | 18204 | 49 |
P2RY6,GAB1,PLEK,CSF3R,CD74,SH2B3,ITGB2,FYB1,HCK,PLXND1,INPP5D,MLKL,CSF1R,ITGAX,PLXNC1,MARCO |
4.012e-05 | -10.12 | Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB) | gene3d domains | 2.30.29.30 | 431 | 8 | 14470 | 44 |
ELMO1,PREX1,ABR,DAPP1,SH2B3,PLEK,GAB1,SNX17 |
4.047e-05 | -10.11 | bounding membrane of organelle | cellular component | GO:0098588 | 2198 | 16 | 19108 | 47 |
SNX17,ITGAX,ITM2B,UNC93B1,MARCO,RAC2,RMC1,PSAP,CD74,VMP1,CSF3R,ITGB2,MFNG,CD68,SMPD4,CMTM6 |
4.233e-05 | -10.07 | regulation of molecular function | biological process | GO:0065009 | 2005 | 16 | 18204 | 49 |
CSF1R,PLXND1,RXRA,SPOCK3,PLXNC1,CD74,VMP1,P2RY6,PLEK,ABR,PREX1,ITGB2,RASGRP2,MAP3K11,PSAP,HCK |
4.562e-05 | -10.00 | ruffle organization | biological process | GO:0031529 | 26 | 3 | 18204 | 49 |
CSF1R,PLEK,CYFIP1 |
4.926e-05 | -9.92 | regulation of cell morphogenesis | biological process | GO:0022604 | 246 | 6 | 18204 | 49 |
PLXNC1,PLXND1,HCK,CSF1R,CYFIP1,ITGB2 |
5.057e-05 | -9.89 | endocytosis | biological process | GO:0006897 | 499 | 8 | 18204 | 49 |
P2RY6,SNX17,DOCK2,MYO1F,HCK,MARCO,ELMO1,ITGB2 |
5.420e-05 | -9.82 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 6 | 14470 | 44 |
DOCK2,FYB1,MYO1F,MAP3K11,HCK,ELMO1 |
5.629e-05 | -9.78 | positive regulation of molecular function | biological process | GO:0044093 | 1192 | 12 | 18204 | 49 |
CSF1R,ABR,PLEK,P2RY6,VMP1,CD74,PSAP,MAP3K11,RXRA,ITGB2,PREX1,RASGRP2 |
5.731e-05 | -9.77 | regulation of catalytic activity | biological process | GO:0050790 | 1395 | 13 | 18204 | 49 |
CSF1R,PLXND1,SPOCK3,PLXNC1,CD74,PLEK,ABR,P2RY6,PSAP,PREX1,ITGB2,RASGRP2,MAP3K11 |
6.176e-05 | -9.69 | CSF3R (colony stimulating factor 3 receptor) | protein interactions | 1441 | 30 | 3 | 19454 | 50 |
INPP5D,CSF3R,HCK |
6.416e-05 | -9.65 | small GTPase-mediated signal transduction | biological process | GO:0007264 | 258 | 6 | 18204 | 49 |
DOCK2,ABR,CYFIP1,RASGRP2,ELMO1,RAC2 |
6.674e-05 | -9.61 | phagocytosis | biological process | GO:0006909 | 159 | 5 | 18204 | 49 |
P2RY6,ELMO1,ITGB2,HCK,MARCO |
6.895e-05 | -9.58 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 14 | 16828 | 44 |
ELMO1,SPOCK3,HCK,DPYD,DAPP1,CSF1R,ZFP36L1,CD74,MLKL,MAP3K11,CPN1,NCAM2,VMP1,DOCK2 |
8.117e-05 | -9.42 | response to external stimulus | biological process | GO:0009605 | 1882 | 15 | 18204 | 49 |
GAB1,CSF3R,CD74,ITGB2,PREX1,RAC2,TNFAIP8L2,HCK,UNC93B1,DOCK2,MLKL,CSF1R,CD68,ITGAX,MARCO |
8.491e-05 | -9.37 | lysosome | cellular component | GO:0005764 | 762 | 9 | 19108 | 47 |
HCK,CD74,PSAP,TNFAIP8L2,RMC1,CMTM6,CD68,CSF3R,UNC93B1 |
8.491e-05 | -9.37 | lytic vacuole | cellular component | GO:0000323 | 762 | 9 | 19108 | 47 |
CMTM6,CD68,CSF3R,UNC93B1,HCK,PSAP,CD74,RMC1,TNFAIP8L2 |
8.704e-05 | -9.35 | positive regulation of catalytic activity | biological process | GO:0043085 | 868 | 10 | 18204 | 49 |
PSAP,MAP3K11,PREX1,ITGB2,RASGRP2,CSF1R,ABR,PLEK,P2RY6,CD74 |
8.963e-05 | -9.32 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 33 | 16828 | 44 |
PLXNC1,CSF1R,PSAP,SPOCK3,PREX1,RXRA,ABR,NCAM2,DOCK2,VMP1,CSF3R,THRB,RAC2,SMPD4,GAB1,MFNG,PLEK,ANKRD44,HCK,DPYD,SNX17,MYO1F,PLXND1,ITGAX,SH2B3,ADAM33,ELMO1,CPN1,MAP3K11,MLKL,ZFP36L1,MARCO,ITM2B |
9.493e-05 | -9.26 | cell-cell adhesion | biological process | GO:0098609 | 546 | 8 | 18204 | 49 |
VMP1,ZFP36L1,PLEK,NCAM2,ITGB2,RAC2,ENTPD1,ITGAX |
9.572e-05 | -9.25 | Regulation of RAC1 activity | Pathway Interaction DB | rac1_reg_pathway | 39 | 4 | 2226 | 15 |
PREX1,ELMO1,ABR,DOCK2 |
9.785e-05 | -9.23 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 4 | 18094 | 49 |
ITGB2,CD74,MARCO,ITM2B |
1.048e-04 | -9.16 | HCK (HCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3055 | 183 | 5 | 19454 | 50 |
HCK,CSF3R,GAB1,ELMO1,INPP5D |
1.084e-04 | -9.13 | cellular response to chemical stimulus | biological process | GO:0070887 | 2411 | 17 | 18204 | 49 |
CYFIP1,CD68,CSF1R,SMPD4,RXRA,SLCO2B1,CD74,ZFP36L1,CSF3R,P2RY6,GAB1,THRB,PREX1,RASGRP2,ITGB2,SH2B3,HCK |
1.179e-04 | -9.05 | cell activation | biological process | GO:0001775 | 725 | 9 | 18204 | 49 |
TNFAIP8L2,ENTPD1,ITGB2,PREX1,MFNG,PLEK,ZFP36L1,DOCK2,CD74 |
1.191e-04 | -9.04 | regulation of hydrolase activity | biological process | GO:0051336 | 726 | 9 | 18204 | 49 |
PLXNC1,PSAP,SPOCK3,RASGRP2,PREX1,PLXND1,PLEK,ABR,P2RY6 |
1.229e-04 | -9.00 | phagocytosis, engulfment | biological process | GO:0006911 | 36 | 3 | 18204 | 49 |
ITGB2,ELMO1,MARCO |
1.246e-04 | -8.99 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 13 | 18204 | 49 |
PREX1,RASGRP2,RAC2,SH2B3,MAP3K11,HCK,ABR,ZFP36L1,PLEK,ELMO1,DOCK2,CYFIP1,INPP5D |
1.297e-04 | -8.95 | Chemokine signaling pathway | KEGG pathways | hsa04062 | 182 | 6 | 7161 | 32 |
ELMO1,DOCK2,RAC2,RASGRP2,HCK,PREX1 |
1.297e-04 | -8.95 | Chemokine signaling pathway | KEGG pathways | ko04062 | 182 | 6 | 7161 | 32 |
RASGRP2,HCK,PREX1,ELMO1,DOCK2,RAC2 |
1.408e-04 | -8.87 | Hemostasis | REACTOME pathways | R-HSA-109582 | 632 | 10 | 10285 | 41 |
ITGAX,RAC2,PLEK,DOCK2,SH2B3,PSAP,ITGB2,RASGRP2,CD74,INPP5D |
1.478e-04 | -8.82 | regulation of thyroid hormone mediated signaling pathway | biological process | GO:0002155 | 7 | 2 | 18204 | 49 |
THRB,RXRA |
1.525e-04 | -8.79 | TRIP10 (thyroid hormone receptor interactor 10) | protein interactions | 9322 | 105 | 4 | 19454 | 50 |
THRB,RXRA,CYFIP1,INPP5D |
1.554e-04 | -8.77 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 28 | 16828 | 44 |
MFNG,GAB1,CSF3R,DOCK2,ABR,PREX1,DAPP1,PSAP,CSF1R,PLXNC1,MARCO,CD68,ZFP36L1,MAP3K11,MLKL,CPN1,SLCO2B1,ELMO1,ADAM33,ITGAX,PLXND1,SNX17,MYO1F,DPYD,HCK,ENTPD1,ANKRD44,P2RY6 |
1.638e-04 | -8.72 | SH2 | pfam domains | PF00017 | 100 | 4 | 17795 | 49 |
DAPP1,SH2B3,HCK,INPP5D |
1.675e-04 | -8.69 | Immune System | REACTOME pathways | R-HSA-168256 | 2101 | 19 | 10285 | 41 |
ITGB2,CD68,CSF1R,CSF3R,DAPP1,ITGAX,DOCK2,FYB1,CD74,HCK,RASGRP2,CYFIP1,GAB1,INPP5D,MAP3K11,ELMO1,CMTM6,UNC93B1,PSAP |
1.750e-04 | -8.65 | SRC (SRC proto-oncogene, non-receptor tyrosine kinase) | protein interactions | 6714 | 624 | 8 | 19454 | 50 |
FYB1,CYFIP1,GAB1,RXRA,CSF1R,THRB,DAPP1,HCK |
1.802e-04 | -8.62 | nef (Nef) | protein interactions | 156110 | 802 | 9 | 19454 | 50 |
CD74,ELMO1,RAC2,DOCK2,RXRA,ITGAX,CSF1R,PSAP,HCK |
1.808e-04 | -8.62 | vacuolar membrane | cellular component | GO:0005774 | 490 | 7 | 19108 | 47 |
CD68,CMTM6,CSF3R,VMP1,RMC1,CD74,PSAP |
1.824e-04 | -8.61 | KIT (KIT proto-oncogene, receptor tyrosine kinase) | protein interactions | 3815 | 110 | 4 | 19454 | 50 |
CSF1R,INPP5D,SH2B3,HCK |
1.847e-04 | -8.60 | positive regulation of response to stimulus | biological process | GO:0048584 | 2266 | 16 | 18204 | 49 |
RXRA,RBM47,MARCO,CYFIP1,CSF1R,INPP5D,RAC2,FYB1,ITGB2,MAP3K11,HCK,UNC93B1,CD74,P2RY6,MFNG,THRB |
1.973e-04 | -8.53 | PSI | interpro domains | IPR016201 | 42 | 3 | 18521 | 50 |
ITGB2,PLXNC1,PLXND1 |
1.999e-04 | -8.52 | The role of Nef in HIV-1 replication and disease pathogenesis | REACTOME pathways | R-HSA-164952 | 29 | 3 | 10285 | 41 |
ELMO1,DOCK2,HCK |
2.007e-04 | -8.51 | SH2DOMAIN | prints domains | PR00401 | 72 | 4 | 5227 | 22 |
DAPP1,INPP5D,HCK,SH2B3 |
2.039e-04 | -8.50 | CRKL (CRK like proto-oncogene, adaptor protein) | protein interactions | 1399 | 211 | 5 | 19454 | 50 |
GAB1,ELMO1,DOCK2,INPP5D,HCK |
2.081e-04 | -8.48 | regulation of immune system process | biological process | GO:0002682 | 1584 | 13 | 18204 | 49 |
CD68,CSF1R,INPP5D,CD74,ZFP36L1,CSF3R,HCK,UNC93B1,RBM47,TNFAIP8L2,RAC2,FYB1,ITGB2 |
2.093e-04 | -8.47 | MTOR (mechanistic target of rapamycin kinase) | protein interactions | 2475 | 335 | 6 | 19454 | 50 |
VMP1,CD74,RAC2,UNC93B1,P2RY6,PREX1 |
2.113e-04 | -8.46 | cytoplasmic vesicle | cellular component | GO:0031410 | 2521 | 16 | 19108 | 47 |
CD74,PSAP,RMC1,HCK,CYFIP1,ITGB2,CSF3R,CMTM6,CD68,SNX17,ITM2B,ITGAX,DOCK2,UNC93B1,RAC2,MARCO |
2.122e-04 | -8.46 | SH2 | interpro domains | IPR000980 | 109 | 4 | 18521 | 50 |
INPP5D,DAPP1,HCK,SH2B3 |
2.173e-04 | -8.43 | intracellular vesicle | cellular component | GO:0097708 | 2527 | 16 | 19108 | 47 |
UNC93B1,DOCK2,MARCO,RAC2,SNX17,ITGAX,ITM2B,CSF3R,ITGB2,CD68,CMTM6,RMC1,PSAP,CD74,HCK,CYFIP1 |
2.194e-04 | -8.42 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 31 | 16828 | 44 |
ZFP36L1,ITM2B,MARCO,MLKL,CPN1,ELMO1,ADAM33,ITGAX,SH2B3,DPYD,PLXND1,MYO1F,SNX17,ANKRD44,PLEK,SMPD4,RAC2,GAB1,MFNG,CSF3R,THRB,NCAM2,DOCK2,VMP1,PREX1,ABR,RXRA,SPOCK3,PLXNC1,PSAP,CSF1R |
2.402e-04 | -8.33 | plasma membrane invagination | biological process | GO:0099024 | 45 | 3 | 18204 | 49 |
ITGB2,ELMO1,MARCO |
2.430e-04 | -8.32 | PH | smart domains | SM00233 | 259 | 6 | 9717 | 34 |
GAB1,ABR,PREX1,DAPP1,PLEK,SH2B3 |
2.437e-04 | -8.32 | SH2_dom_sf | interpro domains | IPR036860 | 113 | 4 | 18521 | 50 |
SH2B3,HCK,INPP5D,DAPP1 |
2.473e-04 | -8.31 | positive regulation of immune system process | biological process | GO:0002684 | 986 | 10 | 18204 | 49 |
ZFP36L1,CD74,INPP5D,CSF1R,ITGB2,RAC2,FYB1,RBM47,UNC93B1,HCK |
2.540e-04 | -8.28 | Plexin_RBD | interpro domains | IPR046800 | 9 | 2 | 18521 | 50 |
PLXND1,PLXNC1 |
2.540e-04 | -8.28 | Plexin_cytoplasmic_RasGAP_dom | interpro domains | IPR013548 | 9 | 2 | 18521 | 50 |
PLXND1,PLXNC1 |
2.612e-04 | -8.25 | SH3-like_dom_sf | interpro domains | IPR036028 | 212 | 5 | 18521 | 50 |
HCK,FYB1,DOCK2,MYO1F,MAP3K11 |
2.641e-04 | -8.24 | Plexin_cytopl | pfam domains | PF08337 | 9 | 2 | 17795 | 49 |
PLXNC1,PLXND1 |
2.641e-04 | -8.24 | Plexin_RBD | pfam domains | PF20170 | 9 | 2 | 17795 | 49 |
PLXND1,PLXNC1 |
2.765e-04 | -8.19 | enzyme binding | molecular function | GO:0019899 | 2086 | 15 | 18094 | 49 |
RBM47,SH2B3,PLEK,THRB,MLKL,CYFIP1,CSF1R,MAP3K11,CD74,PSAP,DOCK2,ITGAX,PREX1,RXRA,ITGB2 |
2.875e-04 | -8.15 | FCER2 (Fc epsilon receptor II) | protein interactions | 2208 | 10 | 2 | 19454 | 50 |
ITGB2,ITGAX |
2.876e-04 | -8.15 | DOK1 (docking protein 1) | protein interactions | 1796 | 50 | 3 | 19454 | 50 |
INPP5D,ITGB2,HCK |
2.887e-04 | -8.15 | TM9SF3 (transmembrane 9 superfamily member 3) | protein interactions | 56889 | 124 | 4 | 19454 | 50 |
P2RY6,RAC2,RBM47,UNC93B1 |
3.121e-04 | -8.07 | chemotaxis | biological process | GO:0006935 | 345 | 6 | 18204 | 49 |
CSF3R,GAB1,RAC2,DOCK2,ITGB2,PREX1 |
3.150e-04 | -8.06 | positive regulation of monocyte differentiation | biological process | GO:0045657 | 10 | 2 | 18204 | 49 |
CD74,ZFP36L1 |
3.170e-04 | -8.06 | Plexin | interpro domains | IPR031148 | 10 | 2 | 18521 | 50 |
PLXND1,PLXNC1 |
3.219e-04 | -8.04 | taxis | biological process | GO:0042330 | 347 | 6 | 18204 | 49 |
DOCK2,PREX1,ITGB2,RAC2,GAB1,CSF3R |
3.231e-04 | -8.04 | SH3_domain | interpro domains | IPR001452 | 222 | 5 | 18521 | 50 |
DOCK2,FYB1,HCK,MYO1F,MAP3K11 |
3.356e-04 | -8.00 | EIF2B4 (eukaryotic translation initiation factor 2B subunit delta) | protein interactions | 8890 | 129 | 4 | 19454 | 50 |
MFNG,P2RY6,CD74,UNC93B1 |
3.419e-04 | -7.98 | ELMO2 (engulfment and cell motility 2) | protein interactions | 63916 | 53 | 3 | 19454 | 50 |
DOCK2,RAC2,ELMO1 |
3.485e-04 | -7.96 | regulation of granulocyte chemotaxis | biological process | GO:0071622 | 51 | 3 | 18204 | 49 |
CSF1R,CD74,RAC2 |
3.515e-04 | -7.95 | SH2 domain | gene3d domains | 3.30.505.10 | 111 | 4 | 14470 | 44 |
DAPP1,SH2B3,HCK,INPP5D |
3.691e-04 | -7.90 | guanyl-nucleotide exchange factor activity | molecular function | GO:0005085 | 228 | 5 | 18094 | 49 |
ELMO1,PREX1,RASGRP2,DOCK2,ABR |
3.692e-04 | -7.90 | membrane invagination | biological process | GO:0010324 | 52 | 3 | 18204 | 49 |
MARCO,ITGB2,ELMO1 |
3.844e-04 | -7.86 | regulation of dendritic cell antigen processing and presentation | biological process | GO:0002604 | 11 | 2 | 18204 | 49 |
CD74,CD68 |
3.958e-04 | -7.83 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 13 | 18204 | 49 |
CD74,ZFP36L1,PLEK,GAB1,UNC93B1,CYFIP1,CSF1R,PLXND1,INPP5D,RXRA,RBM47,PLXNC1,ITGAX |
4.094e-04 | -7.80 | PSI | smart domains | SM00423 | 42 | 3 | 9717 | 34 |
ITGB2,PLXND1,PLXNC1 |
4.117e-04 | -7.80 | azurophil granule membrane | cellular component | GO:0035577 | 59 | 3 | 19108 | 47 |
PSAP,CD68,CMTM6 |
4.152e-04 | -7.79 | mononuclear cell differentiation | biological process | GO:1903131 | 364 | 6 | 18204 | 49 |
PREX1,CD74,DOCK2,ZFP36L1,CSF1R,MFNG |
4.203e-04 | -7.77 | ROBO4 (roundabout guidance receptor 4) | protein interactions | 54538 | 12 | 2 | 19454 | 50 |
THRB,RXRA |
4.203e-04 | -7.77 | RWDD1 (RWD domain containing 1) | protein interactions | 51389 | 12 | 2 | 19454 | 50 |
CD74,P2RY6 |
4.291e-04 | -7.75 | MET (MET proto-oncogene, receptor tyrosine kinase) | protein interactions | 4233 | 248 | 5 | 19454 | 50 |
SH2B3,HCK,ITM2B,INPP5D,GAB1 |
4.300e-04 | -7.75 | regulation of response to stimulus | biological process | GO:0048583 | 4104 | 22 | 18204 | 49 |
HCK,UNC93B1,TNFAIP8L2,CD74,P2RY6,RXRA,MARCO,DOCK2,PREX1,ITGB2,FYB1,RAC2,SH2B3,MAP3K11,ABR,PLEK,THRB,MFNG,RBM47,CYFIP1,CSF1R,INPP5D |
4.301e-04 | -7.75 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 8 | 19454 | 50 |
CSF3R,RAC2,GAB1,INPP5D,CYFIP1,HCK,DAPP1,CSF1R |
4.324e-04 | -7.75 | SH2 | smart domains | SM00252 | 103 | 4 | 9717 | 34 |
DAPP1,HCK,SH2B3,INPP5D |
4.336e-04 | -7.74 | locomotion | biological process | GO:0040011 | 367 | 6 | 18204 | 49 |
DOCK2,GAB1,CSF3R,ITGB2,PREX1,RAC2 |
4.357e-04 | -7.74 | neutrophil chemotaxis | biological process | GO:0030593 | 55 | 3 | 18204 | 49 |
CSF3R,PREX1,ITGB2 |
4.467e-04 | -7.71 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 4 | 17795 | 49 |
CSF1R,MAP3K11,MLKL,HCK |
4.527e-04 | -7.70 | import into cell | biological process | GO:0098657 | 687 | 8 | 18204 | 49 |
P2RY6,DOCK2,MYO1F,SNX17,MARCO,HCK,ITGB2,ELMO1 |
4.532e-04 | -7.70 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 4 | 18521 | 50 |
CSF1R,HCK,MLKL,MAP3K11 |
4.540e-04 | -7.70 | semaphorin receptor complex | cellular component | GO:0002116 | 13 | 2 | 19108 | 47 |
PLXNC1,PLXND1 |
4.563e-04 | -7.69 | cellular response to organic substance | biological process | GO:0071310 | 1716 | 13 | 18204 | 49 |
SMPD4,CD68,CSF1R,CYFIP1,RXRA,THRB,CSF3R,ZFP36L1,P2RY6,GAB1,CD74,HCK,SH2B3 |
4.605e-04 | -7.68 | negative thymic T cell selection | biological process | GO:0045060 | 12 | 2 | 18204 | 49 |
DOCK2,CD74 |
4.605e-04 | -7.68 | positive thymic T cell selection | biological process | GO:0045059 | 12 | 2 | 18204 | 49 |
DOCK2,CD74 |
4.660e-04 | -7.67 | semaphorin receptor activity | molecular function | GO:0017154 | 12 | 2 | 18094 | 49 |
PLXND1,PLXNC1 |
4.958e-04 | -7.61 | TMEM209 (transmembrane protein 209) | protein interactions | 84928 | 143 | 4 | 19454 | 50 |
RBM47,RAC2,P2RY6,UNC93B1 |
4.973e-04 | -7.61 | PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) | protein interactions | 5295 | 394 | 6 | 19454 | 50 |
CSF1R,HCK,INPP5D,RAC2,GAB1,RXRA |
5.131e-04 | -7.58 | B Cell Receptor Signaling Pathway | WikiPathways | WP23 | 98 | 4 | 5310 | 21 |
DAPP1,RAC2,GAB1,INPP5D |
5.137e-04 | -7.57 | PLCG1 (phospholipase C gamma 1) | protein interactions | 5335 | 258 | 5 | 19454 | 50 |
GAB1,INPP5D,HCK,DAPP1,SH2B3 |
5.328e-04 | -7.54 | SH2 | prosite domains | PS50001 | 107 | 4 | 12186 | 43 |
DAPP1,SH2B3,HCK,INPP5D |
5.432e-04 | -7.52 | negative T cell selection | biological process | GO:0043383 | 13 | 2 | 18204 | 49 |
DOCK2,CD74 |
5.895e-04 | -7.44 | immune effector process | biological process | GO:0002252 | 389 | 6 | 18204 | 49 |
CD74,DOCK2,INPP5D,MFNG,UNC93B1,HCK |
5.960e-04 | -7.43 | DGKE (diacylglycerol kinase epsilon) | protein interactions | 8526 | 64 | 3 | 19454 | 50 |
CD74,P2RY6,UNC93B1 |
6.021e-04 | -7.42 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 44 |
P2RY6,CSF1R,MYO1F,PLXNC1,DPYD,ITGB2,ITGAX,ELMO1,PREX1,NCAM2,SLCO2B1,RBM47 |
6.037e-04 | -7.41 | amide binding | molecular function | GO:0033218 | 254 | 5 | 18094 | 49 |
ITM2B,MARCO,CD74,PSAP,ITGB2 |
6.277e-04 | -7.37 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 44 |
CD74,ELMO1,ZFP36L1,VMP1,CPN1,MLKL,HCK,DPYD |
6.293e-04 | -7.37 | SH3 | smart domains | SM00326 | 202 | 5 | 9717 | 34 |
DOCK2,MYO1F,HCK,FYB1,MAP3K11 |
6.381e-04 | -7.36 | specific granule | cellular component | GO:0042581 | 160 | 4 | 19108 | 47 |
ITGB2,DOCK2,CYFIP1,CMTM6 |
6.411e-04 | -7.35 | Fc gamma R-mediated phagocytosis | KEGG pathways | ko04666 | 90 | 4 | 7161 | 32 |
RAC2,DOCK2,INPP5D,HCK |
6.411e-04 | -7.35 | Fc gamma R-mediated phagocytosis | KEGG pathways | hsa04666 | 90 | 4 | 7161 | 32 |
INPP5D,DOCK2,HCK,RAC2 |
6.479e-04 | -7.34 | peptide binding | molecular function | GO:0042277 | 258 | 5 | 18094 | 49 |
ITGB2,ITM2B,CD74,MARCO,RXRA |
6.661e-04 | -7.31 | scalp | COSMIC cancer mutations | scalp | 2110 | 14 | 16828 | 44 |
RBM47,MARCO,NCAM2,SLCO2B1,ITGB2,ITGAX,ADAM33,ELMO1,PREX1,P2RY6,MYO1F,CSF1R,PLXNC1,DPYD |
6.883e-04 | -7.28 | regulation of cell motility | biological process | GO:2000145 | 1122 | 10 | 18204 | 49 |
PLXND1,CSF1R,GAB1,P2RY6,CD74,ITGAX,PLXNC1,SPOCK3,PREX1,RAC2 |
6.890e-04 | -7.28 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 21 | 16828 | 44 |
CSF3R,SLCO2B1,NCAM2,VMP1,DOCK2,RBM47,PLEK,CD74,PLXNC1,DPYD,SNX17,PSAP,PLXND1,ANKRD44,PREX1,RXRA,ELMO1,ABR,SPOCK3,SH2B3,ITGAX |
7.044e-04 | -7.26 | PPP6R1 (protein phosphatase 6 regulatory subunit 1) | protein interactions | 22870 | 157 | 4 | 19454 | 50 |
UNC93B1,ANKRD44,CD74,P2RY6 |
7.119e-04 | -7.25 | T cell differentiation in thymus | biological process | GO:0033077 | 65 | 3 | 18204 | 49 |
CD74,DOCK2,ZFP36L1 |
7.288e-04 | -7.22 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 2 | 18204 | 49 |
P2RY6,PLEK |
7.392e-04 | -7.21 | regulation of actin polymerization or depolymerization | biological process | GO:0008064 | 152 | 4 | 18204 | 49 |
PREX1,CYFIP1,PLEK,HCK |
7.444e-04 | -7.20 | neutrophil migration | biological process | GO:1990266 | 66 | 3 | 18204 | 49 |
ITGB2,PREX1,CSF3R |
7.466e-04 | -7.20 | lysosomal membrane | cellular component | GO:0005765 | 446 | 6 | 19108 | 47 |
CD68,CMTM6,RMC1,CD74,CSF3R,PSAP |
7.466e-04 | -7.20 | lytic vacuole membrane | cellular component | GO:0098852 | 446 | 6 | 19108 | 47 |
CMTM6,CD68,CD74,PSAP,CSF3R,RMC1 |
7.514e-04 | -7.19 | immune response | biological process | GO:0006955 | 1349 | 11 | 18204 | 49 |
MFNG,CD74,UNC93B1,HCK,TNFAIP8L2,FYB1,CSF1R,CD68,INPP5D,DOCK2,MARCO |
7.643e-04 | -7.18 | anatomical structure development | biological process | GO:0048856 | 5207 | 25 | 18204 | 49 |
RXRA,ITGAX,DOCK2,PLXND1,ITM2B,HCK,UNC93B1,VMP1,CD74,CSF3R,ZFP36L1,GAB1,NCAM2,RBM47,CYFIP1,CSF1R,RAC2,ITGB2,PREX1,SH2B3,PSAP,SNX17,PLEK,MFNG,THRB |
7.852e-04 | -7.15 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 18 | 18204 | 49 |
RAC2,SH2B3,UNC93B1,TNFAIP8L2,CD74,GAB1,PLEK,ZFP36L1,CSF3R,THRB,RXRA,RBM47,ITGAX,PLXNC1,CYFIP1,CSF1R,PLXND1,INPP5D |
7.952e-04 | -7.14 | regulation of actin filament length | biological process | GO:0030832 | 155 | 4 | 18204 | 49 |
HCK,PLEK,CYFIP1,PREX1 |
8.822e-04 | -7.03 | regulation of GTPase activity | biological process | GO:0043087 | 278 | 5 | 18204 | 49 |
ABR,RASGRP2,PREX1,PLXND1,PLXNC1 |
8.870e-04 | -7.03 | EIF2B5 (eukaryotic translation initiation factor 2B subunit epsilon) | protein interactions | 8893 | 167 | 4 | 19454 | 50 |
UNC93B1,CD68,P2RY6,CD74 |
9.145e-04 | -7.00 | regulation of locomotion | biological process | GO:0040012 | 1164 | 10 | 18204 | 49 |
CSF1R,PLXND1,CD74,GAB1,P2RY6,SPOCK3,ITGAX,PLXNC1,PREX1,RAC2 |
9.350e-04 | -6.97 | leukocyte differentiation | biological process | GO:0002521 | 425 | 6 | 18204 | 49 |
DOCK2,PREX1,CD74,ZFP36L1,CSF1R,MFNG |
9.407e-04 | -6.97 | protein trimerization | biological process | GO:0070206 | 17 | 2 | 18204 | 49 |
CD74,MLKL |
9.458e-04 | -6.96 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 44 | 16828 | 44 |
RAC2,THRB,VMP1,PREX1,ITGB2,RASGRP2,PLXNC1,DAPP1,CSF1R,CMTM6,CD68,ITM2B,CD74,SLCO2B1,MLKL,CPN1,ELMO1,ADAM33,DPYD,HCK,P2RY6,ENTPD1,PLEK,RBM47,SMPD4,GAB1,MFNG,CSF3R,NCAM2,DOCK2,ABR,RXRA,TNFAIP8L2,SPOCK3,PSAP,ZFP36L1,MARCO,MAP3K11,SH2B3,ITGAX,PLXND1,MYO1F,SNX17,ANKRD44 |
9.466e-04 | -6.96 | Thyroglobulin_1_sf | interpro domains | IPR036857 | 17 | 2 | 18521 | 50 |
CD74,SPOCK3 |
9.466e-04 | -6.96 | Thyroglobulin_1 | interpro domains | IPR000716 | 17 | 2 | 18521 | 50 |
SPOCK3,CD74 |
9.738e-04 | -6.93 | positive regulation of cell migration | biological process | GO:0030335 | 592 | 7 | 18204 | 49 |
ITGAX,PREX1,RAC2,CSF1R,GAB1,P2RY6,CD74 |
9.762e-04 | -6.93 | response to chemical | biological process | GO:0042221 | 3743 | 20 | 18204 | 49 |
CD74,P2RY6,GAB1,ZFP36L1,CSF3R,THRB,RASGRP2,ITGB2,PREX1,RAC2,SH2B3,HCK,DOCK2,CYFIP1,CSF1R,CD68,CPN1,SMPD4,RXRA,SLCO2B1 |
9.839e-04 | -6.92 | Thyroglobulin_1 | pfam domains | PF00086 | 17 | 2 | 17795 | 49 |
CD74,SPOCK3 |
1.021e-03 | -6.89 | Innate Immune System | REACTOME pathways | R-HSA-168249 | 1285 | 13 | 10285 | 41 |
UNC93B1,CMTM6,PSAP,CYFIP1,GAB1,HCK,RASGRP2,ELMO1,MAP3K11,DOCK2,ITGAX,CD68,ITGB2 |
1.043e-03 | -6.87 | leukocyte activation | biological process | GO:0045321 | 599 | 7 | 18204 | 49 |
MFNG,TNFAIP8L2,PREX1,ITGB2,DOCK2,CD74,ZFP36L1 |
1.051e-03 | -6.86 | SH3 | prosite domains | PS50002 | 222 | 5 | 12186 | 43 |
MAP3K11,HCK,DOCK2,MYO1F,FYB1 |
1.055e-03 | -6.85 | secretory granule membrane | cellular component | GO:0030667 | 317 | 5 | 19108 | 47 |
PSAP,ITGB2,CD68,ITGAX,CMTM6 |
1.056e-03 | -6.85 | retinoic acid receptor signaling pathway | biological process | GO:0048384 | 18 | 2 | 18204 | 49 |
THRB,RXRA |
1.065e-03 | -6.84 | lymphocyte differentiation | biological process | GO:0030098 | 290 | 5 | 18204 | 49 |
MFNG,PREX1,DOCK2,CD74,ZFP36L1 |
1.166e-03 | -6.75 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 3 | 18204 | 49 |
CYFIP1,PLXND1,PLXNC1 |
1.194e-03 | -6.73 | Thyroglobulin type-1 | gene3d domains | 4.10.800.10 | 17 | 2 | 14470 | 44 |
CD74,SPOCK3 |
1.195e-03 | -6.73 | SCAMP3 (secretory carrier membrane protein 3) | protein interactions | 10067 | 181 | 4 | 19454 | 50 |
UNC93B1,RAC2,P2RY6,RBM47 |
1.223e-03 | -6.71 | defense response | biological process | GO:0006952 | 1431 | 11 | 18204 | 49 |
ITGB2,HCK,UNC93B1,MARCO,TNFAIP8L2,ITGAX,CD74,CSF3R,CD68,CSF1R,MLKL |
1.261e-03 | -6.68 | positive regulation of cell motility | biological process | GO:2000147 | 619 | 7 | 18204 | 49 |
CSF1R,P2RY6,GAB1,CD74,ITGAX,RAC2,PREX1 |
1.293e-03 | -6.65 | regulation of cell adhesion | biological process | GO:0030155 | 807 | 8 | 18204 | 49 |
CD74,PLXND1,RAC2,ITGB2,PREX1,SH2B3,TNFAIP8L2,PLXNC1 |
1.307e-03 | -6.64 | regulation of antigen processing and presentation | biological process | GO:0002577 | 20 | 2 | 18204 | 49 |
CD74,CD68 |
1.314e-03 | -6.64 | developmental process | biological process | GO:0032502 | 5716 | 26 | 18204 | 49 |
MFNG,THRB,PLEK,SNX17,PSAP,SH2B3,ITGB2,PREX1,RAC2,CSF1R,CYFIP1,RBM47,NCAM2,GAB1,CSF3R,ZFP36L1,CD74,VMP1,HCK,UNC93B1,ITM2B,PLXND1,LRMDA,DOCK2,ITGAX,RXRA |
1.360e-03 | -6.60 | WSB2 (WD repeat and SOCS box containing 2) | protein interactions | 55884 | 85 | 3 | 19454 | 50 |
CSF3R,PREX1,SMPD4 |
1.367e-03 | -6.59 | TIG | pfam domains | PF01833 | 20 | 2 | 17795 | 49 |
PLXNC1,PLXND1 |
1.373e-03 | -6.59 | positive regulation of cell development | biological process | GO:0010720 | 458 | 6 | 18204 | 49 |
CD74,CYFIP1,ZFP36L1,PLXND1,INPP5D,PLXNC1 |
1.396e-03 | -6.57 | regulation of cell activation | biological process | GO:0050865 | 630 | 7 | 18204 | 49 |
INPP5D,TNFAIP8L2,ZFP36L1,PLEK,SH2B3,RAC2,CD74 |
1.398e-03 | -6.57 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 13 | 16828 | 44 |
CSF3R,THRB,MLKL,SMPD4,RBM47,MARCO,PLXNC1,HCK,CSF1R,ITGAX,RXRA,ELMO1,ABR |
1.398e-03 | -6.57 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 13 | 16828 | 44 |
ITGAX,ELMO1,ABR,RXRA,HCK,PLXNC1,CSF1R,SMPD4,RBM47,MARCO,CSF3R,MLKL,THRB |
1.398e-03 | -6.57 | granulocyte chemotaxis | biological process | GO:0071621 | 82 | 3 | 18204 | 49 |
CSF3R,PREX1,ITGB2 |
1.432e-03 | -6.55 | negative regulation of cell adhesion | biological process | GO:0007162 | 310 | 5 | 18204 | 49 |
SH2B3,CD74,PLXND1,TNFAIP8L2,PLXNC1 |
1.432e-03 | -6.55 | nodular | COSMIC cancer mutations | nodular | 1515 | 11 | 16828 | 44 |
THRB,SLCO2B1,CSF3R,DOCK2,ANKRD44,TNFAIP8L2,RBM47,ADAM33,PLEK,ITGB2,SPOCK3 |
1.434e-03 | -6.55 | kidney-carcinoma | COSMIC cancer mutations | kidney-carcinoma | 3720 | 19 | 16828 | 44 |
VMP1,CPN1,THRB,MLKL,MAP3K11,MFNG,GAB1,RAC2,ANKRD44,CSF1R,SNX17,DPYD,HCK,RASGRP2,ITGB2,ITGAX,ADAM33,RXRA,PREX1 |
1.435e-03 | -6.55 | positive regulation of locomotion | biological process | GO:0040017 | 633 | 7 | 18204 | 49 |
RAC2,PREX1,ITGAX,CD74,GAB1,P2RY6,CSF1R |
1.442e-03 | -6.54 | T cell differentiation | biological process | GO:0030217 | 182 | 4 | 18204 | 49 |
ZFP36L1,DOCK2,CD74,PREX1 |
1.443e-03 | -6.54 | thymic T cell selection | biological process | GO:0045061 | 21 | 2 | 18204 | 49 |
CD74,DOCK2 |
1.447e-03 | -6.54 | SLAMF7 (SLAM family member 7) | protein interactions | 57823 | 22 | 2 | 19454 | 50 |
INPP5D,CMTM6 |
1.447e-03 | -6.54 | FCGR2B (Fc gamma receptor IIb) | protein interactions | 2213 | 22 | 2 | 19454 | 50 |
GAB1,INPP5D |
1.450e-03 | -6.54 | guanyl-nucleotide exchange factor complex | cellular component | GO:0032045 | 23 | 2 | 19108 | 47 |
ELMO1,RMC1 |
1.452e-03 | -6.54 | GDS_CDC24_CS | interpro domains | IPR001331 | 21 | 2 | 18521 | 50 |
ABR,PREX1 |
1.455e-03 | -6.53 | PLCG2 (phospholipase C gamma 2) | protein interactions | 5336 | 87 | 3 | 19454 | 50 |
GAB1,HCK,DAPP1 |
1.500e-03 | -6.50 | positive regulation of hydrolase activity | biological process | GO:0051345 | 466 | 6 | 18204 | 49 |
PLEK,ABR,P2RY6,RASGRP2,PREX1,PSAP |
1.509e-03 | -6.50 | DEP | pfam domains | PF00610 | 21 | 2 | 17795 | 49 |
PLEK,PREX1 |
1.519e-03 | -6.49 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 10 | 16828 | 44 |
CSF3R,THRB,ANKRD44,DOCK2,PLEK,TNFAIP8L2,ADAM33,RBM47,SPOCK3,ITGB2 |
1.528e-03 | -6.48 | positive regulation of immune response | biological process | GO:0050778 | 640 | 7 | 18204 | 49 |
FYB1,ITGB2,CD74,INPP5D,UNC93B1,HCK,RBM47 |
1.536e-03 | -6.48 | T cell activation | biological process | GO:0042110 | 315 | 5 | 18204 | 49 |
TNFAIP8L2,ZFP36L1,PREX1,CD74,DOCK2 |
1.543e-03 | -6.47 | endocytic vesicle membrane | cellular component | GO:0030666 | 203 | 4 | 19108 | 47 |
MARCO,RAC2,CSF3R,CD74 |
1.564e-03 | -6.46 | TY | smart domains | SM00211 | 17 | 2 | 9717 | 34 |
SPOCK3,CD74 |
1.594e-03 | -6.44 | DEP_dom | interpro domains | IPR000591 | 22 | 2 | 18521 | 50 |
PREX1,PLEK |
1.599e-03 | -6.44 | THYROGLOBULIN_1_2 | prosite domains | PS51162 | 17 | 2 | 12186 | 43 |
CD74,SPOCK3 |
1.599e-03 | -6.44 | THYROGLOBULIN_1_1 | prosite domains | PS00484 | 17 | 2 | 12186 | 43 |
CD74,SPOCK3 |
1.604e-03 | -6.44 | IPO13 (importin 13) | protein interactions | 9670 | 90 | 3 | 19454 | 50 |
UNC93B1,CD74,P2RY6 |
1.615e-03 | -6.43 | endocytic vesicle | cellular component | GO:0030139 | 349 | 5 | 19108 | 47 |
RAC2,MARCO,CD74,CSF3R,UNC93B1 |
1.631e-03 | -6.42 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 8 | 18204 | 49 |
DOCK2,ABR,CYFIP1,ZFP36L1,RASGRP2,RAC2,ELMO1,MAP3K11 |
1.632e-03 | -6.42 | TMEM237 (transmembrane protein 237) | protein interactions | 65062 | 197 | 4 | 19454 | 50 |
RAC2,ADAM33,CMTM6,UNC93B1 |
1.632e-03 | -6.42 | molecular transducer activity | molecular function | GO:0060089 | 1474 | 11 | 18094 | 49 |
CSF1R,PLXNC1,P2RY6,ITGAX,MARCO,CD74,PLXND1,ITGB2,CSF3R,RXRA,THRB |
1.632e-03 | -6.42 | signaling receptor activity | molecular function | GO:0038023 | 1474 | 11 | 18094 | 49 |
PLXND1,CSF3R,ITGB2,THRB,RXRA,PLXNC1,CSF1R,P2RY6,ITGAX,MARCO,CD74 |
1.655e-03 | -6.40 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 3 | 19454 | 50 |
GAB1,CSF1R,HCK |
1.657e-03 | -6.40 | PH_DOMAIN | prosite domains | PS50003 | 246 | 5 | 12186 | 43 |
ABR,PLEK,GAB1,PREX1,DAPP1 |
1.671e-03 | -6.39 | lymphocyte activation | biological process | GO:0046649 | 476 | 6 | 18204 | 49 |
TNFAIP8L2,PREX1,MFNG,ZFP36L1,DOCK2,CD74 |
1.671e-03 | -6.39 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 29 | 16828 | 44 |
PREX1,RXRA,ABR,SPOCK3,ITGB2,RASGRP2,PSAP,CMTM6,PLEK,RAC2,SMPD4,GAB1,CSF3R,THRB,NCAM2,DOCK2,VMP1,ADAM33,ELMO1,ITGAX,SH2B3,DPYD,MYO1F,SNX17,ANKRD44,ENTPD1,MARCO,CPN1,MLKL |
1.713e-03 | -6.37 | NRAS (NRAS proto-oncogene, GTPase) | protein interactions | 4893 | 683 | 7 | 19454 | 50 |
GAB1,CYFIP1,FYB1,ITM2B,PREX1,RASGRP2,THRB |
1.723e-03 | -6.36 | GSTCD (glutathione S-transferase C-terminal domain containing) | protein interactions | 79807 | 24 | 2 | 19454 | 50 |
DAPP1,CSF1R |
1.730e-03 | -6.36 | PH | pfam domains | PF00169 | 187 | 4 | 17795 | 49 |
SH2B3,GAB1,DAPP1,PLEK |
1.732e-03 | -6.36 | amyloid-beta clearance | biological process | GO:0097242 | 23 | 2 | 18204 | 49 |
MARCO,ITGB2 |
1.752e-03 | -6.35 | response to organic substance | biological process | GO:0010033 | 2498 | 15 | 18204 | 49 |
THRB,CD74,GAB1,P2RY6,CSF3R,ZFP36L1,HCK,ITGB2,SH2B3,CSF1R,CD68,CPN1,SMPD4,CYFIP1,RXRA |
1.758e-03 | -6.34 | cell development | biological process | GO:0048468 | 2236 | 14 | 18204 | 49 |
RBM47,NCAM2,CSF1R,PLXND1,DOCK2,CYFIP1,RAC2,PREX1,SH2B3,MFNG,THRB,CD74,PLEK,ZFP36L1 |
1.762e-03 | -6.34 | C19orf25 (chromosome 19 open reading frame 25) | protein interactions | 148223 | 93 | 3 | 19454 | 50 |
P2RY6,MFNG,UNC93B1 |
1.809e-03 | -6.31 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 11 | 18094 | 49 |
MARCO,CD74,HCK,DOCK2,ITGAX,UNC93B1,PLXNC1,SNX17,SH2B3,FYB1,ITGB2 |
1.844e-03 | -6.30 | Rho_GTPase_activation_prot | interpro domains | IPR008936 | 90 | 3 | 18521 | 50 |
PLXNC1,ABR,PLXND1 |
1.866e-03 | -6.28 | regulation of cell migration | biological process | GO:0030334 | 1061 | 9 | 18204 | 49 |
PLXND1,CSF1R,P2RY6,GAB1,CD74,PLXNC1,ITGAX,RAC2,PREX1 |
1.870e-03 | -6.28 | ADAT3 (adenosine deaminase tRNA specific 3) | protein interactions | 113179 | 25 | 2 | 19454 | 50 |
ANKRD44,THRB |
1.886e-03 | -6.27 | positive regulation of neutrophil chemotaxis | biological process | GO:0090023 | 24 | 2 | 18204 | 49 |
CD74,RAC2 |
1.886e-03 | -6.27 | respiratory burst | biological process | GO:0045730 | 24 | 2 | 18204 | 49 |
HCK,RAC2 |
1.888e-03 | -6.27 | ARCN1 (archain 1) | protein interactions | 372 | 205 | 4 | 19454 | 50 |
RMC1,UNC93B1,CD74,P2RY6 |
1.910e-03 | -6.26 | vesicle-mediated transport | biological process | GO:0016192 | 1283 | 10 | 18204 | 49 |
ELMO1,ITGB2,HCK,MARCO,PLEK,CMTM6,P2RY6,SNX17,DOCK2,MYO1F |
1.911e-03 | -6.26 | cell differentiation | biological process | GO:0030154 | 3645 | 19 | 18204 | 49 |
RBM47,RXRA,NCAM2,CSF1R,LRMDA,PLXND1,DOCK2,CYFIP1,HCK,PSAP,RAC2,PREX1,ITGB2,SH2B3,THRB,MFNG,CD74,PLEK,ZFP36L1 |
1.913e-03 | -6.26 | human chr7p14.2-p14.1 | chromosome location | human chr7p14.2-p14.1 | 1 | 1 | 26134 | 50 |
ELMO1 |
1.913e-03 | -6.26 | human chr10q22.2-q22.3 | chromosome location | human chr10q22.2-q22.3 | 1 | 1 | 26134 | 50 |
LRMDA |
1.931e-03 | -6.25 | cellular developmental process | biological process | GO:0048869 | 3648 | 19 | 18204 | 49 |
HCK,PSAP,RAC2,PREX1,ITGB2,SH2B3,MFNG,THRB,CD74,PLEK,ZFP36L1,RBM47,RXRA,NCAM2,CSF1R,LRMDA,PLXND1,DOCK2,CYFIP1 |
1.945e-03 | -6.24 | positive regulation of transporter activity | biological process | GO:0032411 | 92 | 3 | 18204 | 49 |
P2RY6,VMP1,RXRA |
1.945e-03 | -6.24 | positive regulation of leukocyte chemotaxis | biological process | GO:0002690 | 92 | 3 | 18204 | 49 |
CSF1R,CD74,RAC2 |
1.987e-03 | -6.22 | SOCS3 (suppressor of cytokine signaling 3) | protein interactions | 9021 | 97 | 3 | 19454 | 50 |
CSF3R,CSF1R,GAB1 |
1.999e-03 | -6.22 | positive regulation of ERK1 and ERK2 cascade | biological process | GO:0070374 | 199 | 4 | 18204 | 49 |
CSF1R,MARCO,CD74,P2RY6 |
2.023e-03 | -6.20 | SEMA7A (semaphorin 7A (JohnMiltonHagen blood group)) | protein interactions | 8482 | 26 | 2 | 19454 | 50 |
PLXNC1,UNC93B1 |
2.025e-03 | -6.20 | lipid binding | molecular function | GO:0008289 | 861 | 8 | 18094 | 49 |
PSAP,HCK,RASGRP2,PREX1,DAPP1,SNX17,FYB1,RXRA |
2.027e-03 | -6.20 | Cell surface interactions at the vascular wall | REACTOME pathways | R-HSA-202733 | 136 | 4 | 10285 | 41 |
INPP5D,ITGB2,ITGAX,CD74 |
2.047e-03 | -6.19 | Rac protein signal transduction | biological process | GO:0016601 | 25 | 2 | 18204 | 49 |
ELMO1,CYFIP1 |
2.059e-03 | -6.19 | Integrin_dom_sf | interpro domains | IPR032695 | 25 | 2 | 18521 | 50 |
ITGB2,ITGAX |
2.074e-03 | -6.18 | ESYT2 (extended synaptotagmin 2) | protein interactions | 57488 | 353 | 5 | 19454 | 50 |
UNC93B1,RAC2,P2RY6,VMP1,SMPD4 |
2.102e-03 | -6.16 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 20 | 16828 | 44 |
ELMO1,ANKRD44,DPYD,HCK,PLXNC1,PSAP,PLXND1,SMPD4,GAB1,CD74,ZFP36L1,ITM2B,MARCO,NCAM2,DOCK2,VMP1,SLCO2B1,MLKL,CPN1,THRB |
2.168e-03 | -6.13 | UMPS (uridine monophosphate synthetase) | protein interactions | 7372 | 100 | 3 | 19454 | 50 |
VMP1,SNX17,RMC1 |
2.181e-03 | -6.13 | MECR (mitochondrial trans-2-enoyl-CoA reductase) | protein interactions | 51102 | 27 | 2 | 19454 | 50 |
RXRA,THRB |
2.183e-03 | -6.13 | Rap1 signaling pathway | KEGG pathways | hsa04015 | 210 | 5 | 7161 | 32 |
FYB1,RAC2,ITGB2,RASGRP2,CSF1R |
2.183e-03 | -6.13 | Rap1 signaling pathway | KEGG pathways | ko04015 | 210 | 5 | 7161 | 32 |
RASGRP2,CSF1R,RAC2,FYB1,ITGB2 |
2.197e-03 | -6.12 | granulocyte migration | biological process | GO:0097530 | 96 | 3 | 18204 | 49 |
PREX1,ITGB2,CSF3R |
2.201e-03 | -6.12 | regulation of actin cytoskeleton organization | biological process | GO:0032956 | 342 | 5 | 18204 | 49 |
CYFIP1,PLEK,PREX1,HCK,CSF1R |
2.214e-03 | -6.11 | positive regulation of granulocyte chemotaxis | biological process | GO:0071624 | 26 | 2 | 18204 | 49 |
RAC2,CD74 |
2.228e-03 | -6.11 | cellular response to hormone stimulus | biological process | GO:0032870 | 504 | 6 | 18204 | 49 |
RXRA,THRB,CYFIP1,ZFP36L1,GAB1,P2RY6 |
2.264e-03 | -6.09 | Class I PI3K signaling events | Pathway Interaction DB | pi3kcipathway | 41 | 3 | 2226 | 15 |
HCK,DAPP1,PREX1 |
2.370e-03 | -6.05 | YES1 (YES proto-oncogene 1, Src family tyrosine kinase) | protein interactions | 7525 | 364 | 5 | 19454 | 50 |
CYFIP1,CSF1R,RAC2,GAB1,HCK |
2.394e-03 | -6.03 | DEP | smart domains | SM00049 | 21 | 2 | 9717 | 34 |
PREX1,PLEK |
2.446e-03 | -6.01 | Farnesoid X Receptor Pathway | WikiPathways | WP2879 | 19 | 2 | 5310 | 21 |
SLCO2B1,RXRA |
2.448e-03 | -6.01 | DEP | prosite domains | PS50186 | 21 | 2 | 12186 | 43 |
PREX1,PLEK |
2.448e-03 | -6.01 | DH_1 | prosite domains | PS00741 | 21 | 2 | 12186 | 43 |
PREX1,ABR |
2.460e-03 | -6.01 | NOS2-CD74 complex | cellular component | GO:0035693 | 1 | 1 | 19108 | 47 |
CD74 |
2.462e-03 | -6.01 | Semaphorin interactions | REACTOME pathways | R-HSA-373755 | 68 | 3 | 10285 | 41 |
PLXND1,RAC2,PLXNC1 |
2.466e-03 | -6.01 | defense response to symbiont | biological process | GO:0140546 | 894 | 8 | 18204 | 49 |
CD74,MLKL,CSF1R,TNFAIP8L2,ITGAX,UNC93B1,HCK,MARCO |
2.466e-03 | -6.01 | regulation of anatomical structure morphogenesis | biological process | GO:0022603 | 894 | 8 | 18204 | 49 |
ITGB2,ITGAX,PLXNC1,HCK,GAB1,CYFIP1,PLXND1,CSF1R |
2.467e-03 | -6.00 | hematopoietic progenitor cell differentiation | biological process | GO:0002244 | 100 | 3 | 18204 | 49 |
SH2B3,PLEK,RBM47 |
2.540e-03 | -5.98 | Other semaphorin interactions | REACTOME pathways | R-HSA-416700 | 19 | 2 | 10285 | 41 |
PLXND1,PLXNC1 |
2.559e-03 | -5.97 | SGCA (sarcoglycan alpha) | protein interactions | 6442 | 106 | 3 | 19454 | 50 |
CMTM6,SMPD4,ITM2B |
2.566e-03 | -5.97 | positive regulation of lamellipodium assembly | biological process | GO:0010592 | 28 | 2 | 18204 | 49 |
CYFIP1,RAC2 |
2.570e-03 | -5.96 | pparg.L (peroxisome proliferator activated receptor gamma L homeolog) | protein interactions | 397769 | 1 | 1 | 19454 | 50 |
RXRA |
2.570e-03 | -5.96 | ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) | protein interactions | 103239106 | 1 | 1 | 19454 | 50 |
VMP1 |
2.570e-03 | -5.96 | Parp1 (poly (ADP-ribose) polymerase 1) | protein interactions | 25591 | 1 | 1 | 19454 | 50 |
RXRA |
2.570e-03 | -5.96 | SCGB3A2 (secretoglobin family 3A member 2) | protein interactions | 117156 | 1 | 1 | 19454 | 50 |
MARCO |
2.581e-03 | -5.96 | Plexin_repeat | interpro domains | IPR002165 | 28 | 2 | 18521 | 50 |
PLXNC1,PLXND1 |
2.601e-03 | -5.95 | negative regulation of cell activation | biological process | GO:0050866 | 214 | 4 | 18204 | 49 |
TNFAIP8L2,INPP5D,CD74,SH2B3 |
2.603e-03 | -5.95 | NHLRC2 (NHL repeat containing 2) | protein interactions | 374354 | 372 | 5 | 19454 | 50 |
PLEK,MYO1F,RASGRP2,RAC2,ITGAX |
2.631e-03 | -5.94 | integrin complex | cellular component | GO:0008305 | 31 | 2 | 19108 | 47 |
ITGAX,ITGB2 |
2.682e-03 | -5.92 | PSI | pfam domains | PF01437 | 28 | 2 | 17795 | 49 |
PLXND1,PLXNC1 |
2.688e-03 | -5.92 | PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) | protein interactions | 5296 | 226 | 4 | 19454 | 50 |
HCK,GAB1,RAC2,CSF1R |
2.690e-03 | -5.92 | CLEC4G (C-type lectin domain family 4 member G) | protein interactions | 339390 | 30 | 2 | 19454 | 50 |
CPN1,MAP3K11 |
2.690e-03 | -5.92 | PECAM1 (platelet and endothelial cell adhesion molecule 1) | protein interactions | 5175 | 30 | 2 | 19454 | 50 |
INPP5D,HCK |
2.690e-03 | -5.92 | cell chemotaxis | biological process | GO:0060326 | 216 | 4 | 18204 | 49 |
CSF3R,GAB1,ITGB2,PREX1 |
2.690e-03 | -5.92 | regulation of myeloid cell differentiation | biological process | GO:0045637 | 216 | 4 | 18204 | 49 |
INPP5D,ZFP36L1,CSF3R,CD74 |
2.692e-03 | -5.92 | ganglioside GM1 transport to membrane | biological process | GO:1905572 | 1 | 1 | 18204 | 49 |
PSAP |
2.692e-03 | -5.92 | positive regulation of endothelial tube morphogenesis | biological process | GO:1905956 | 1 | 1 | 18204 | 49 |
ITGAX |
2.692e-03 | -5.92 | positive regulation of inositol-polyphosphate 5-phosphatase activity | biological process | GO:0010925 | 1 | 1 | 18204 | 49 |
PLEK |
2.692e-03 | -5.92 | pyrimidine deoxyribonucleoside catabolic process | biological process | GO:0046127 | 1 | 1 | 18204 | 49 |
DPYD |
2.692e-03 | -5.92 | positive regulation of beta-galactosidase activity | biological process | GO:1903771 | 1 | 1 | 18204 | 49 |
PSAP |
2.692e-03 | -5.92 | cellular response to pyrimidine ribonucleotide | biological process | GO:1905835 | 1 | 1 | 18204 | 49 |
P2RY6 |
2.692e-03 | -5.92 | regulation of cell diameter | biological process | GO:0060305 | 1 | 1 | 18204 | 49 |
PLEK |
2.692e-03 | -5.92 | response to pyrimidine ribonucleotide | biological process | GO:1905834 | 1 | 1 | 18204 | 49 |
P2RY6 |
2.692e-03 | -5.92 | thymidine catabolic process | biological process | GO:0006214 | 1 | 1 | 18204 | 49 |
DPYD |
2.692e-03 | -5.92 | protein secretion by platelet | biological process | GO:0070560 | 1 | 1 | 18204 | 49 |
PLEK |
2.692e-03 | -5.92 | regulation of inositol-polyphosphate 5-phosphatase activity | biological process | GO:0010924 | 1 | 1 | 18204 | 49 |
PLEK |
2.692e-03 | -5.92 | phospholipase C-inhibiting G protein-coupled receptor signaling pathway | biological process | GO:0030845 | 1 | 1 | 18204 | 49 |
PLEK |
2.692e-03 | -5.92 | macrophage migration inhibitory factor signaling pathway | biological process | GO:0035691 | 1 | 1 | 18204 | 49 |
CD74 |
2.698e-03 | -5.92 | SLC39A14 (solute carrier family 39 member 14) | protein interactions | 23516 | 108 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
2.700e-03 | -5.91 | PLEK_DEP | interpro domains | IPR037371 | 1 | 1 | 18521 | 50 |
PLEK |
2.700e-03 | -5.91 | UNC93B1 | interpro domains | IPR043268 | 1 | 1 | 18521 | 50 |
UNC93B1 |
2.700e-03 | -5.91 | DPD_II | interpro domains | IPR028261 | 1 | 1 | 18521 | 50 |
DPYD |
2.700e-03 | -5.91 | SNX17_FERM-like_dom | interpro domains | IPR037836 | 1 | 1 | 18521 | 50 |
SNX17 |
2.700e-03 | -5.91 | M14_CPN | interpro domains | IPR033814 | 1 | 1 | 18521 | 50 |
CPN1 |
2.700e-03 | -5.91 | FYB_hSH3 | interpro domains | IPR035540 | 1 | 1 | 18521 | 50 |
FYB1 |
2.700e-03 | -5.91 | ABR_PH | interpro domains | IPR037865 | 1 | 1 | 18521 | 50 |
ABR |
2.700e-03 | -5.91 | RBM47_RRM1 | interpro domains | IPR047044 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | MHCII_invariant_trimer_sf | interpro domains | IPR036613 | 1 | 1 | 18521 | 50 |
CD74 |
2.700e-03 | -5.91 | RBM47_RRM2 | interpro domains | IPR034440 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | DHR2_DOCK2 | interpro domains | IPR026799 | 1 | 1 | 18521 | 50 |
DOCK2 |
2.700e-03 | -5.91 | HCK_SH2 | interpro domains | IPR035851 | 1 | 1 | 18521 | 50 |
HCK |
2.700e-03 | -5.91 | CSF-1_receptor | interpro domains | IPR030658 | 1 | 1 | 18521 | 50 |
CSF1R |
2.700e-03 | -5.91 | CD74_antigen | interpro domains | IPR043530 | 1 | 1 | 18521 | 50 |
CD74 |
2.700e-03 | -5.91 | DAPP1_SH2 | interpro domains | IPR035843 | 1 | 1 | 18521 | 50 |
DAPP1 |
2.700e-03 | -5.91 | Integrin_b-2_sf | interpro domains | IPR015439 | 1 | 1 | 18521 | 50 |
ITGB2 |
2.700e-03 | -5.91 | Plexin-C1_Sema | interpro domains | IPR041853 | 1 | 1 | 18521 | 50 |
PLXNC1 |
2.700e-03 | -5.91 | SNX17_FERM_N | interpro domains | IPR028666 | 1 | 1 | 18521 | 50 |
SNX17 |
2.700e-03 | -5.91 | RMC1_C | interpro domains | IPR009755 | 1 | 1 | 18521 | 50 |
RMC1 |
2.700e-03 | -5.91 | RMC1 | interpro domains | IPR040371 | 1 | 1 | 18521 | 50 |
RMC1 |
2.700e-03 | -5.91 | Plexin-D1_Sema | interpro domains | IPR042719 | 1 | 1 | 18521 | 50 |
PLXND1 |
2.700e-03 | -5.91 | MHC_II-assoc_invar/CLIP_MHC-bd | interpro domains | IPR015386 | 1 | 1 | 18521 | 50 |
CD74 |
2.700e-03 | -5.91 | MHC_II-assoc_invar_chain | interpro domains | IPR022339 | 1 | 1 | 18521 | 50 |
CD74 |
2.700e-03 | -5.91 | SH2B3_SH2 | interpro domains | IPR035059 | 1 | 1 | 18521 | 50 |
SH2B3 |
2.700e-03 | -5.91 | P2Y6_rcpt | interpro domains | IPR001973 | 1 | 1 | 18521 | 50 |
P2RY6 |
2.700e-03 | -5.91 | Sphingomy_SMPD4 | interpro domains | IPR024129 | 1 | 1 | 18521 | 50 |
SMPD4 |
2.700e-03 | -5.91 | RBM47_RRM3 | interpro domains | IPR034445 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | RMC1_N | interpro domains | IPR049040 | 1 | 1 | 18521 | 50 |
RMC1 |
2.700e-03 | -5.91 | LRMDA | interpro domains | IPR043313 | 1 | 1 | 18521 | 50 |
LRMDA |
2.700e-03 | -5.91 | MHC_II-assoc_invariant_trimer | interpro domains | IPR011988 | 1 | 1 | 18521 | 50 |
CD74 |
2.708e-03 | -5.91 | MHC class II protein binding, via antigen binding groove | molecular function | GO:0042658 | 1 | 1 | 18094 | 49 |
CD74 |
2.708e-03 | -5.91 | granulocyte colony-stimulating factor binding | molecular function | GO:0051916 | 1 | 1 | 18094 | 49 |
CSF3R |
2.708e-03 | -5.91 | sphingomyelin phosphodiesterase D activity | molecular function | GO:0050290 | 1 | 1 | 18094 | 49 |
SMPD4 |
2.708e-03 | -5.91 | uracil binding | molecular function | GO:0002058 | 1 | 1 | 18094 | 49 |
DPYD |
2.708e-03 | -5.91 | ganglioside GP1c binding | molecular function | GO:1905577 | 1 | 1 | 18094 | 49 |
PSAP |
2.708e-03 | -5.91 | ganglioside GM3 binding | molecular function | GO:1905575 | 1 | 1 | 18094 | 49 |
PSAP |
2.708e-03 | -5.91 | pyrimidine nucleobase binding | molecular function | GO:0002061 | 1 | 1 | 18094 | 49 |
DPYD |
2.708e-03 | -5.91 | ITPase activity | molecular function | GO:0103023 | 1 | 1 | 18094 | 49 |
ENTPD1 |
2.708e-03 | -5.91 | dihydropyrimidine dehydrogenase (NADP+) activity | molecular function | GO:0017113 | 1 | 1 | 18094 | 49 |
DPYD |
2.708e-03 | -5.91 | ganglioside GM2 binding | molecular function | GO:1905574 | 1 | 1 | 18094 | 49 |
PSAP |
2.731e-03 | -5.90 | PRKCD (protein kinase C delta) | protein interactions | 5580 | 227 | 4 | 19454 | 50 |
INPP5D,CSF3R,ITGB2,RMC1 |
2.732e-03 | -5.90 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 18 | 16828 | 44 |
ZFP36L1,MARCO,ITM2B,SMPD4,GAB1,CD74,SLCO2B1,THRB,NCAM2,DOCK2,VMP1,ELMO1,PLXNC1,DPYD,HCK,PSAP,PLXND1,ANKRD44 |
2.754e-03 | -5.89 | MHC2-interact | pfam domains | PF09307 | 1 | 1 | 17795 | 49 |
CD74 |
2.754e-03 | -5.89 | Fer4_20 | pfam domains | PF14691 | 1 | 1 | 17795 | 49 |
DPYD |
2.754e-03 | -5.89 | Fer4_21 | pfam domains | PF14697 | 1 | 1 | 17795 | 49 |
DPYD |
2.754e-03 | -5.89 | RMC1_N | pfam domains | PF21029 | 1 | 1 | 17795 | 49 |
RMC1 |
2.754e-03 | -5.89 | mit_SMPDase | pfam domains | PF14724 | 1 | 1 | 17795 | 49 |
SMPD4 |
2.754e-03 | -5.89 | MHCassoc_trimer | pfam domains | PF08831 | 1 | 1 | 17795 | 49 |
CD74 |
2.754e-03 | -5.89 | RMC1_C | pfam domains | PF07035 | 1 | 1 | 17795 | 49 |
RMC1 |
2.770e-03 | -5.89 | plasma membrane raft | cellular component | GO:0044853 | 114 | 3 | 19108 | 47 |
ITGB2,ENTPD1,HCK |
2.784e-03 | -5.88 | phosphatidylinositol-3,4-bisphosphate binding | molecular function | GO:0043325 | 29 | 2 | 18094 | 49 |
PLEK,DAPP1 |
2.789e-03 | -5.88 | NOTCH2NLA (notch 2 N-terminal like A) | protein interactions | 388677 | 378 | 5 | 19454 | 50 |
DOCK2,INPP5D,P2RY6,ITGB2,HCK |
2.804e-03 | -5.88 | ntegrin, alpha v. Chain A, domain 3 | gene3d domains | 2.60.40.1510 | 26 | 2 | 14470 | 44 |
ITGAX,ITGB2 |
2.830e-03 | -5.87 | Neutrophil degranulation | REACTOME pathways | R-HSA-6798695 | 487 | 7 | 10285 | 41 |
DOCK2,CMTM6,ITGAX,PSAP,CD68,CYFIP1,ITGB2 |
2.834e-03 | -5.87 | positive regulation of myeloid cell differentiation | biological process | GO:0045639 | 105 | 3 | 18204 | 49 |
INPP5D,CD74,ZFP36L1 |
2.836e-03 | -5.87 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 40 | 16828 | 44 |
PSAP,CSF1R,RASGRP2,PLXNC1,CMTM6,ABR,RXRA,TNFAIP8L2,PREX1,ITGB2,SPOCK3,THRB,CSF3R,DOCK2,VMP1,NCAM2,PLEK,RBM47,MFNG,GAB1,RAC2,SMPD4,PLXND1,SNX17,MYO1F,HCK,DPYD,ENTPD1,ANKRD44,ELMO1,ITGAX,SH2B3,MLKL,MAP3K11,CPN1,SLCO2B1,ITM2B,MARCO,ZFP36L1,CD74 |
2.908e-03 | -5.84 | NBPF19 (NBPF member 19) | protein interactions | 101060226 | 231 | 4 | 19454 | 50 |
ITGB2,HCK,DOCK2,P2RY6 |
2.911e-03 | -5.84 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 8 | 16828 | 44 |
SH2B3,PREX1,ELMO1,ANKRD44,NCAM2,DOCK2,DPYD,HCK |
2.911e-03 | -5.84 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 8 | 16828 | 44 |
SH2B3,PREX1,ELMO1,ANKRD44,NCAM2,DOCK2,HCK,DPYD |
2.914e-03 | -5.84 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 9 | 16828 | 44 |
DOCK2,CSF3R,PLXNC1,HCK,CSF1R,MAP3K11,MLKL,SH2B3,GAB1 |
2.914e-03 | -5.84 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 9 | 16828 | 44 |
DOCK2,PLXNC1,CSF3R,HCK,CSF1R,MLKL,MAP3K11,SH2B3,GAB1 |
2.954e-03 | -5.82 | HLA-B (major histocompatibility complex, class I, B) | protein interactions | 3106 | 232 | 4 | 19454 | 50 |
RAC2,SMPD4,ADAM33,ITM2B |
2.961e-03 | -5.82 | IPT_dom | interpro domains | IPR002909 | 30 | 2 | 18521 | 50 |
PLXNC1,PLXND1 |
3.041e-03 | -5.80 | - | gene3d domains | 6.20.50.10 | 1 | 1 | 14470 | 44 |
ITGB2 |
3.041e-03 | -5.80 | MHC class II-associated invariant chain, trimerisation domain | gene3d domains | 1.10.870.10 | 1 | 1 | 14470 | 44 |
CD74 |
3.057e-03 | -5.79 | RASA3 (RAS p21 protein activator 3) | protein interactions | 22821 | 32 | 2 | 19454 | 50 |
HCK,RAC2 |
3.057e-03 | -5.79 | ALPL (alkaline phosphatase, biomineralization associated) | protein interactions | 249 | 32 | 2 | 19454 | 50 |
VMP1,RAC2 |
3.117e-03 | -5.77 | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 3 | 16828 | 44 |
SH2B3,CSF3R,CSF1R |
3.117e-03 | -5.77 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 3 | 16828 | 44 |
SH2B3,CSF1R,CSF3R |
3.140e-03 | -5.76 | antigen processing and presentation of exogenous peptide antigen via MHC class II | biological process | GO:0019886 | 31 | 2 | 18204 | 49 |
UNC93B1,CD74 |
3.140e-03 | -5.76 | positive regulation of calcium ion transmembrane transporter activity | biological process | GO:1901021 | 31 | 2 | 18204 | 49 |
P2RY6,VMP1 |
3.141e-03 | -5.76 | CTSL (cathepsin L) | protein interactions | 1514 | 236 | 4 | 19454 | 50 |
CD74,PSAP,ITM2B,RXRA |
3.144e-03 | -5.76 | ACVR1 (activin A receptor type 1) | protein interactions | 90 | 114 | 3 | 19454 | 50 |
THRB,RXRA,PLEK |
3.159e-03 | -5.76 | Semap_dom_sf | interpro domains | IPR036352 | 31 | 2 | 18521 | 50 |
PLXNC1,PLXND1 |
3.159e-03 | -5.76 | Semap_dom | interpro domains | IPR001627 | 31 | 2 | 18521 | 50 |
PLXND1,PLXNC1 |
3.249e-03 | -5.73 | ELMO3 (engulfment and cell motility 3) | protein interactions | 79767 | 33 | 2 | 19454 | 50 |
ELMO1,RAC2 |
3.249e-03 | -5.73 | HS6ST1 (heparan sulfate 6-O-sulfotransferase 1) | protein interactions | 9394 | 33 | 2 | 19454 | 50 |
MFNG,ITM2B |
3.302e-03 | -5.71 | THEM6 (thioesterase superfamily member 6) | protein interactions | 51337 | 116 | 3 | 19454 | 50 |
RAC2,P2RY6,UNC93B1 |
3.308e-03 | -5.71 | cellular response to cytokine stimulus | biological process | GO:0071345 | 734 | 7 | 18204 | 49 |
CD74,SH2B3,ZFP36L1,CSF3R,CSF1R,HCK,SMPD4 |
3.335e-03 | -5.70 | SLC1A5 (solute carrier family 1 member 5) | protein interactions | 6510 | 240 | 4 | 19454 | 50 |
P2RY6,RAC2,UNC93B1,RMC1 |
3.345e-03 | -5.70 | actin cytoskeleton organization | biological process | GO:0030036 | 547 | 6 | 18204 | 49 |
PLEK,MYO1F,DOCK2,PREX1,RAC2,ELMO1 |
3.406e-03 | -5.68 | localization within membrane | biological process | GO:0051668 | 549 | 6 | 18204 | 49 |
CMTM6,DOCK2,ITGB2,FYB1,SNX17,PSAP |
3.436e-03 | -5.67 | STT3B (STT3 oligosaccharyltransferase complex catalytic subunit B) | protein interactions | 201595 | 242 | 4 | 19454 | 50 |
UNC93B1,MLKL,RAC2,P2RY6 |
3.446e-03 | -5.67 | ELMO1 (engulfment and cell motility 1) | protein interactions | 9844 | 34 | 2 | 19454 | 50 |
HCK,DOCK2 |
3.446e-03 | -5.67 | SEMA4F (ssemaphorin 4F) | protein interactions | 10505 | 34 | 2 | 19454 | 50 |
ADAM33,ITM2B |
3.553e-03 | -5.64 | regulation of neutrophil chemotaxis | biological process | GO:0090022 | 33 | 2 | 18204 | 49 |
CD74,RAC2 |
3.553e-03 | -5.64 | antigen processing and presentation of peptide antigen via MHC class II | biological process | GO:0002495 | 33 | 2 | 18204 | 49 |
UNC93B1,CD74 |
3.553e-03 | -5.64 | positive regulation of neutrophil migration | biological process | GO:1902624 | 33 | 2 | 18204 | 49 |
RAC2,CD74 |
3.622e-03 | -5.62 | B cell receptor signaling pathway | KEGG pathways | hsa04662 | 70 | 3 | 7161 | 32 |
DAPP1,RAC2,INPP5D |
3.622e-03 | -5.62 | B cell receptor signaling pathway | KEGG pathways | ko04662 | 70 | 3 | 7161 | 32 |
INPP5D,DAPP1,RAC2 |
3.623e-03 | -5.62 | regulation of actin filament-based process | biological process | GO:0032970 | 384 | 5 | 18204 | 49 |
PLEK,CYFIP1,PREX1,HCK,CSF1R |
3.623e-03 | -5.62 | cytokine-mediated signaling pathway | biological process | GO:0019221 | 384 | 5 | 18204 | 49 |
HCK,CSF1R,CSF3R,SH2B3,CD74 |
3.649e-03 | -5.61 | Mbp (myelin basic protein) | protein interactions | 17196 | 35 | 2 | 19454 | 50 |
HCK,FYB1 |
3.649e-03 | -5.61 | JAG1 (jagged canonical Notch ligand 1) | protein interactions | 182 | 35 | 2 | 19454 | 50 |
RAC2,MFNG |
3.724e-03 | -5.59 | ligand-binding face of the semaphorins, domain 2 | gene3d domains | 3.30.1680.10 | 30 | 2 | 14470 | 44 |
ITGB2,PLXNC1 |
3.749e-03 | -5.59 | SYK (spleen associated tyrosine kinase) | protein interactions | 6850 | 248 | 4 | 19454 | 50 |
INPP5D,GAB1,ITGB2,CSF3R |
3.769e-03 | -5.58 | positive T cell selection | biological process | GO:0043368 | 34 | 2 | 18204 | 49 |
CD74,DOCK2 |
3.769e-03 | -5.58 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | biological process | GO:0002504 | 34 | 2 | 18204 | 49 |
UNC93B1,CD74 |
3.769e-03 | -5.58 | regulation of B cell differentiation | biological process | GO:0045577 | 34 | 2 | 18204 | 49 |
ZFP36L1,INPP5D |
3.887e-03 | -5.55 | positive regulation of response to external stimulus | biological process | GO:0032103 | 564 | 6 | 18204 | 49 |
CSF1R,RBM47,UNC93B1,HCK,CD74,RAC2 |
3.893e-03 | -5.55 | EIF2B3 (eukaryotic translation initiation factor 2B subunit gamma) | protein interactions | 8891 | 123 | 3 | 19454 | 50 |
UNC93B1,CD74,P2RY6 |
3.899e-03 | -5.55 | cell leading edge | cellular component | GO:0031252 | 428 | 5 | 19108 | 47 |
PLEK,RASGRP2,RAC2,CYFIP1,PLXND1 |
3.949e-03 | -5.53 | IPT | smart domains | SM00429 | 27 | 2 | 9717 | 34 |
PLXNC1,PLXND1 |
4.050e-03 | -5.51 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 4 | 16828 | 44 |
VMP1,PREX1,CSF1R,PLXND1 |
4.146e-03 | -5.49 | endosome | cellular component | GO:0005768 | 1067 | 8 | 19108 | 47 |
RMC1,SNX17,PSAP,CD74,ITM2B,UNC93B1,CD68,CMTM6 |
4.209e-03 | -5.47 | P2Y6PRNOCPTR | prints domains | PR01068 | 1 | 1 | 5227 | 22 |
P2RY6 |
4.209e-03 | -5.47 | CD74ANTIGEN | prints domains | PR01990 | 1 | 1 | 5227 | 22 |
CD74 |
4.218e-03 | -5.47 | positive regulation of lamellipodium organization | biological process | GO:1902745 | 36 | 2 | 18204 | 49 |
RAC2,CYFIP1 |
4.220e-03 | -5.47 | leukocyte migration | biological process | GO:0050900 | 245 | 4 | 18204 | 49 |
HCK,ITGB2,PREX1,CSF3R |
4.296e-03 | -5.45 | Signaling by Interleukins | REACTOME pathways | R-HSA-449147 | 525 | 7 | 10285 | 41 |
CSF3R,MAP3K11,CSF1R,INPP5D,HCK,ITGB2,ITGAX |
4.316e-03 | -5.45 | env (Envelope surface glycoprotein gp160, precursor) | protein interactions | 155971 | 1501 | 10 | 19454 | 50 |
INPP5D,ITM2B,CD74,SMPD4,RXRA,ITGB2,ITGAX,MAP3K11,ABR,HCK |
4.322e-03 | -5.44 | regulation of leukocyte chemotaxis | biological process | GO:0002688 | 122 | 3 | 18204 | 49 |
CSF1R,RAC2,CD74 |
4.352e-03 | -5.44 | BTK (Bruton tyrosine kinase) | protein interactions | 695 | 128 | 3 | 19454 | 50 |
HCK,DAPP1,GAB1 |
4.352e-03 | -5.44 | RAB18 (RAB18, member RAS oncogene family) | protein interactions | 22931 | 128 | 3 | 19454 | 50 |
P2RY6,VMP1,UNC93B1 |
4.451e-03 | -5.41 | cellular response to low-density lipoprotein particle stimulus | biological process | GO:0071404 | 37 | 2 | 18204 | 49 |
CD68,ITGB2 |
4.451e-03 | -5.41 | response to lipoprotein particle | biological process | GO:0055094 | 37 | 2 | 18204 | 49 |
CD68,ITGB2 |
4.545e-03 | -5.39 | HM13 (histocompatibility minor 13) | protein interactions | 81502 | 130 | 3 | 19454 | 50 |
RAC2,UNC93B1,CMTM6 |
4.545e-03 | -5.39 | YIPF5 (Yip1 domain family member 5) | protein interactions | 81555 | 130 | 3 | 19454 | 50 |
UNC93B1,P2RY6,RAC2 |
4.691e-03 | -5.36 | heterotypic cell-cell adhesion | biological process | GO:0034113 | 38 | 2 | 18204 | 49 |
ITGB2,ITGAX |
4.742e-03 | -5.35 | OSBPL8 (oxysterol binding protein like 8) | protein interactions | 114882 | 265 | 4 | 19454 | 50 |
CD74,P2RY6,RAC2,UNC93B1 |
4.747e-03 | -5.35 | response to hormone | biological process | GO:0009725 | 784 | 7 | 18204 | 49 |
ZFP36L1,CYFIP1,GAB1,P2RY6,THRB,CPN1,RXRA |
4.750e-03 | -5.35 | RAC3 (Rac family small GTPase 3) | protein interactions | 5881 | 615 | 6 | 19454 | 50 |
MAP3K11,SMPD4,GAB1,RAC2,CYFIP1,ITM2B |
4.782e-03 | -5.34 | SH3DOMAIN | prints domains | PR00452 | 83 | 3 | 5227 | 22 |
MYO1F,HCK,MAP3K11 |
4.785e-03 | -5.34 | Fcgamma receptor (FCGR) dependent phagocytosis | REACTOME pathways | R-HSA-2029480 | 86 | 3 | 10285 | 41 |
ELMO1,CYFIP1,HCK |
4.835e-03 | -5.33 | regulation of myeloid leukocyte differentiation | biological process | GO:0002761 | 127 | 3 | 18204 | 49 |
INPP5D,CD74,ZFP36L1 |
4.843e-03 | -5.33 | PLAUR (plasminogen activator, urokinase receptor) | protein interactions | 5329 | 133 | 3 | 19454 | 50 |
PSAP,ITGB2,HCK |
4.913e-03 | -5.32 | integrin alphaL-beta2 complex | cellular component | GO:0034687 | 2 | 1 | 19108 | 47 |
ITGB2 |
4.913e-03 | -5.32 | CSF1-CSF1R complex | cellular component | GO:1990682 | 2 | 1 | 19108 | 47 |
CSF1R |
4.913e-03 | -5.32 | macrophage migration inhibitory factor receptor complex | cellular component | GO:0035692 | 2 | 1 | 19108 | 47 |
CD74 |
4.913e-03 | -5.32 | integrin alphaM-beta2 complex | cellular component | GO:0034688 | 2 | 1 | 19108 | 47 |
ITGB2 |
4.913e-03 | -5.32 | peripheral region of growth cone | cellular component | GO:0090725 | 2 | 1 | 19108 | 47 |
CYFIP1 |
4.942e-03 | -5.31 | regulation of B cell activation | biological process | GO:0050864 | 128 | 3 | 18204 | 49 |
ZFP36L1,CD74,INPP5D |
4.980e-03 | -5.30 | RXRG (retinoid X receptor gamma) | protein interactions | 6258 | 41 | 2 | 19454 | 50 |
RXRA,THRB |
4.980e-03 | -5.30 | PSMC3IP (PSMC3 interacting protein) | protein interactions | 29893 | 41 | 2 | 19454 | 50 |
THRB,RXRA |
4.980e-03 | -5.30 | ATP8 (ATP synthase F0 subunit 8) | protein interactions | 4509 | 41 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
4.999e-03 | -5.30 | PGRMC2 (progesterone receptor membrane component 2) | protein interactions | 10424 | 269 | 4 | 19454 | 50 |
RAC2,VMP1,P2RY6,CD74 |
5.062e-03 | -5.29 | defense response to other organism | biological process | GO:0098542 | 1006 | 8 | 18204 | 49 |
CSF1R,MLKL,CD74,UNC93B1,HCK,MARCO,TNFAIP8L2,ITGAX |
5.103e-03 | -5.28 | G alpha (12/13) signalling events | REACTOME pathways | R-HSA-416482 | 88 | 3 | 10285 | 41 |
ABR,PREX1,RAC2 |
5.186e-03 | -5.26 | Sema | smart domains | SM00630 | 31 | 2 | 9717 | 34 |
PLXNC1,PLXND1 |
5.187e-03 | -5.26 | cellular response to lipoprotein particle stimulus | biological process | GO:0071402 | 40 | 2 | 18204 | 49 |
ITGB2,CD68 |
5.220e-03 | -5.26 | NR2F6 (nuclear receptor subfamily 2 group F member 6) | protein interactions | 2063 | 42 | 2 | 19454 | 50 |
THRB,RXRA |
5.259e-03 | -5.25 | C3 (complement C3) | protein interactions | 718 | 137 | 3 | 19454 | 50 |
ITGB2,ITGAX,CPN1 |
5.300e-03 | -5.24 | SEMA | prosite domains | PS51004 | 31 | 2 | 12186 | 43 |
PLXNC1,PLXND1 |
5.366e-03 | -5.23 | ATP5MG (ATP synthase membrane subunit g) | protein interactions | 10632 | 138 | 3 | 19454 | 50 |
UNC93B1,RBM47,P2RY6 |
5.376e-03 | -5.23 | regulation of prostaglandin-E synthase activity | biological process | GO:2000361 | 2 | 1 | 18204 | 49 |
ITGB2 |
5.376e-03 | -5.23 | negative regulation of dopamine metabolic process | biological process | GO:0045963 | 2 | 1 | 18204 | 49 |
ITGB2 |
5.376e-03 | -5.23 | negative regulation of synaptic vesicle recycling | biological process | GO:1903422 | 2 | 1 | 18204 | 49 |
CYFIP1 |
5.376e-03 | -5.23 | negative regulation of neutrophil differentiation | biological process | GO:0045659 | 2 | 1 | 18204 | 49 |
INPP5D |
5.376e-03 | -5.23 | retinal cone cell apoptotic process | biological process | GO:0097474 | 2 | 1 | 18204 | 49 |
THRB |
5.376e-03 | -5.23 | beta-alanine biosynthetic process | biological process | GO:0019483 | 2 | 1 | 18204 | 49 |
DPYD |
5.376e-03 | -5.23 | female courtship behavior | biological process | GO:0008050 | 2 | 1 | 18204 | 49 |
THRB |
5.376e-03 | -5.23 | uracil catabolic process | biological process | GO:0006212 | 2 | 1 | 18204 | 49 |
DPYD |
5.376e-03 | -5.23 | negative regulation of catecholamine metabolic process | biological process | GO:0045914 | 2 | 1 | 18204 | 49 |
ITGB2 |
5.376e-03 | -5.23 | regulation of Kit signaling pathway | biological process | GO:1900234 | 2 | 1 | 18204 | 49 |
SH2B3 |
5.376e-03 | -5.23 | positive regulation of macrophage migration inhibitory factor signaling pathway | biological process | GO:2000448 | 2 | 1 | 18204 | 49 |
CD74 |
5.376e-03 | -5.23 | negative regulation of inositol phosphate biosynthetic process | biological process | GO:0010920 | 2 | 1 | 18204 | 49 |
PLEK |
5.376e-03 | -5.23 | negative regulation of Kit signaling pathway | biological process | GO:1900235 | 2 | 1 | 18204 | 49 |
SH2B3 |
5.376e-03 | -5.23 | execution phase of necroptosis | biological process | GO:0097528 | 2 | 1 | 18204 | 49 |
MLKL |
5.376e-03 | -5.23 | positive regulation of prostaglandin-E synthase activity | biological process | GO:2000363 | 2 | 1 | 18204 | 49 |
ITGB2 |
5.376e-03 | -5.23 | synaptic target recognition | biological process | GO:0008039 | 2 | 1 | 18204 | 49 |
PLXND1 |
5.392e-03 | -5.22 | Helical_ferredxn | interpro domains | IPR009051 | 2 | 1 | 18521 | 50 |
DPYD |
5.392e-03 | -5.22 | SNX17-31_FERM_F1 | interpro domains | IPR048763 | 2 | 1 | 18521 | 50 |
SNX17 |
5.392e-03 | -5.22 | Pleckstrin | interpro domains | IPR037370 | 2 | 1 | 18521 | 50 |
PLEK |
5.392e-03 | -5.22 | Abr/Bcr | interpro domains | IPR037769 | 2 | 1 | 18521 | 50 |
ABR |
5.392e-03 | -5.22 | Bcr-Abl_oncoprot_oligo | interpro domains | IPR015123 | 2 | 1 | 18521 | 50 |
ABR |
5.392e-03 | -5.22 | Nuc_recep-AF1 | interpro domains | IPR021780 | 2 | 1 | 18521 | 50 |
RXRA |
5.392e-03 | -5.22 | Ie/If_SH3 | interpro domains | IPR035507 | 2 | 1 | 18521 | 50 |
MYO1F |
5.392e-03 | -5.22 | Tis11B_N | interpro domains | IPR007635 | 2 | 1 | 18521 | 50 |
ZFP36L1 |
5.392e-03 | -5.22 | SNX17-31_FERM_F2 | interpro domains | IPR048767 | 2 | 1 | 18521 | 50 |
SNX17 |
5.392e-03 | -5.22 | Neural_cell_adh | interpro domains | IPR009138 | 2 | 1 | 18521 | 50 |
NCAM2 |
5.392e-03 | -5.22 | Bcr-Abl_oncoprot_oligo_sf | interpro domains | IPR036481 | 2 | 1 | 18521 | 50 |
ABR |
5.392e-03 | -5.22 | SNX17/31_FERM | interpro domains | IPR040842 | 2 | 1 | 18521 | 50 |
SNX17 |
5.392e-03 | -5.22 | Cytoplasmic_FMR1-int | interpro domains | IPR008081 | 2 | 1 | 18521 | 50 |
CYFIP1 |
5.392e-03 | -5.22 | Saposin_chordata | interpro domains | IPR021165 | 2 | 1 | 18521 | 50 |
PSAP |
5.392e-03 | -5.22 | Dihydroorotate_DH_cat | interpro domains | IPR005720 | 2 | 1 | 18521 | 50 |
DPYD |
5.409e-03 | -5.22 | macrophage colony-stimulating factor receptor activity | molecular function | GO:0005011 | 2 | 1 | 18094 | 49 |
CSF1R |
5.409e-03 | -5.22 | macrophage migration inhibitory factor binding | molecular function | GO:0035718 | 2 | 1 | 18094 | 49 |
CD74 |
5.409e-03 | -5.22 | G protein-coupled UDP receptor activity | molecular function | GO:0045029 | 2 | 1 | 18094 | 49 |
P2RY6 |
5.443e-03 | -5.21 | cell adhesion mediated by integrin | biological process | GO:0033627 | 41 | 2 | 18204 | 49 |
ITGAX,ITGB2 |
5.443e-03 | -5.21 | antigen processing and presentation of exogenous peptide antigen | biological process | GO:0002478 | 41 | 2 | 18204 | 49 |
UNC93B1,CD74 |
5.443e-03 | -5.21 | regulation of lamellipodium assembly | biological process | GO:0010591 | 41 | 2 | 18204 | 49 |
RAC2,CYFIP1 |
5.468e-03 | -5.21 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 10 | 18204 | 49 |
RXRA,ITGAX,PLXNC1,CD74,GAB1,CYFIP1,CSF3R,ZFP36L1,PLXND1,INPP5D |
5.471e-03 | -5.21 | HMOX2 (heme oxygenase 2) | protein interactions | 3163 | 276 | 4 | 19454 | 50 |
CD74,P2RY6,RAC2,UNC93B1 |
5.500e-03 | -5.20 | DHO_dh | pfam domains | PF01180 | 2 | 1 | 17795 | 49 |
DPYD |
5.500e-03 | -5.20 | SNX17-31_F2_FERM | pfam domains | PF21271 | 2 | 1 | 17795 | 49 |
SNX17 |
5.500e-03 | -5.20 | Bcr-Abl_Oligo | pfam domains | PF09036 | 2 | 1 | 17795 | 49 |
ABR |
5.500e-03 | -5.20 | Nuc_recep-AF1 | pfam domains | PF11825 | 2 | 1 | 17795 | 49 |
RXRA |
5.500e-03 | -5.20 | FragX_IP | pfam domains | PF05994 | 2 | 1 | 17795 | 49 |
CYFIP1 |
5.500e-03 | -5.20 | SNX17_FERM_C | pfam domains | PF18116 | 2 | 1 | 17795 | 49 |
SNX17 |
5.500e-03 | -5.20 | Tis11B_N | pfam domains | PF04553 | 2 | 1 | 17795 | 49 |
ZFP36L1 |
5.500e-03 | -5.20 | SNX17-27-31_F1_FERM | pfam domains | PF21273 | 2 | 1 | 17795 | 49 |
SNX17 |
5.552e-03 | -5.19 | membrane raft | cellular component | GO:0045121 | 290 | 4 | 19108 | 47 |
ITGB2,INPP5D,ENTPD1,HCK |
5.553e-03 | -5.19 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 5 | 16828 | 44 |
CSF1R,MAP3K11,MLKL,CSF3R,HCK |
5.612e-03 | -5.18 | regulation of actin filament polymerization | biological process | GO:0030833 | 134 | 3 | 18204 | 49 |
CYFIP1,PREX1,HCK |
5.687e-03 | -5.17 | membrane microdomain | cellular component | GO:0098857 | 292 | 4 | 19108 | 47 |
HCK,ENTPD1,INPP5D,ITGB2 |
5.696e-03 | -5.17 | NCAPD3 (non-SMC condensin II complex subunit D3) | protein interactions | 23310 | 141 | 3 | 19454 | 50 |
UNC93B1,CD74,P2RY6 |
5.721e-03 | -5.16 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 27 | 16828 | 44 |
RBM47,GAB1,MFNG,SMPD4,RAC2,CSF3R,DOCK2,NCAM2,RXRA,ABR,PREX1,ITGB2,SPOCK3,CSF1R,PSAP,PLXNC1,RASGRP2,ZFP36L1,SLCO2B1,ELMO1,ITGAX,MYO1F,PLXND1,DPYD,HCK,ENTPD1,ANKRD44 |
5.760e-03 | -5.16 | regulation of developmental process | biological process | GO:0050793 | 2540 | 14 | 18204 | 49 |
PREX1,ITGB2,HCK,GAB1,ZFP36L1,CSF3R,CD74,RXRA,ITGAX,PLXNC1,CYFIP1,PLXND1,INPP5D,CSF1R |
5.788e-03 | -5.15 | regulation of leukocyte proliferation | biological process | GO:0070663 | 268 | 4 | 18204 | 49 |
CD74,RAC2,INPP5D,CSF1R |
5.864e-03 | -5.14 | regulation of actin filament organization | biological process | GO:0110053 | 269 | 4 | 18204 | 49 |
HCK,PLEK,CYFIP1,PREX1 |
5.899e-03 | -5.13 | regulation of signal transduction | biological process | GO:0009966 | 3114 | 16 | 18204 | 49 |
MAP3K11,SH2B3,PREX1,MFNG,THRB,ABR,PLEK,P2RY6,CD74,RBM47,MARCO,RXRA,INPP5D,CSF1R,CYFIP1,DOCK2 |
5.922e-03 | -5.13 | ATP13A3 (ATPase 13A3) | protein interactions | 79572 | 143 | 3 | 19454 | 50 |
RAC2,P2RY6,UNC93B1 |
5.952e-03 | -5.12 | actin filament-based process | biological process | GO:0030029 | 616 | 6 | 18204 | 49 |
RAC2,ELMO1,PREX1,DOCK2,MYO1F,PLEK |
5.967e-03 | -5.12 | myeloid leukocyte migration | biological process | GO:0097529 | 137 | 3 | 18204 | 49 |
CSF3R,ITGB2,PREX1 |
5.967e-03 | -5.12 | cell recognition | biological process | GO:0008037 | 137 | 3 | 18204 | 49 |
PLXND1,DOCK2,NCAM2 |
5.973e-03 | -5.12 | EPOR (erythropoietin receptor) | protein interactions | 2057 | 45 | 2 | 19454 | 50 |
INPP5D,GAB1 |
5.973e-03 | -5.12 | SKAP2 (src kinase associated phosphoprotein 2) | protein interactions | 8935 | 45 | 2 | 19454 | 50 |
HCK,FYB1 |
5.974e-03 | -5.12 | erythrocyte development | biological process | GO:0048821 | 43 | 2 | 18204 | 49 |
SH2B3,RAC2 |
5.974e-03 | -5.12 | regulation of bone resorption | biological process | GO:0045124 | 43 | 2 | 18204 | 49 |
INPP5D,CSF1R |
5.974e-03 | -5.12 | semaphorin-plexin signaling pathway | biological process | GO:0071526 | 43 | 2 | 18204 | 49 |
PLXND1,PLXNC1 |
5.982e-03 | -5.12 | secretory granule | cellular component | GO:0030141 | 897 | 7 | 19108 | 47 |
CMTM6,CD68,ITGB2,DOCK2,CYFIP1,ITGAX,PSAP |
6.037e-03 | -5.11 | COPG2 (COPI coat complex subunit gamma 2) | protein interactions | 26958 | 144 | 3 | 19454 | 50 |
CD74,P2RY6,UNC93B1 |
6.073e-03 | -5.10 | Alpha-helical ferredoxin | gene3d domains | 1.10.1060.10 | 2 | 1 | 14470 | 44 |
DPYD |
6.073e-03 | -5.10 | Bcr-Abl oncoprotein oligomerisation domain | gene3d domains | 4.10.280.30 | 2 | 1 | 14470 | 44 |
ABR |
6.088e-03 | -5.10 | regulation of axonogenesis | biological process | GO:0050770 | 138 | 3 | 18204 | 49 |
CYFIP1,PLXND1,PLXNC1 |
6.108e-03 | -5.10 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 5 | 19454 | 50 |
CSF3R,HCK,DAPP1,SH2B3,GAB1 |
6.234e-03 | -5.08 | TM4SF18 (transmembrane 4 L six family member 18) | protein interactions | 116441 | 46 | 2 | 19454 | 50 |
ITGB2,UNC93B1 |
6.272e-03 | -5.07 | SPTLC1 (serine palmitoyltransferase long chain base subunit 1) | protein interactions | 10558 | 146 | 3 | 19454 | 50 |
P2RY6,VMP1,UNC93B1 |
6.458e-03 | -5.04 | Focal Adhesion | WikiPathways | WP306 | 195 | 4 | 5310 | 21 |
ITGAX,ITGB2,HCK,RAC2 |
6.461e-03 | -5.04 | positive regulation of chemotaxis | biological process | GO:0050921 | 141 | 3 | 18204 | 49 |
CD74,RAC2,CSF1R |
6.478e-03 | -5.04 | organic cyclic compound catabolic process | biological process | GO:1901361 | 441 | 5 | 18204 | 49 |
ENTPD1,SLCO2B1,SNX17,DPYD,ZFP36L1 |
6.481e-03 | -5.04 | bone | COSMIC cancer mutations | bone | 8157 | 30 | 16828 | 44 |
CSF1R,DAPP1,PSAP,PLXNC1,ABR,PREX1,CSF3R,DOCK2,VMP1,RBM47,MFNG,GAB1,MYO1F,SNX17,PLXND1,DPYD,HCK,ENTPD1,ANKRD44,P2RY6,ADAM33,ELMO1,ITGAX,CPN1,MLKL,MAP3K11,SLCO2B1,MARCO,ZFP36L1,CD68 |
6.512e-03 | -5.03 | ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) | protein interactions | 481 | 148 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
6.527e-03 | -5.03 | regulation of neutrophil migration | biological process | GO:1902622 | 45 | 2 | 18204 | 49 |
CD74,RAC2 |
6.527e-03 | -5.03 | regulation of leukocyte degranulation | biological process | GO:0043300 | 45 | 2 | 18204 | 49 |
ITGB2,RAC2 |
6.577e-03 | -5.02 | actin filament organization | biological process | GO:0007015 | 278 | 4 | 18204 | 49 |
MYO1F,PREX1,RAC2,ELMO1 |
6.620e-03 | -5.02 | response to cytokine | biological process | GO:0034097 | 834 | 7 | 18204 | 49 |
HCK,SH2B3,SMPD4,CSF1R,ZFP36L1,CSF3R,CD74 |
6.654e-03 | -5.01 | azurophil granule | cellular component | GO:0042582 | 156 | 3 | 19108 | 47 |
CMTM6,CD68,PSAP |
6.654e-03 | -5.01 | primary lysosome | cellular component | GO:0005766 | 156 | 3 | 19108 | 47 |
CMTM6,CD68,PSAP |
6.660e-03 | -5.01 | KRTAP10-7 (keratin associated protein 10-7) | protein interactions | 386675 | 292 | 4 | 19454 | 50 |
P2RY6,INPP5D,DOCK2,HCK |
6.732e-03 | -5.00 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 44 |
DPYD,RASGRP2,PLXND1,CSF1R,P2RY6,ELMO1,RXRA,SPOCK3,MAP3K11,NCAM2,VMP1,RBM47,RAC2,MFNG,GAB1 |
6.732e-03 | -5.00 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 44 |
MFNG,GAB1,RAC2,RBM47,VMP1,NCAM2,MAP3K11,SPOCK3,RXRA,ELMO1,P2RY6,CSF1R,PLXND1,RASGRP2,DPYD |
6.812e-03 | -4.99 | neuron recognition | biological process | GO:0008038 | 46 | 2 | 18204 | 49 |
PLXND1,NCAM2 |
6.812e-03 | -4.99 | mRNA transcription by RNA polymerase II | biological process | GO:0042789 | 46 | 2 | 18204 | 49 |
THRB,RXRA |
6.812e-03 | -4.99 | regulation of myelination | biological process | GO:0031641 | 46 | 2 | 18204 | 49 |
CYFIP1,ITGAX |
6.834e-03 | -4.99 | regulation of cell development | biological process | GO:0060284 | 839 | 7 | 18204 | 49 |
CYFIP1,ZFP36L1,CSF3R,CD74,INPP5D,PLXND1,PLXNC1 |
6.853e-03 | -4.98 | Znf_hrmn_rcpt | interpro domains | IPR001628 | 46 | 2 | 18521 | 50 |
THRB,RXRA |
6.909e-03 | -4.97 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia | 149 | 3 | 16828 | 44 |
CSF3R,CSF1R,SH2B3 |
6.909e-03 | -4.97 | chronic_myelomonocytic_leukaemia | COSMIC cancer mutations | chronic_myelomonocytic_leukaemia | 149 | 3 | 16828 | 44 |
SH2B3,CSF3R,CSF1R |
6.937e-03 | -4.97 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 25 | 16828 | 44 |
P2RY6,ANKRD44,DPYD,MYO1F,PLXND1,SH2B3,ITGAX,ELMO1,SLCO2B1,CPN1,MLKL,MARCO,ITM2B,PLXNC1,SPOCK3,ITGB2,PREX1,RXRA,TNFAIP8L2,NCAM2,DOCK2,VMP1,CSF3R,THRB,RAC2 |
7.049e-03 | -4.95 | GPR173 (G protein-coupled receptor 173) | protein interactions | 54328 | 49 | 2 | 19454 | 50 |
UNC93B1,CMTM6 |
7.049e-03 | -4.95 | ZNHIT3 (zinc finger HIT-type containing 3) | protein interactions | 9326 | 49 | 2 | 19454 | 50 |
THRB,RXRA |
7.049e-03 | -4.95 | MCRIP1 (MAPK regulated corepressor interacting protein 1) | protein interactions | 348262 | 49 | 2 | 19454 | 50 |
RBM47,P2RY6 |
7.103e-03 | -4.95 | T cell selection | biological process | GO:0045058 | 47 | 2 | 18204 | 49 |
CD74,DOCK2 |
7.103e-03 | -4.95 | regulation of erythrocyte differentiation | biological process | GO:0045646 | 47 | 2 | 18204 | 49 |
ZFP36L1,INPP5D |
7.116e-03 | -4.95 | zf-C4 | pfam domains | PF00105 | 46 | 2 | 17795 | 49 |
RXRA,THRB |
7.135e-03 | -4.94 | TMEM43 (transmembrane protein 43) | protein interactions | 79188 | 153 | 3 | 19454 | 50 |
P2RY6,RMC1,UNC93B1 |
7.145e-03 | -4.94 | Nuclear_hrmn_rcpt | interpro domains | IPR001723 | 47 | 2 | 18521 | 50 |
RXRA,THRB |
7.147e-03 | -4.94 | mouth | COSMIC cancer mutations | mouth | 9004 | 32 | 16828 | 44 |
CSF3R,DOCK2,NCAM2,PLEK,RBM47,GAB1,MFNG,RAC2,SMPD4,PSAP,DAPP1,CSF1R,RASGRP2,PLXNC1,ABR,RXRA,PREX1,ITGB2,SPOCK3,MAP3K11,CPN1,SLCO2B1,ZFP36L1,CD74,PLXND1,MYO1F,HCK,DPYD,ENTPD1,ANKRD44,ELMO1,ITGAX |
7.163e-03 | -4.94 | late endosome | cellular component | GO:0005770 | 312 | 4 | 19108 | 47 |
CD74,PSAP,RMC1,CD68 |
7.199e-03 | -4.93 | lung-carcinoma | COSMIC cancer mutations | lung-carcinoma | 4255 | 19 | 16828 | 44 |
ITGB2,ITGAX,ADAM33,PREX1,ANKRD44,SNX17,CSF1R,RASGRP2,DPYD,HCK,GAB1,MFNG,RAC2,VMP1,THRB,CPN1,MAP3K11,MLKL,CSF3R |
7.230e-03 | -4.93 | cytokine binding | molecular function | GO:0019955 | 146 | 3 | 18094 | 49 |
CSF1R,CSF3R,CD74 |
7.246e-03 | -4.93 | leukocyte chemotaxis | biological process | GO:0030595 | 147 | 3 | 18204 | 49 |
CSF3R,PREX1,ITGB2 |
7.252e-03 | -4.93 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 28 | 16828 | 44 |
HCK,DPYD,PLXND1,SNX17,MYO1F,ANKRD44,P2RY6,ENTPD1,ELMO1,ADAM33,ITGAX,SLCO2B1,MLKL,MAP3K11,CPN1,CD68,ZFP36L1,MARCO,PLXNC1,DAPP1,PSAP,CSF1R,PREX1,ABR,CSF3R,DOCK2,GAB1,MFNG |
7.313e-03 | -4.92 | Integrin-mediated Cell Adhesion | WikiPathways | WP185 | 103 | 3 | 5310 | 21 |
RAC2,ITGB2,ITGAX |
7.399e-03 | -4.91 | coronary vasculature development | biological process | GO:0060976 | 48 | 2 | 18204 | 49 |
PLXND1,SNX17 |
7.423e-03 | -4.90 | PCNA (proliferating cell nuclear antigen) | protein interactions | 5111 | 477 | 5 | 19454 | 50 |
UNC93B1,RMC1,CMTM6,CYFIP1,CD74 |
7.443e-03 | -4.90 | Nucl_hrmn_rcpt_lig-bd | interpro domains | IPR000536 | 48 | 2 | 18521 | 50 |
THRB,RXRA |
7.443e-03 | -4.90 | Kazal_dom | interpro domains | IPR002350 | 48 | 2 | 18521 | 50 |
SLCO2B1,SPOCK3 |
7.443e-03 | -4.90 | NHR-like_dom_sf | interpro domains | IPR035500 | 48 | 2 | 18521 | 50 |
RXRA,THRB |
7.519e-03 | -4.89 | positive regulation of leukocyte migration | biological process | GO:0002687 | 149 | 3 | 18204 | 49 |
CD74,RAC2,CSF1R |
7.597e-03 | -4.88 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 34 | 16828 | 44 |
PLXNC1,RASGRP2,CSF1R,PSAP,SPOCK3,ITGB2,PREX1,TNFAIP8L2,RXRA,ABR,NCAM2,VMP1,DOCK2,CSF3R,THRB,RAC2,GAB1,MFNG,RBM47,PLEK,ANKRD44,DPYD,SNX17,MYO1F,PLXND1,SH2B3,ITGAX,ADAM33,ELMO1,SLCO2B1,MAP3K11,CD74,ZFP36L1,MARCO |
7.607e-03 | -4.88 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 24 | 18204 | 49 |
VMP1,CD74,ZFP36L1,GAB1,P2RY6,HCK,UNC93B1,PLXND1,DOCK2,MARCO,ITGAX,RXRA,THRB,MFNG,PLEK,RAC2,PREX1,ITGB2,MAP3K11,CSF1R,INPP5D,CYFIP1,RBM47,PLXNC1 |
7.617e-03 | -4.88 | CD247 (CD247 molecule) | protein interactions | 919 | 51 | 2 | 19454 | 50 |
SH2B3,DOCK2 |
7.634e-03 | -4.88 | tertiary granule | cellular component | GO:0070820 | 164 | 3 | 19108 | 47 |
ITGB2,ITGAX,CYFIP1 |
7.691e-03 | -4.87 | Grip1 (glutamate receptor interacting protein 1) | protein interactions | 74053 | 3 | 1 | 19454 | 50 |
RXRA |
7.700e-03 | -4.87 | platelet aggregation | biological process | GO:0070527 | 49 | 2 | 18204 | 49 |
ENTPD1,PLEK |
7.729e-03 | -4.86 | Hormone_recep | pfam domains | PF00104 | 48 | 2 | 17795 | 49 |
RXRA,THRB |
7.909e-03 | -4.84 | EVI5 (ecotropic viral integration site 5) | protein interactions | 7813 | 52 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
7.909e-03 | -4.84 | ATP5F1E (ATP synthase F1 subunit epsilon) | protein interactions | 514 | 52 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
7.928e-03 | -4.84 | COG6 (component of oligomeric golgi complex 6) | protein interactions | 57511 | 159 | 3 | 19454 | 50 |
P2RY6,CD68,UNC93B1 |
7.928e-03 | -4.84 | STYK1 (serine/threonine/tyrosine kinase 1) | protein interactions | 55359 | 159 | 3 | 19454 | 50 |
MYO1F,GAB1,SMPD4 |
7.941e-03 | -4.84 | cellular response to insulin stimulus | biological process | GO:0032869 | 152 | 3 | 18204 | 49 |
GAB1,ZFP36L1,CYFIP1 |
8.007e-03 | -4.83 | mRNA transcription | biological process | GO:0009299 | 50 | 2 | 18204 | 49 |
RXRA,THRB |
8.007e-03 | -4.83 | antigen processing and presentation of exogenous antigen | biological process | GO:0019884 | 50 | 2 | 18204 | 49 |
UNC93B1,CD74 |
8.021e-03 | -4.83 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 8 | 19454 | 50 |
SH2B3,ITGB2,CYFIP1,GAB1,CD74,ZFP36L1,NCAM2,MAP3K11 |
8.054e-03 | -4.82 | beta-alanine metabolic process | biological process | GO:0019482 | 3 | 1 | 18204 | 49 |
DPYD |
8.054e-03 | -4.82 | septum transversum development | biological process | GO:0003343 | 3 | 1 | 18204 | 49 |
ZFP36L1 |
8.054e-03 | -4.82 | response to raffinose | biological process | GO:1901545 | 3 | 1 | 18204 | 49 |
ZFP36L1 |
8.054e-03 | -4.82 | regulation of macrophage migration inhibitory factor signaling pathway | biological process | GO:2000446 | 3 | 1 | 18204 | 49 |
CD74 |
8.054e-03 | -4.82 | uracil metabolic process | biological process | GO:0019860 | 3 | 1 | 18204 | 49 |
DPYD |
8.054e-03 | -4.82 | positive regulation of ATPase-coupled calcium transmembrane transporter activity | biological process | GO:1901896 | 3 | 1 | 18204 | 49 |
VMP1 |
8.054e-03 | -4.82 | regulation of translation at postsynapse, modulating synaptic transmission | biological process | GO:0099578 | 3 | 1 | 18204 | 49 |
CYFIP1 |
8.054e-03 | -4.82 | proepicardium development | biological process | GO:0003342 | 3 | 1 | 18204 | 49 |
ZFP36L1 |
8.054e-03 | -4.82 | cellular response to raffinose | biological process | GO:0097403 | 3 | 1 | 18204 | 49 |
ZFP36L1 |
8.054e-03 | -4.82 | courtship behavior | biological process | GO:0007619 | 3 | 1 | 18204 | 49 |
THRB |
8.054e-03 | -4.82 | leukocyte migration involved in immune response | biological process | GO:0002522 | 3 | 1 | 18204 | 49 |
HCK |
8.054e-03 | -4.82 | thymine metabolic process | biological process | GO:0019859 | 3 | 1 | 18204 | 49 |
DPYD |
8.054e-03 | -4.82 | thyroid hormone mediated signaling pathway | biological process | GO:0002154 | 3 | 1 | 18204 | 49 |
THRB |
8.054e-03 | -4.82 | thymine catabolic process | biological process | GO:0006210 | 3 | 1 | 18204 | 49 |
DPYD |
8.054e-03 | -4.82 | regulation of neutrophil differentiation | biological process | GO:0045658 | 3 | 1 | 18204 | 49 |
INPP5D |
8.054e-03 | -4.82 | monocyte homeostasis | biological process | GO:0035702 | 3 | 1 | 18204 | 49 |
SH2B3 |
8.054e-03 | -4.82 | membrane raft polarization | biological process | GO:0001766 | 3 | 1 | 18204 | 49 |
DOCK2 |
8.054e-03 | -4.82 | purine nucleobase catabolic process | biological process | GO:0006145 | 3 | 1 | 18204 | 49 |
DPYD |
8.054e-03 | -4.82 | myeloid dendritic cell activation involved in immune response | biological process | GO:0002277 | 3 | 1 | 18204 | 49 |
DOCK2 |
8.054e-03 | -4.82 | positive regulation of intracellular mRNA localization | biological process | GO:1904582 | 3 | 1 | 18204 | 49 |
ZFP36L1 |
8.077e-03 | -4.82 | regulation of ERK1 and ERK2 cascade | biological process | GO:0070372 | 295 | 4 | 18204 | 49 |
CSF1R,MARCO,P2RY6,CD74 |
8.078e-03 | -4.82 | SNX17/27/31-like | interpro domains | IPR037831 | 3 | 1 | 18521 | 50 |
SNX17 |
8.078e-03 | -4.82 | FYB1/2-like | interpro domains | IPR043443 | 3 | 1 | 18521 | 50 |
FYB1 |
8.078e-03 | -4.82 | LAMP_CS | interpro domains | IPR018134 | 3 | 1 | 18521 | 50 |
CD68 |
8.078e-03 | -4.82 | Fringe | interpro domains | IPR017374 | 3 | 1 | 18521 | 50 |
MFNG |
8.078e-03 | -4.82 | SapB_1 | interpro domains | IPR007856 | 3 | 1 | 18521 | 50 |
PSAP |
8.078e-03 | -4.82 | ITM2 | interpro domains | IPR040145 | 3 | 1 | 18521 | 50 |
ITM2B |
8.078e-03 | -4.82 | Saposin | interpro domains | IPR008373 | 3 | 1 | 18521 | 50 |
PSAP |
8.078e-03 | -4.82 | Phe_ZIP | interpro domains | IPR015012 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.078e-03 | -4.82 | ZFP36-like | interpro domains | IPR045877 | 3 | 1 | 18521 | 50 |
ZFP36L1 |
8.078e-03 | -4.82 | ITGAX-like_Ig_3 | interpro domains | IPR048633 | 3 | 1 | 18521 | 50 |
ITGAX |
8.078e-03 | -4.82 | hSH3 | interpro domains | IPR029294 | 3 | 1 | 18521 | 50 |
FYB1 |
8.078e-03 | -4.82 | MLK1-3_SH3 | interpro domains | IPR035779 | 3 | 1 | 18521 | 50 |
MAP3K11 |
8.078e-03 | -4.82 | SAP_A | interpro domains | IPR003119 | 3 | 1 | 18521 | 50 |
PSAP |
8.078e-03 | -4.82 | Phe_ZIP_sf | interpro domains | IPR036290 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.078e-03 | -4.82 | ELMO_ARM | interpro domains | IPR024574 | 3 | 1 | 18521 | 50 |
ELMO1 |
8.078e-03 | -4.82 | SH2B | interpro domains | IPR030523 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.085e-03 | -4.82 | leukocyte proliferation | biological process | GO:0070661 | 153 | 3 | 18204 | 49 |
RAC2,DOCK2,CSF1R |
8.103e-03 | -4.82 | ganglioside GT1b binding | molecular function | GO:1905576 | 3 | 1 | 18094 | 49 |
PSAP |
8.103e-03 | -4.82 | apyrase activity | molecular function | GO:0004050 | 3 | 1 | 18094 | 49 |
ENTPD1 |
8.103e-03 | -4.82 | O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity | molecular function | GO:0033829 | 3 | 1 | 18094 | 49 |
MFNG |
8.103e-03 | -4.82 | vitamin D response element binding | molecular function | GO:0070644 | 3 | 1 | 18094 | 49 |
RXRA |
8.103e-03 | -4.82 | G protein-coupled ADP receptor activity | molecular function | GO:0001621 | 3 | 1 | 18094 | 49 |
P2RY6 |
8.103e-03 | -4.82 | ganglioside GM1 binding | molecular function | GO:1905573 | 3 | 1 | 18094 | 49 |
PSAP |
8.103e-03 | -4.82 | ICAM-3 receptor activity | molecular function | GO:0030369 | 3 | 1 | 18094 | 49 |
ITGB2 |
8.103e-03 | -4.82 | G protein-coupled UTP receptor activity | molecular function | GO:0045030 | 3 | 1 | 18094 | 49 |
P2RY6 |
8.103e-03 | -4.82 | DNA binding domain binding | molecular function | GO:0050692 | 3 | 1 | 18094 | 49 |
RXRA |
8.206e-03 | -4.80 | CLEC7A (C-type lectin domain containing 7A) | protein interactions | 64581 | 53 | 2 | 19454 | 50 |
ADAM33,CD74 |
8.206e-03 | -4.80 | FCGR2A (Fc gamma receptor IIa) | protein interactions | 2212 | 53 | 2 | 19454 | 50 |
ADAM33,HCK |
8.238e-03 | -4.80 | Phe_ZIP | pfam domains | PF08916 | 3 | 1 | 17795 | 49 |
SH2B3 |
8.238e-03 | -4.80 | SapA | pfam domains | PF02199 | 3 | 1 | 17795 | 49 |
PSAP |
8.238e-03 | -4.80 | ELMO_ARM | pfam domains | PF11841 | 3 | 1 | 17795 | 49 |
ELMO1 |
8.238e-03 | -4.80 | SapB_1 | pfam domains | PF05184 | 3 | 1 | 17795 | 49 |
PSAP |
8.238e-03 | -4.80 | hSH3 | pfam domains | PF14603 | 3 | 1 | 17795 | 49 |
FYB1 |
8.238e-03 | -4.80 | ITGAX-like_Ig_3 | pfam domains | PF21520 | 3 | 1 | 17795 | 49 |
ITGAX |
8.293e-03 | -4.79 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 34 | 16828 | 44 |
CSF1R,PSAP,PLXNC1,RASGRP2,ABR,PREX1,ITGB2,SPOCK3,THRB,CSF3R,DOCK2,VMP1,NCAM2,RBM47,GAB1,MFNG,SMPD4,RAC2,MYO1F,SNX17,PLXND1,HCK,DPYD,P2RY6,ANKRD44,ADAM33,ELMO1,ITGAX,SH2B3,CPN1,MLKL,MAP3K11,SLCO2B1,MARCO |
8.320e-03 | -4.79 | regulation of bone remodeling | biological process | GO:0046850 | 51 | 2 | 18204 | 49 |
CSF1R,INPP5D |
8.377e-03 | -4.78 | myeloid leukocyte activation | biological process | GO:0002274 | 155 | 3 | 18204 | 49 |
DOCK2,ITGB2,PREX1 |
8.382e-03 | -4.78 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 34 | 16828 | 44 |
THRB,CSF3R,VMP1,DOCK2,NCAM2,RBM47,GAB1,MFNG,SMPD4,RAC2,CSF1R,PSAP,PLXNC1,RASGRP2,ABR,PREX1,ITGB2,SPOCK3,CPN1,MLKL,MAP3K11,SLCO2B1,MARCO,SNX17,MYO1F,PLXND1,DPYD,HCK,ANKRD44,P2RY6,ADAM33,ELMO1,ITGAX,SH2B3 |
8.390e-03 | -4.78 | regulation of biological quality | biological process | GO:0065008 | 2936 | 15 | 18204 | 49 |
HCK,ENTPD1,SH2B3,PREX1,ITGB2,THRB,PLEK,ZFP36L1,VMP1,PLXNC1,RBM47,PLXND1,CSF1R,CMTM6,CYFIP1 |
8.401e-03 | -4.78 | CYTOFMRPINTP | prints domains | PR01698 | 2 | 1 | 5227 | 22 |
CYFIP1 |
8.401e-03 | -4.78 | NCAMFAMILY | prints domains | PR01838 | 2 | 1 | 5227 | 22 |
NCAM2 |
8.484e-03 | -4.77 | GRAMD1A (GRAM domain containing 1A) | protein interactions | 57655 | 163 | 3 | 19454 | 50 |
CD74,P2RY6,UNC93B1 |
8.484e-03 | -4.77 | DNAJB12 (DnaJ heat shock protein family (Hsp40) member B12) | protein interactions | 54788 | 163 | 3 | 19454 | 50 |
UNC93B1,P2RY6,CD74 |
8.497e-03 | -4.77 | SEC62 (SEC62 homolog, preprotein translocation factor) | protein interactions | 7095 | 493 | 5 | 19454 | 50 |
UNC93B1,MFNG,P2RY6,VMP1,SMPD4 |
8.507e-03 | -4.77 | LCP2 (lymphocyte cytosolic protein 2) | protein interactions | 3937 | 54 | 2 | 19454 | 50 |
HCK,FYB1 |
8.525e-03 | -4.76 | protein autophosphorylation | biological process | GO:0046777 | 156 | 3 | 18204 | 49 |
MAP3K11,CSF1R,HCK |
8.604e-03 | -4.76 | cell motility | biological process | GO:0048870 | 1101 | 8 | 18204 | 49 |
CSF3R,GAB1,ELMO1,ITGB2,DOCK2,PREX1,PLXND1,HCK |
8.639e-03 | -4.75 | positive regulation of MAPK cascade | biological process | GO:0043410 | 473 | 5 | 18204 | 49 |
MARCO,CSF1R,CD74,P2RY6,MAP3K11 |
8.672e-03 | -4.75 | protein complex involved in cell adhesion | cellular component | GO:0098636 | 57 | 2 | 19108 | 47 |
ITGB2,ITGAX |
8.689e-03 | -4.75 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 24 | 16828 | 44 |
MARCO,ITM2B,ZFP36L1,SLCO2B1,ADAM33,ELMO1,ANKRD44,MYO1F,SNX17,PLXND1,HCK,DPYD,MFNG,SMPD4,RBM47,DOCK2,VMP1,CSF3R,SPOCK3,RXRA,ABR,PREX1,PLXNC1,RASGRP2 |
8.729e-03 | -4.74 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 24 | 16828 | 44 |
SLCO2B1,MARCO,ITM2B,ZFP36L1,ANKRD44,MYO1F,SNX17,PLXND1,HCK,DPYD,ADAM33,ELMO1,VMP1,DOCK2,CSF3R,MFNG,SMPD4,RBM47,PLXNC1,RASGRP2,SPOCK3,RXRA,ABR,PREX1 |
8.739e-03 | -4.74 | nuclear receptor activity | molecular function | GO:0004879 | 52 | 2 | 18094 | 49 |
RXRA,THRB |
8.755e-03 | -4.74 | immune response-activating signaling pathway | biological process | GO:0002757 | 302 | 4 | 18204 | 49 |
FYB1,HCK,UNC93B1,INPP5D |
8.771e-03 | -4.74 | RASA1 (RAS p21 protein activator 1) | protein interactions | 5921 | 165 | 3 | 19454 | 50 |
CSF1R,GAB1,HCK |
8.771e-03 | -4.74 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myeloproliferative_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myeloproliferative_neoplasm | 54 | 2 | 16828 | 44 |
SH2B3,CSF3R |
8.771e-03 | -4.74 | myeloproliferative_neoplasm | COSMIC cancer mutations | myeloproliferative_neoplasm | 54 | 2 | 16828 | 44 |
SH2B3,CSF3R |
8.789e-03 | -4.73 | regulation of MAPK cascade | biological process | GO:0043408 | 669 | 6 | 18204 | 49 |
CSF1R,P2RY6,CD74,MARCO,SH2B3,MAP3K11 |
8.814e-03 | -4.73 | DOCK1 (dedicator of cytokinesis 1) | protein interactions | 1793 | 55 | 2 | 19454 | 50 |
ELMO1,RAC2 |
8.843e-03 | -4.73 | LGALS1 (galectin 1) | protein interactions | 3956 | 317 | 4 | 19454 | 50 |
RAC2,PLXND1,HCK,CD68 |
8.915e-03 | -4.72 | positive regulation of signal transduction | biological process | GO:0009967 | 1593 | 10 | 18204 | 49 |
MARCO,RBM47,MAP3K11,RXRA,THRB,MFNG,CSF1R,CYFIP1,P2RY6,CD74 |
8.917e-03 | -4.72 | TBL2 (transducin beta like 2) | protein interactions | 26608 | 166 | 3 | 19454 | 50 |
UNC93B1,P2RY6,RAC2 |
8.917e-03 | -4.72 | CPD (carboxypeptidase D) | protein interactions | 1362 | 166 | 3 | 19454 | 50 |
CSF1R,CPN1,RAC2 |
8.917e-03 | -4.72 | STT3A (STT3 oligosaccharyltransferase complex catalytic subunit A) | protein interactions | 3703 | 166 | 3 | 19454 | 50 |
UNC93B1,P2RY6,RAC2 |
8.926e-03 | -4.72 | CBL (Cbl proto-oncogene) | protein interactions | 867 | 499 | 5 | 19454 | 50 |
HCK,CSF1R,INPP5D,FYB1,MAP3K11 |
8.962e-03 | -4.71 | regulation of platelet activation | biological process | GO:0010543 | 53 | 2 | 18204 | 49 |
PLEK,SH2B3 |
8.962e-03 | -4.71 | regulation of lamellipodium organization | biological process | GO:1902743 | 53 | 2 | 18204 | 49 |
RAC2,CYFIP1 |
8.975e-03 | -4.71 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 35 | 16828 | 44 |
PREX1,TNFAIP8L2,ABR,SPOCK3,ITGB2,PLXNC1,RASGRP2,CSF1R,PSAP,PLEK,SMPD4,RAC2,GAB1,CSF3R,THRB,NCAM2,VMP1,DOCK2,ADAM33,ELMO1,ITGAX,DPYD,HCK,MYO1F,SNX17,PLXND1,ANKRD44,P2RY6,ENTPD1,ZFP36L1,MARCO,ITM2B,SLCO2B1,CPN1,MLKL |
8.975e-03 | -4.71 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 35 | 16828 | 44 |
CPN1,MLKL,SLCO2B1,MARCO,ITM2B,ZFP36L1,MYO1F,SNX17,PLXND1,HCK,DPYD,ENTPD1,ANKRD44,P2RY6,ADAM33,ELMO1,ITGAX,THRB,CSF3R,VMP1,DOCK2,NCAM2,PLEK,GAB1,RAC2,SMPD4,CSF1R,PSAP,PLXNC1,RASGRP2,TNFAIP8L2,ABR,PREX1,ITGB2,SPOCK3 |
9.063e-03 | -4.70 | CIP2A (cellular inhibitor of PP2A) | protein interactions | 57650 | 167 | 3 | 19454 | 50 |
P2RY6,MFNG,UNC93B1 |
9.063e-03 | -4.70 | MACO1 (macoilin 1) | protein interactions | 55219 | 167 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
9.066e-03 | -4.70 | ligand-activated transcription factor activity | molecular function | GO:0098531 | 53 | 2 | 18094 | 49 |
THRB,RXRA |
9.095e-03 | -4.70 | - | gene3d domains | 3.30.70.20 | 3 | 1 | 14470 | 44 |
DPYD |
9.095e-03 | -4.70 | - | gene3d domains | 1.20.80.60 | 3 | 1 | 14470 | 44 |
SNX17 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.810 | 3 | 1 | 14470 | 44 |
ELMO1 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.140.110 | 3 | 1 | 14470 | 44 |
SH2B3 |
9.212e-03 | -4.69 | GAB1 (GRB2 associated binding protein 1) | protein interactions | 2549 | 168 | 3 | 19454 | 50 |
INPP5D,GAB1,HCK |
9.212e-03 | -4.69 | KLK10 (kallikrein related peptidase 10) | protein interactions | 5655 | 168 | 3 | 19454 | 50 |
RAC2,ITGB2,MYO1F |
9.212e-03 | -4.69 | NUP133 (nucleoporin 133) | protein interactions | 55746 | 168 | 3 | 19454 | 50 |
UNC93B1,P2RY6,PSAP |
9.290e-03 | -4.68 | regulation of alcohol biosynthetic process | biological process | GO:1902930 | 54 | 2 | 18204 | 49 |
P2RY6,PLEK |
9.301e-03 | -4.68 | regulation of response to external stimulus | biological process | GO:0032101 | 1116 | 8 | 18204 | 49 |
CSF1R,CD74,RBM47,UNC93B1,HCK,TNFAIP8L2,RAC2,SH2B3 |
9.328e-03 | -4.67 | Retinoid X Receptor | gene3d domains | 1.10.565.10 | 48 | 2 | 14470 | 44 |
RXRA,THRB |
9.329e-03 | -4.67 | ITGB1 (integrin subunit beta 1) | protein interactions | 3688 | 322 | 4 | 19454 | 50 |
SNX17,RXRA,P2RY6,RAC2 |
9.429e-03 | -4.66 | ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) | protein interactions | 488 | 323 | 4 | 19454 | 50 |
RMC1,UNC93B1,VMP1,P2RY6 |
9.442e-03 | -4.66 | ICAM2 (intercellular adhesion molecule 2) | protein interactions | 3384 | 57 | 2 | 19454 | 50 |
ITM2B,ITGB2 |
9.442e-03 | -4.66 | CSF1R (colony stimulating factor 1 receptor) | protein interactions | 1436 | 57 | 2 | 19454 | 50 |
INPP5D,CSF1R |
9.442e-03 | -4.66 | EVI5L (ecotropic viral integration site 5 like) | protein interactions | 115704 | 57 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
9.442e-03 | -4.66 | FXN (frataxin) | protein interactions | 2395 | 57 | 2 | 19454 | 50 |
DAPP1,PSAP |
9.442e-03 | -4.66 | KNG1 (kininogen 1) | protein interactions | 3827 | 57 | 2 | 19454 | 50 |
ITGB2,CPN1 |
9.513e-03 | -4.66 | GLMN (glomulin, FKBP associated protein) | protein interactions | 11146 | 170 | 3 | 19454 | 50 |
UNC93B1,MFNG,PSAP |
9.513e-03 | -4.66 | PIK3C2A (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha) | protein interactions | 5286 | 170 | 3 | 19454 | 50 |
RBM47,RAC2,P2RY6 |
9.513e-03 | -4.66 | BZW1 (basic leucine zipper and W2 domains 1) | protein interactions | 9689 | 170 | 3 | 19454 | 50 |
PREX1,P2RY6,UNC93B1 |
9.521e-03 | -4.65 | RHOU (ras homolog family member U) | protein interactions | 58480 | 507 | 5 | 19454 | 50 |
GAB1,CYFIP1,ITM2B,PLEK,SNX17 |
9.579e-03 | -4.65 | human chr11q13.4 | chromosome location | human chr11q13.4 | 77 | 2 | 26134 | 50 |
P2RY6,SLCO2B1 |
9.606e-03 | -4.65 | receptor-mediated endocytosis | biological process | GO:0006898 | 163 | 3 | 18204 | 49 |
MARCO,SNX17,ITGB2 |
9.630e-03 | -4.64 | CYB5R3 (cytochrome b5 reductase 3) | protein interactions | 1727 | 325 | 4 | 19454 | 50 |
RAC2,ADAM33,VMP1,UNC93B1 |
9.665e-03 | -4.64 | PLSCR1 (phospholipid scramblase 1) | protein interactions | 5359 | 171 | 3 | 19454 | 50 |
MFNG,DOCK2,P2RY6 |
9.680e-03 | -4.64 | response to other organism | biological process | GO:0051707 | 1363 | 9 | 18204 | 49 |
MLKL,CD68,CSF1R,CD74,TNFAIP8L2,ITGAX,UNC93B1,HCK,MARCO |
9.758e-03 | -4.63 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 15 | 16828 | 44 |
ELMO1,PREX1,ITGAX,SPOCK3,CSF1R,DPYD,RASGRP2,ANKRD44,RBM47,GAB1,SMPD4,THRB,SLCO2B1,DOCK2,NCAM2 |
9.763e-03 | -4.63 | NAXE (NAD(P)HX epimerase) | protein interactions | 128240 | 58 | 2 | 19454 | 50 |
DPYD,SNX17 |
9.763e-03 | -4.63 | SELENOF (selenoprotein F) | protein interactions | 9403 | 58 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
9.763e-03 | -4.63 | MAP3K11 (mitogen-activated protein kinase kinase kinase 11) | protein interactions | 4296 | 58 | 2 | 19454 | 50 |
MAP3K11,RAC2 |
9.767e-03 | -4.63 | positive regulation of leukocyte proliferation | biological process | GO:0070665 | 164 | 3 | 18204 | 49 |
CSF1R,CD74,RAC2 |
9.767e-03 | -4.63 | negative regulation of lymphocyte activation | biological process | GO:0051250 | 164 | 3 | 18204 | 49 |
INPP5D,TNFAIP8L2,CD74 |
9.803e-03 | -4.63 | central region of growth cone | cellular component | GO:0090724 | 4 | 1 | 19108 | 47 |
CYFIP1 |
9.806e-03 | -4.62 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 35 | 16828 | 44 |
PLXND1,SNX17,MYO1F,DPYD,ENTPD1,ANKRD44,P2RY6,ELMO1,ADAM33,ITGAX,SH2B3,MAP3K11,MLKL,CPN1,SLCO2B1,MARCO,CD68,CD74,DAPP1,PSAP,CSF1R,PLXNC1,CMTM6,RXRA,PREX1,SPOCK3,THRB,CSF3R,DOCK2,VMP1,NCAM2,PLEK,GAB1,SMPD4,RAC2 |
9.806e-03 | -4.62 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 35 | 16828 | 44 |
NCAM2,DOCK2,VMP1,CSF3R,THRB,SMPD4,RAC2,GAB1,PLEK,CMTM6,PLXNC1,CSF1R,DAPP1,PSAP,SPOCK3,PREX1,RXRA,SLCO2B1,CPN1,MAP3K11,MLKL,CD74,CD68,MARCO,P2RY6,ANKRD44,ENTPD1,DPYD,MYO1F,SNX17,PLXND1,ITGAX,SH2B3,ADAM33,ELMO1 |
9.814e-03 | -4.62 | response to external biotic stimulus | biological process | GO:0043207 | 1366 | 9 | 18204 | 49 |
ITGAX,TNFAIP8L2,MARCO,UNC93B1,HCK,CD74,MLKL,CSF1R,CD68 |
9.838e-03 | -4.62 | leading edge membrane | cellular component | GO:0031256 | 180 | 3 | 19108 | 47 |
PLXND1,PLEK,RASGRP2 |
9.881e-03 | -4.62 | ficolin-1-rich granule membrane | cellular component | GO:0101003 | 61 | 2 | 19108 | 47 |
ITGB2,ITGAX |
9.898e-03 | -4.62 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 11 | 16828 | 44 |
DOCK2,NCAM2,ANKRD44,CPN1,PLXND1,PLXNC1,DPYD,GAB1,RAC2,MARCO,PREX1 |
9.907e-03 | -4.61 | KPNB1 (karyopherin subunit beta 1) | protein interactions | 3837 | 512 | 5 | 19454 | 50 |
UNC93B1,THRB,CD74,SMPD4,P2RY6 |
9.956e-03 | -4.61 | UTP and CTP dephosphorylation I | BIOCYC pathways | META_PWY-7185 | 3 | 1 | 902 | 3 |
ENTPD1 |
9.956e-03 | -4.61 | UTP and CTP dephosphorylation II | BIOCYC pathways | META_PWY-7177 | 3 | 1 | 902 | 3 |
ENTPD1 |
9.956e-03 | -4.61 | uracil degradation I (reductive) | BIOCYC pathways | META_PWY-3982 | 3 | 1 | 902 | 3 |
DPYD |
9.956e-03 | -4.61 | thymine degradation | BIOCYC pathways | HUMAN_PWY-6430 | 3 | 1 | 902 | 3 |
DPYD |
9.956e-03 | -4.61 | uracil degradation | BIOCYC pathways | HUMAN_PWY-3982 | 3 | 1 | 902 | 3 |
DPYD |
9.964e-03 | -4.61 | leukocyte cell-cell adhesion | biological process | GO:0007159 | 56 | 2 | 18204 | 49 |
ITGB2,RAC2 |
9.972e-03 | -4.61 | larynx | COSMIC cancer mutations | larynx | 1948 | 11 | 16828 | 44 |
PREX1,MARCO,RAC2,GAB1,PLXNC1,DPYD,CPN1,PLXND1,NCAM2,ANKRD44,DOCK2 |
1.001e-02 | -4.60 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 9 | 16828 | 44 |
PLXNC1,DPYD,NCAM2,DOCK2,PLEK,ELMO1,SMPD4,RAC2,CD74 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
RXRA,THRB |
1.003e-02 | -4.60 | regulation of transport | biological process | GO:0051049 | 1621 | 10 | 18204 | 49 |
P2RY6,CYFIP1,CD74,DOCK2,SNX17,VMP1,ITGB2,RAC2,RXRA,HCK |
1.009e-02 | -4.60 | CNNM4 (cyclin and CBS domain divalent metal cation transport mediator 4) | protein interactions | 26504 | 59 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
1.009e-02 | -4.60 | lymphocyte mediated immunity | biological process | GO:0002449 | 166 | 3 | 18204 | 49 |
CD74,INPP5D,UNC93B1 |
1.011e-02 | -4.59 | Nuclear Receptors | WikiPathways | WP170 | 39 | 2 | 5310 | 21 |
RXRA,THRB |
1.013e-02 | -4.59 | SURF4 (surfeit 4) | protein interactions | 6836 | 174 | 3 | 19454 | 50 |
PSAP,P2RY6,UNC93B1 |
1.013e-02 | -4.59 | SLC1A1 (solute carrier family 1 member 1) | protein interactions | 6505 | 174 | 3 | 19454 | 50 |
SNX17,CMTM6,VMP1 |
1.014e-02 | -4.59 | anion binding | molecular function | GO:0043168 | 2412 | 13 | 18094 | 49 |
RXRA,RAC2,DAPP1,HCK,PLEK,MYO1F,ENTPD1,MLKL,CSF1R,ITM2B,DPYD,MAP3K11,PSAP |
1.019e-02 | -4.59 | specific granule lumen | cellular component | GO:0035580 | 62 | 2 | 19108 | 47 |
CYFIP1,DOCK2 |
1.024e-02 | -4.58 | FCGR1BP (Fc gamma receptor Ib, pseudogene) | protein interactions | 2210 | 4 | 1 | 19454 | 50 |
INPP5D |
1.024e-02 | -4.58 | Map6 (microtubule-associated protein 6) | protein interactions | 29457 | 4 | 1 | 19454 | 50 |
PLXND1 |
1.024e-02 | -4.58 | Hdac2 (histone deacetylase 2) | protein interactions | 15182 | 4 | 1 | 19454 | 50 |
THRB |
1.024e-02 | -4.58 | EPGN (epithelial mitogen) | protein interactions | 255324 | 4 | 1 | 19454 | 50 |
ADAM33 |
1.030e-02 | -4.58 | nucleoside-triphosphatase regulator activity | molecular function | GO:0060589 | 491 | 5 | 18094 | 49 |
PREX1,RASGRP2,ABR,DOCK2,ELMO1 |
1.030e-02 | -4.58 | GTPase regulator activity | molecular function | GO:0030695 | 491 | 5 | 18094 | 49 |
RASGRP2,PREX1,DOCK2,ABR,ELMO1 |
1.031e-02 | -4.57 | regulation of myeloid leukocyte mediated immunity | biological process | GO:0002886 | 57 | 2 | 18204 | 49 |
RAC2,ITGB2 |
1.035e-02 | -4.57 | SEC63 (SEC63 homolog, protein translocation regulator) | protein interactions | 11231 | 332 | 4 | 19454 | 50 |
RBM47,P2RY6,SMPD4,UNC93B1 |
1.042e-02 | -4.56 | haematopoietic_and_lymphoid_tissue-other-idiopathic_erythrocytosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-other-idiopathic_erythrocytosis | 4 | 1 | 16828 | 44 |
SH2B3 |
1.042e-02 | -4.56 | idiopathic_erythrocytosis | COSMIC cancer mutations | idiopathic_erythrocytosis | 4 | 1 | 16828 | 44 |
SH2B3 |
1.042e-02 | -4.56 | DOCK2 (dedicator of cytokinesis 2) | protein interactions | 1794 | 60 | 2 | 19454 | 50 |
RAC2,ELMO1 |
1.044e-02 | -4.56 | ruffle | cellular component | GO:0001726 | 184 | 3 | 19108 | 47 |
PLEK,RASGRP2,CYFIP1 |
1.046e-02 | -4.56 | SAPA | smart domains | SM00162 | 3 | 1 | 9717 | 34 |
PSAP |
1.049e-02 | -4.56 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 27 | 16828 | 44 |
SMPD4,RAC2,GAB1,PLEK,RBM47,DOCK2,VMP1,THRB,SPOCK3,PREX1,ABR,RXRA,RASGRP2,PLXNC1,CSF1R,CD74,ITM2B,SLCO2B1,MLKL,ITGAX,ELMO1,ADAM33,ANKRD44,P2RY6,DPYD,PLXND1,MYO1F |
1.049e-02 | -4.56 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 27 | 16828 | 44 |
PLEK,RBM47,SMPD4,RAC2,GAB1,THRB,DOCK2,VMP1,PREX1,ABR,RXRA,SPOCK3,RASGRP2,PLXNC1,CSF1R,ITM2B,CD74,SLCO2B1,MLKL,ELMO1,ADAM33,ITGAX,DPYD,PLXND1,MYO1F,P2RY6,ANKRD44 |
1.055e-02 | -4.55 | SAP_A | prosite domains | PS51110 | 3 | 1 | 12186 | 43 |
PSAP |
1.055e-02 | -4.55 | LAMP_2 | prosite domains | PS00311 | 3 | 1 | 12186 | 43 |
CD68 |
1.056e-02 | -4.55 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 13 | 16828 | 44 |
SMPD4,GAB1,NCAM2,DOCK2,SLCO2B1,THRB,ITGAX,PREX1,ELMO1,ANKRD44,RASGRP2,DPYD,CSF1R |
1.063e-02 | -4.54 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 6 | 18204 | 49 |
P2RY6,PLEK,MAP3K11,CD74,MARCO,CSF1R |
1.063e-02 | -4.54 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 6 | 18204 | 49 |
CSF1R,MARCO,CD74,P2RY6,PLEK,MAP3K11 |
1.069e-02 | -4.54 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 9 | 18204 | 49 |
PLXNC1,ITGAX,RXRA,PLXND1,INPP5D,CYFIP1,ZFP36L1,GAB1,CD74 |
1.071e-02 | -4.54 | small_intestine-carcinoid-endocrine_tumour | COSMIC cancer mutations | small_intestine-carcinoid-endocrine_tumour | 175 | 3 | 16828 | 44 |
PLXND1,CSF1R,VMP1 |
1.072e-02 | -4.54 | respiratory burst after phagocytosis | biological process | GO:0045728 | 4 | 1 | 18204 | 49 |
HCK |
1.072e-02 | -4.54 | positive regulation of neutrophil degranulation | biological process | GO:0043315 | 4 | 1 | 18204 | 49 |
ITGB2 |
1.072e-02 | -4.54 | negative regulation of female receptivity | biological process | GO:0007621 | 4 | 1 | 18204 | 49 |
THRB |
1.072e-02 | -4.54 | CMP catabolic process | biological process | GO:0006248 | 4 | 1 | 18204 | 49 |
DPYD |
1.072e-02 | -4.54 | erythrocyte enucleation | biological process | GO:0043131 | 4 | 1 | 18204 | 49 |
RAC2 |
1.072e-02 | -4.54 | positive regulation of mast cell proliferation | biological process | GO:0070668 | 4 | 1 | 18204 | 49 |
RAC2 |
1.072e-02 | -4.54 | dichotomous subdivision of terminal units involved in salivary gland branching | biological process | GO:0060666 | 4 | 1 | 18204 | 49 |
PLXND1 |
1.072e-02 | -4.54 | regulation of inositol trisphosphate biosynthetic process | biological process | GO:0032960 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | negative regulation of mature B cell apoptotic process | biological process | GO:0002906 | 4 | 1 | 18204 | 49 |
CD74 |
1.072e-02 | -4.54 | negative regulation of dendritic cell antigen processing and presentation | biological process | GO:0002605 | 4 | 1 | 18204 | 49 |
CD68 |
1.072e-02 | -4.54 | macrophage colony-stimulating factor signaling pathway | biological process | GO:0038145 | 4 | 1 | 18204 | 49 |
CSF1R |
1.072e-02 | -4.54 | positive regulation of inositol trisphosphate biosynthetic process | biological process | GO:0032962 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | enucleate erythrocyte maturation | biological process | GO:0043354 | 4 | 1 | 18204 | 49 |
RAC2 |
1.072e-02 | -4.54 | regulation of mature B cell apoptotic process | biological process | GO:0002905 | 4 | 1 | 18204 | 49 |
CD74 |
1.072e-02 | -4.54 | positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | biological process | GO:0031587 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | regulation of intracellular mRNA localization | biological process | GO:1904580 | 4 | 1 | 18204 | 49 |
ZFP36L1 |
1.072e-02 | -4.54 | enucleation | biological process | GO:0090601 | 4 | 1 | 18204 | 49 |
RAC2 |
1.072e-02 | -4.54 | mast cell proliferation | biological process | GO:0070662 | 4 | 1 | 18204 | 49 |
RAC2 |
1.076e-02 | -4.53 | VTT_dom | interpro domains | IPR032816 | 4 | 1 | 18521 | 50 |
VMP1 |
1.076e-02 | -4.53 | TNFAIP8_sf | interpro domains | IPR038355 | 4 | 1 | 18521 | 50 |
TNFAIP8L2 |
1.076e-02 | -4.53 | SapB_2 | interpro domains | IPR008138 | 4 | 1 | 18521 | 50 |
PSAP |
1.076e-02 | -4.53 | 4Fe4S_Fe_S_CS | interpro domains | IPR017900 | 4 | 1 | 18521 | 50 |
DPYD |
1.076e-02 | -4.53 | Gab1-4-like | interpro domains | IPR046355 | 4 | 1 | 18521 | 50 |
GAB1 |
1.076e-02 | -4.53 | TNFAIP8-like | interpro domains | IPR008477 | 4 | 1 | 18521 | 50 |
TNFAIP8L2 |
1.076e-02 | -4.53 | MLK1-4 | interpro domains | IPR016231 | 4 | 1 | 18521 | 50 |
MAP3K11 |
1.076e-02 | -4.53 | Retinoid-X_rcpt/HNF4 | interpro domains | IPR000003 | 4 | 1 | 18521 | 50 |
RXRA |
1.076e-02 | -4.53 | ThyrH_rcpt | interpro domains | IPR001728 | 4 | 1 | 18521 | 50 |
THRB |
1.076e-02 | -4.53 | CYRIA/CYRIB_Rac1-bd | interpro domains | IPR009828 | 4 | 1 | 18521 | 50 |
CYFIP1 |
1.076e-02 | -4.53 | IgC2-like_lig-bd | interpro domains | IPR010457 | 4 | 1 | 18521 | 50 |
CSF3R |
1.076e-02 | -4.53 | Adaptor_Cbl_N_dom_sf | interpro domains | IPR036537 | 4 | 1 | 18521 | 50 |
MLKL |
1.076e-02 | -4.53 | VPS8 (VPS8 subunit of CORVET complex) | protein interactions | 23355 | 61 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.079e-02 | -4.53 | CDP phosphatase activity | molecular function | GO:0036384 | 4 | 1 | 18094 | 49 |
ENTPD1 |
1.079e-02 | -4.53 | nucleobase binding | molecular function | GO:0002054 | 4 | 1 | 18094 | 49 |
DPYD |
1.079e-02 | -4.53 | stem cell factor receptor binding | molecular function | GO:0005173 | 4 | 1 | 18094 | 49 |
SH2B3 |
1.079e-02 | -4.53 | G protein-coupled pyrimidinergic nucleotide receptor activity | molecular function | GO:0071553 | 4 | 1 | 18094 | 49 |
P2RY6 |
1.079e-02 | -4.53 | IDP phosphatase activity | molecular function | GO:1990003 | 4 | 1 | 18094 | 49 |
ENTPD1 |
1.081e-02 | -4.53 | human chr22q13.1 | chromosome location | human chr22q13.1 | 82 | 2 | 26134 | 50 |
RAC2,MFNG |
1.097e-02 | -4.51 | Lep_receptor_Ig | pfam domains | PF06328 | 4 | 1 | 17795 | 49 |
CSF3R |
1.097e-02 | -4.51 | DUF758 | pfam domains | PF05527 | 4 | 1 | 17795 | 49 |
TNFAIP8L2 |
1.097e-02 | -4.51 | SNARE_assoc | pfam domains | PF09335 | 4 | 1 | 17795 | 49 |
VMP1 |
1.097e-02 | -4.51 | CYRIA-B_Rac1-bd | pfam domains | PF07159 | 4 | 1 | 17795 | 49 |
CYFIP1 |
1.097e-02 | -4.51 | SapB_2 | pfam domains | PF03489 | 4 | 1 | 17795 | 49 |
PSAP |
1.100e-02 | -4.51 | NOTCH1 (notch receptor 1) | protein interactions | 4851 | 338 | 4 | 19454 | 50 |
RAC2,MFNG,RMC1,ANKRD44 |
1.105e-02 | -4.51 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_associated_with_MDS | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_associated_with_MDS | 177 | 3 | 16828 | 44 |
SH2B3,CSF3R,CSF1R |
1.105e-02 | -4.51 | acute_myeloid_leukaemia_associated_with_MDS | COSMIC cancer mutations | acute_myeloid_leukaemia_associated_with_MDS | 177 | 3 | 16828 | 44 |
CSF1R,CSF3R,SH2B3 |
1.109e-02 | -4.50 | acute_leukaemia_of_ambiguous_lineage | COSMIC cancer mutations | acute_leukaemia_of_ambiguous_lineage | 61 | 2 | 16828 | 44 |
CSF1R,CSF3R |
1.109e-02 | -4.50 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_leukaemia_of_ambiguous_lineage | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_leukaemia_of_ambiguous_lineage | 61 | 2 | 16828 | 44 |
CSF3R,CSF1R |
1.110e-02 | -4.50 | RNF128 (ring finger protein 128) | protein interactions | 79589 | 62 | 2 | 19454 | 50 |
ITM2B,SNX17 |
1.113e-02 | -4.50 | cell migration | biological process | GO:0016477 | 921 | 7 | 18204 | 49 |
PLXND1,GAB1,CSF3R,DOCK2,HCK,ITGB2,PREX1 |
1.116e-02 | -4.50 | excitatory synapse | cellular component | GO:0060076 | 65 | 2 | 19108 | 47 |
PLXNC1,CYFIP1 |
1.117e-02 | -4.49 | ZnF_C4 | smart domains | SM00399 | 46 | 2 | 9717 | 34 |
RXRA,THRB |
1.121e-02 | -4.49 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 7 | 19454 | 50 |
CYFIP1,GAB1,CD74,ITGB2,NCAM2,P2RY6,ZFP36L1 |
1.122e-02 | -4.49 | protein kinase binding | molecular function | GO:0019901 | 701 | 6 | 18094 | 49 |
MLKL,PLEK,SH2B3,MAP3K11,ITGAX,ITGB2 |
1.126e-02 | -4.49 | regulation of lymphocyte activation | biological process | GO:0051249 | 505 | 5 | 18204 | 49 |
INPP5D,TNFAIP8L2,ZFP36L1,CD74,RAC2 |
1.137e-02 | -4.48 | positive regulation of cytokine-mediated signaling pathway | biological process | GO:0001961 | 60 | 2 | 18204 | 49 |
CD74,RBM47 |
1.140e-02 | -4.47 | CANX (calnexin) | protein interactions | 821 | 1210 | 8 | 19454 | 50 |
P2RY6,PSAP,RMC1,UNC93B1,RAC2,SMPD4,CD74,ITM2B |
1.141e-02 | -4.47 | NUCLEAR_REC_DBD_1 | prosite domains | PS00031 | 46 | 2 | 12186 | 43 |
RXRA,THRB |
1.141e-02 | -4.47 | NUCLEAR_REC_DBD_2 | prosite domains | PS51030 | 46 | 2 | 12186 | 43 |
THRB,RXRA |
1.144e-02 | -4.47 | PRPS1 (phosphoribosyl pyrophosphate synthetase 1) | protein interactions | 5631 | 182 | 3 | 19454 | 50 |
RMC1,HCK,P2RY6 |
1.144e-02 | -4.47 | RAB32 (RAB32, member RAS oncogene family) | protein interactions | 10981 | 63 | 2 | 19454 | 50 |
LRMDA,RAC2 |
1.153e-02 | -4.46 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 9 | 18204 | 49 |
ITGB2,RXRA,CD68,THRB,CPN1,GAB1,P2RY6,CYFIP1,ZFP36L1 |
1.161e-02 | -4.46 | KRTAP1-3 (keratin associated protein 1-3) | protein interactions | 81850 | 183 | 3 | 19454 | 50 |
HCK,INPP5D,DOCK2 |
1.164e-02 | -4.45 | positive regulation of supramolecular fiber organization | biological process | GO:1902905 | 175 | 3 | 18204 | 49 |
HCK,CYFIP1,PLEK |
1.164e-02 | -4.45 | regulation of interleukin-6 production | biological process | GO:0032675 | 175 | 3 | 18204 | 49 |
CD74,UNC93B1,INPP5D |
1.174e-02 | -4.44 | aorta development | biological process | GO:0035904 | 61 | 2 | 18204 | 49 |
PLXND1,SNX17 |
1.174e-02 | -4.44 | negative regulation of G protein-coupled receptor signaling pathway | biological process | GO:0045744 | 61 | 2 | 18204 | 49 |
PLEK,SH2B3 |
1.178e-02 | -4.44 | SAAL1 (serum amyloid A like 1) | protein interactions | 113174 | 184 | 3 | 19454 | 50 |
CD68,UNC93B1,P2RY6 |
1.179e-02 | -4.44 | AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2) | protein interactions | 10555 | 64 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
1.182e-02 | -4.44 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | biological process | GO:0002460 | 176 | 3 | 18204 | 49 |
UNC93B1,INPP5D,CD74 |
1.184e-02 | -4.44 | response to biotic stimulus | biological process | GO:0009607 | 1408 | 9 | 18204 | 49 |
MLKL,CSF1R,CD68,CD74,ITGAX,TNFAIP8L2,MARCO,HCK,UNC93B1 |
1.192e-02 | -4.43 | plasma membrane region | cellular component | GO:0098590 | 1278 | 8 | 19108 | 47 |
ITGB2,RASGRP2,PLEK,P2RY6,ENTPD1,SLCO2B1,PLXND1,HCK |
1.202e-02 | -4.42 | PTPN11 (protein tyrosine phosphatase non-receptor type 11) | protein interactions | 5781 | 347 | 4 | 19454 | 50 |
CSF3R,DAPP1,GAB1,INPP5D |
1.208e-02 | -4.42 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 8 | 16828 | 44 |
ITGAX,ZFP36L1,RXRA,NCAM2,ENTPD1,DOCK2,HCK,DPYD |
1.211e-02 | -4.41 | Tumor necrosis factor alpha-induced protein 8-like | gene3d domains | 1.20.1440.160 | 4 | 1 | 14470 | 44 |
TNFAIP8L2 |
1.211e-02 | -4.41 | Adaptor protein Cbl, N-terminal domain | gene3d domains | 1.20.930.20 | 4 | 1 | 14470 | 44 |
MLKL |
1.211e-02 | -4.41 | positive regulation of myeloid leukocyte differentiation | biological process | GO:0002763 | 62 | 2 | 18204 | 49 |
ZFP36L1,CD74 |
1.212e-02 | -4.41 | HOLI | smart domains | SM00430 | 48 | 2 | 9717 | 34 |
RXRA,THRB |
1.215e-02 | -4.41 | COG5 (component of oligomeric golgi complex 5) | protein interactions | 10466 | 65 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.220e-02 | -4.41 | IL-6 signaling pathway | WikiPathways | WP364 | 43 | 2 | 5310 | 21 |
GAB1,HCK |
1.224e-02 | -4.40 | Mon1-Ccz1 complex | cellular component | GO:0035658 | 5 | 1 | 19108 | 47 |
RMC1 |
1.224e-02 | -4.40 | apolipoprotein B mRNA editing enzyme complex | cellular component | GO:0030895 | 5 | 1 | 19108 | 47 |
RBM47 |
1.226e-02 | -4.40 | SH3_2 | pfam domains | PF07653 | 61 | 2 | 17795 | 49 |
FYB1,DOCK2 |
1.227e-02 | -4.40 | regulation of vesicle-mediated transport | biological process | GO:0060627 | 516 | 5 | 18204 | 49 |
SNX17,RAC2,DOCK2,ITGB2,HCK |
1.238e-02 | -4.39 | SHC1 (SHC adaptor protein 1) | protein interactions | 6464 | 350 | 4 | 19454 | 50 |
CSF3R,CSF1R,INPP5D,GAB1 |
1.238e-02 | -4.39 | EPHA2 (EPH receptor A2) | protein interactions | 1969 | 350 | 4 | 19454 | 50 |
RAC2,GAB1,CSF1R,HCK |
1.238e-02 | -4.39 | NR_LBD | prosite domains | PS51843 | 48 | 2 | 12186 | 43 |
RXRA,THRB |
1.238e-02 | -4.39 | KAZAL_2 | prosite domains | PS51465 | 48 | 2 | 12186 | 43 |
SPOCK3,SLCO2B1 |
1.248e-02 | -4.38 | PIGT (phosphatidylinositol glycan anchor biosynthesis class T) | protein interactions | 51604 | 188 | 3 | 19454 | 50 |
ADAM33,P2RY6,UNC93B1 |
1.250e-02 | -4.38 | HLA-DRB3 (major histocompatibility complex, class II, DR beta 3) | protein interactions | 3125 | 66 | 2 | 19454 | 50 |
ITM2B,CD74 |
1.254e-02 | -4.38 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 44 |
RXRA,THRB |
1.258e-02 | -4.38 | SAPOSIN | prints domains | PR01797 | 3 | 1 | 5227 | 22 |
PSAP |
1.260e-02 | -4.37 | endosome membrane | cellular component | GO:0010008 | 569 | 5 | 19108 | 47 |
ITM2B,CD68,CMTM6,SNX17,RMC1 |
1.263e-02 | -4.37 | regulation of immune response | biological process | GO:0050776 | 944 | 7 | 18204 | 49 |
HCK,UNC93B1,RBM47,FYB1,ITGB2,INPP5D,CD74 |
1.270e-02 | -4.37 | mesothelioma | COSMIC cancer mutations | mesothelioma | 4477 | 19 | 16828 | 44 |
ITGB2,SH2B3,ITGAX,ADAM33,PREX1,ANKRD44,SNX17,CSF1R,HCK,DPYD,RASGRP2,GAB1,MFNG,RAC2,VMP1,CPN1,THRB,MLKL,MAP3K11 |
1.275e-02 | -4.36 | regulation of cytoskeleton organization | biological process | GO:0051493 | 521 | 5 | 18204 | 49 |
CSF1R,HCK,PREX1,PLEK,CYFIP1 |
1.279e-02 | -4.36 | SAMD8 (sterile alpha motif domain containing 8) | protein interactions | 142891 | 5 | 1 | 19454 | 50 |
MFNG |
1.279e-02 | -4.36 | CPN2 (carboxypeptidase N subunit 2) | protein interactions | 1370 | 5 | 1 | 19454 | 50 |
CPN1 |
1.279e-02 | -4.36 | CEMP1 (cementum protein 1) | protein interactions | 752014 | 5 | 1 | 19454 | 50 |
PLXNC1 |
1.279e-02 | -4.36 | Gab2 (growth factor receptor bound protein 2-associated protein 2) | protein interactions | 14389 | 5 | 1 | 19454 | 50 |
INPP5D |
1.279e-02 | -4.36 | ORF48 (ORF48) | protein interactions | 4961458 | 5 | 1 | 19454 | 50 |
ANKRD44 |
1.287e-02 | -4.35 | regulation of B cell proliferation | biological process | GO:0030888 | 64 | 2 | 18204 | 49 |
INPP5D,CD74 |
1.287e-02 | -4.35 | ADAM15 (ADAM metallopeptidase domain 15) | protein interactions | 8751 | 67 | 2 | 19454 | 50 |
ADAM33,HCK |
1.289e-02 | -4.35 | skin-neck-malignant_melanoma | COSMIC cancer mutations | skin-neck-malignant_melanoma | 1223 | 8 | 16828 | 44 |
CSF1R,CPN1,VMP1,MARCO,ADAM33,PREX1,ITGAX,ITGB2 |
1.293e-02 | -4.35 | regulation of cytokine-mediated signaling pathway | biological process | GO:0001959 | 182 | 3 | 18204 | 49 |
RBM47,SH2B3,CD74 |
1.295e-02 | -4.35 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 7 | 16828 | 44 |
ENTPD1,DOCK2,NCAM2,HCK,DPYD,ITGAX,RXRA |
1.310e-02 | -4.34 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 12 | 18204 | 49 |
UNC93B1,ITGB2,MFNG,THRB,ZFP36L1,CSF3R,GAB1,ITGAX,CSF1R,PLXND1,DOCK2,CYFIP1 |
1.311e-02 | -4.33 | DNAJC1 (DnaJ heat shock protein family (Hsp40) member C1) | protein interactions | 64215 | 356 | 4 | 19454 | 50 |
RAC2,SMPD4,P2RY6,UNC93B1 |
1.311e-02 | -4.33 | beta-Alanine Metabolism | SMPDB pathways | SMP0000007 | 9 | 1 | 1369 | 2 |
DPYD |
1.311e-02 | -4.33 | GABA-Transaminase Deficiency | SMPDB pathways | SMP0000351 | 9 | 1 | 1369 | 2 |
DPYD |
1.311e-02 | -4.33 | Carnosinuria- Carnosinemia | SMPDB pathways | SMP0000493 | 9 | 1 | 1369 | 2 |
DPYD |
1.320e-02 | -4.33 | VIPR2 (vasoactive intestinal peptide receptor 2) | protein interactions | 7434 | 192 | 3 | 19454 | 50 |
UNC93B1,SNX17,CMTM6 |
1.320e-02 | -4.33 | UBE3C (ubiquitin protein ligase E3C) | protein interactions | 9690 | 192 | 3 | 19454 | 50 |
P2RY6,CD74,UNC93B1 |
1.324e-02 | -4.32 | SWAP70 (switching B cell complex subunit SWAP70) | protein interactions | 23075 | 68 | 2 | 19454 | 50 |
RAC2,RMC1 |
1.324e-02 | -4.32 | NRBF2 (nuclear receptor binding factor 2) | protein interactions | 29982 | 68 | 2 | 19454 | 50 |
RXRA,THRB |
1.324e-02 | -4.32 | SLC1A3 (solute carrier family 1 member 3) | protein interactions | 6507 | 68 | 2 | 19454 | 50 |
CYFIP1,RAC2 |
1.324e-02 | -4.32 | GEMIN6 (gem nuclear organelle associated protein 6) | protein interactions | 79833 | 68 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
1.326e-02 | -4.32 | UTP and CTP dephosphorylation II | BIOCYC pathways | HUMAN_PWY-7177 | 4 | 1 | 902 | 3 |
ENTPD1 |
1.331e-02 | -4.32 | positive regulation of cytoskeleton organization | biological process | GO:0051495 | 184 | 3 | 18204 | 49 |
PLEK,CYFIP1,HCK |
1.335e-02 | -4.32 | Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate | KEGG pathways | hsa_M00046 | 3 | 1 | 7161 | 32 |
DPYD |
1.335e-02 | -4.32 | Pyrimidine degradation, uracil => beta-alanine, thymine => 3-aminoisobutanoate | KEGG pathways | M00046 | 3 | 1 | 7161 | 32 |
DPYD |
1.335e-02 | -4.32 | PGRMC1 (progesterone receptor membrane component 1) | protein interactions | 10857 | 358 | 4 | 19454 | 50 |
UNC93B1,CD74,VMP1,P2RY6 |
1.337e-02 | -4.31 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 44 |
PREX1,MARCO,ADAM33,ITGB2,ITGAX,CSF1R,CPN1,VMP1 |
1.339e-02 | -4.31 | LTN1 (listerin E3 ubiquitin protein ligase 1) | protein interactions | 26046 | 193 | 3 | 19454 | 50 |
UNC93B1,P2RY6,CD74 |
1.339e-02 | -4.31 | toll-like receptor 7 signaling pathway | biological process | GO:0034154 | 5 | 1 | 18204 | 49 |
UNC93B1 |
1.339e-02 | -4.31 | T cell antigen processing and presentation | biological process | GO:0002457 | 5 | 1 | 18204 | 49 |
UNC93B1 |
1.339e-02 | -4.31 | lymphocyte aggregation | biological process | GO:0071593 | 5 | 1 | 18204 | 49 |
RAC2 |
1.339e-02 | -4.31 | regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | biological process | GO:0031585 | 5 | 1 | 18204 | 49 |
P2RY6 |
1.339e-02 | -4.31 | thymidine metabolic process | biological process | GO:0046104 | 5 | 1 | 18204 | 49 |
DPYD |
1.339e-02 | -4.31 | pyrimidine ribonucleoside monophosphate catabolic process | biological process | GO:0009175 | 5 | 1 | 18204 | 49 |
DPYD |
1.339e-02 | -4.31 | regulation of modification of postsynaptic actin cytoskeleton | biological process | GO:1905274 | 5 | 1 | 18204 | 49 |
CYFIP1 |
1.339e-02 | -4.31 | pyrimidine deoxyribonucleoside metabolic process | biological process | GO:0046125 | 5 | 1 | 18204 | 49 |
DPYD |
1.339e-02 | -4.31 | UMP catabolic process | biological process | GO:0046050 | 5 | 1 | 18204 | 49 |
DPYD |
1.339e-02 | -4.31 | positive regulation of neurotrophin TRK receptor signaling pathway | biological process | GO:0051388 | 5 | 1 | 18204 | 49 |
CYFIP1 |
1.339e-02 | -4.31 | thrombopoietin-mediated signaling pathway | biological process | GO:0038163 | 5 | 1 | 18204 | 49 |
SH2B3 |
1.343e-02 | -4.31 | Lamp2-like_luminal | interpro domains | IPR048528 | 5 | 1 | 18521 | 50 |
CD68 |
1.343e-02 | -4.31 | 4Fe4S_Fe-S-bd | interpro domains | IPR017896 | 5 | 1 | 18521 | 50 |
DPYD |
1.343e-02 | -4.31 | Lysosome-assoc_membr_glycop | interpro domains | IPR002000 | 5 | 1 | 18521 | 50 |
CD68 |
1.343e-02 | -4.31 | Fringe-like_glycosylTrfase | interpro domains | IPR003378 | 5 | 1 | 18521 | 50 |
MFNG |
1.343e-02 | -4.31 | DOCK_N | interpro domains | IPR032376 | 5 | 1 | 18521 | 50 |
DOCK2 |
1.343e-02 | -4.31 | HnRNP_R/Q_splicing_fac | interpro domains | IPR006535 | 5 | 1 | 18521 | 50 |
RBM47 |
1.343e-02 | -4.31 | DOCK_N_sub1 | interpro domains | IPR042455 | 5 | 1 | 18521 | 50 |
DOCK2 |
1.347e-02 | -4.31 | ganglioside binding | molecular function | GO:0035594 | 5 | 1 | 18094 | 49 |
PSAP |
1.347e-02 | -4.31 | phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity | molecular function | GO:0016314 | 5 | 1 | 18094 | 49 |
INPP5D |
1.351e-02 | -4.30 | organophosphate catabolic process | biological process | GO:0046434 | 185 | 3 | 18204 | 49 |
DPYD,SMPD4,ENTPD1 |
1.355e-02 | -4.30 | negative regulation of immune system process | biological process | GO:0002683 | 529 | 5 | 18204 | 49 |
CD68,HCK,INPP5D,TNFAIP8L2,CD74 |
1.357e-02 | -4.30 | CNPY3 (canopy FGF signaling regulator 3) | protein interactions | 10695 | 194 | 3 | 19454 | 50 |
HCK,CD74,VMP1 |
1.360e-02 | -4.30 | lamellipodium | cellular component | GO:0030027 | 203 | 3 | 19108 | 47 |
RAC2,CYFIP1,PLXND1 |
1.361e-02 | -4.30 | YIF1B (Yip1 interacting factor homolog B, membrane trafficking protein) | protein interactions | 90522 | 69 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
1.361e-02 | -4.30 | EVL (Enah/Vasp-like) | protein interactions | 51466 | 69 | 2 | 19454 | 50 |
HCK,FYB1 |
1.364e-02 | -4.29 | homotypic cell-cell adhesion | biological process | GO:0034109 | 66 | 2 | 18204 | 49 |
ENTPD1,PLEK |
1.364e-02 | -4.29 | peptidyl-tyrosine phosphorylation | biological process | GO:0018108 | 66 | 2 | 18204 | 49 |
HCK,CSF1R |
1.369e-02 | -4.29 | PH_19 | pfam domains | PF19057 | 5 | 1 | 17795 | 49 |
ABR |
1.369e-02 | -4.29 | Lamp | pfam domains | PF01299 | 5 | 1 | 17795 | 49 |
CD68 |
1.369e-02 | -4.29 | DOCK_N | pfam domains | PF16172 | 5 | 1 | 17795 | 49 |
DOCK2 |
1.369e-02 | -4.29 | Fringe | pfam domains | PF02434 | 5 | 1 | 17795 | 49 |
MFNG |
1.370e-02 | -4.29 | EMD (emerin) | protein interactions | 2010 | 771 | 6 | 19454 | 50 |
VMP1,SMPD4,P2RY6,RAC2,UNC93B1,RXRA |
1.371e-02 | -4.29 | biological regulation | biological process | GO:0065007 | 12501 | 41 | 18204 | 49 |
THRB,MFNG,SNX17,RMC1,PLEK,ABR,PSAP,ITGB2,PREX1,RAC2,FYB1,SH2B3,MAP3K11,CSF1R,INPP5D,CMTM6,CYFIP1,RBM47,SPOCK3,PLXNC1,CD74,VMP1,P2RY6,GAB1,CSF3R,ZFP36L1,UNC93B1,ENTPD1,HCK,TNFAIP8L2,RASGRP2,ITM2B,CD68,MLKL,DAPP1,PLXND1,DOCK2,MARCO,ITGAX,RXRA,ELMO1 |
1.376e-02 | -4.29 | SGPL1 (sphingosine-1-phosphate lyase 1) | protein interactions | 8879 | 195 | 3 | 19454 | 50 |
P2RY6,CD74,UNC93B1 |
1.380e-02 | -4.28 | Regulation of actin cytoskeleton | KEGG pathways | hsa04810 | 211 | 4 | 7161 | 32 |
ITGAX,ITGB2,RAC2,CYFIP1 |
1.380e-02 | -4.28 | Regulation of actin cytoskeleton | KEGG pathways | ko04810 | 211 | 4 | 7161 | 32 |
ITGB2,ITGAX,RAC2,CYFIP1 |
1.383e-02 | -4.28 | breast-carcinoma-lobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-lobular_carcinoma | 763 | 6 | 16828 | 44 |
RBM47,CSF1R,MLKL,MAP3K11,ZFP36L1,HCK |
1.383e-02 | -4.28 | lobular_carcinoma | COSMIC cancer mutations | lobular_carcinoma | 763 | 6 | 16828 | 44 |
CSF1R,MAP3K11,MLKL,HCK,RBM47,ZFP36L1 |
1.385e-02 | -4.28 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 25 | 18204 | 49 |
PLEK,MFNG,THRB,MAP3K11,PREX1,ITGB2,RAC2,FYB1,CYFIP1,INPP5D,CSF1R,PLXNC1,RBM47,P2RY6,GAB1,ZFP36L1,CD74,VMP1,HCK,UNC93B1,DOCK2,PLXND1,RXRA,ITGAX,MARCO |
1.386e-02 | -4.28 | cytosol | cellular component | GO:0005829 | 5475 | 21 | 19108 | 47 |
PREX1,DPYD,ZFP36L1,MLKL,HCK,CYFIP1,PLEK,FYB1,GAB1,ABR,SNX17,INPP5D,RXRA,ELMO1,SH2B3,MYO1F,RASGRP2,DOCK2,MAP3K11,DAPP1,RAC2 |
1.393e-02 | -4.27 | tertiary granule membrane | cellular component | GO:0070821 | 73 | 2 | 19108 | 47 |
ITGAX,ITGB2 |
1.399e-02 | -4.27 | IL6ST (interleukin 6 cytokine family signal transducer) | protein interactions | 3572 | 70 | 2 | 19454 | 50 |
RAC2,HCK |
1.400e-02 | -4.27 | organelle membrane | cellular component | GO:0031090 | 3742 | 16 | 19108 | 47 |
UNC93B1,MARCO,RAC2,SNX17,ITGAX,ITM2B,ITGB2,CSF3R,MFNG,CD68,SMPD4,CMTM6,RMC1,PSAP,CD74,VMP1 |
1.404e-02 | -4.27 | positive regulation of response to cytokine stimulus | biological process | GO:0060760 | 67 | 2 | 18204 | 49 |
CD74,RBM47 |
1.404e-02 | -4.27 | 4FE4S_FER_1 | prosite domains | PS00198 | 4 | 1 | 12186 | 43 |
DPYD |
1.404e-02 | -4.27 | LAMP_3 | prosite domains | PS51407 | 4 | 1 | 12186 | 43 |
CD68 |
1.406e-02 | -4.26 | innate immune response | biological process | GO:0045087 | 741 | 6 | 18204 | 49 |
UNC93B1,HCK,CSF1R,MARCO,TNFAIP8L2,CD74 |
1.406e-02 | -4.26 | cellular response to lipid | biological process | GO:0071396 | 534 | 5 | 18204 | 49 |
CD68,HCK,ZFP36L1,P2RY6,RXRA |
1.409e-02 | -4.26 | pleura-mesothelioma | COSMIC cancer mutations | pleura-mesothelioma | 4189 | 18 | 16828 | 44 |
ANKRD44,RASGRP2,HCK,DPYD,SNX17,CSF1R,ITGB2,ITGAX,PREX1,ADAM33,VMP1,THRB,CPN1,MLKL,MAP3K11,RAC2,MFNG,GAB1 |
1.410e-02 | -4.26 | intracellular receptor signaling pathway | biological process | GO:0030522 | 188 | 3 | 18204 | 49 |
UNC93B1,THRB,RXRA |
1.427e-02 | -4.25 | RPN1 (ribophorin I) | protein interactions | 6184 | 778 | 6 | 19454 | 50 |
SMPD4,VMP1,RAC2,RMC1,UNC93B1,P2RY6 |
1.433e-02 | -4.25 | NDC1 (NDC1 transmembrane nucleoporin) | protein interactions | 55706 | 198 | 3 | 19454 | 50 |
RAC2,P2RY6,UNC93B1 |
1.436e-02 | -4.24 | Glycosphingolipid metabolism | REACTOME pathways | R-HSA-1660662 | 46 | 2 | 10285 | 41 |
PSAP,SMPD4 |
1.437e-02 | -4.24 | GALK1 (galactokinase 1) | protein interactions | 2584 | 71 | 2 | 19454 | 50 |
RMC1,P2RY6 |
1.437e-02 | -4.24 | HIGD1A (HIG1 hypoxia inducible domain family member 1A) | protein interactions | 25994 | 71 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.439e-02 | -4.24 | Angiopoietin Like Protein 8 Regulatory Pathway | WikiPathways | WP3915 | 132 | 3 | 5310 | 21 |
RXRA,THRB,MAP3K11 |
1.444e-02 | -4.24 | peptidyl-tyrosine modification | biological process | GO:0018212 | 68 | 2 | 18204 | 49 |
HCK,CSF1R |
1.447e-02 | -4.24 | trunk | COSMIC cancer mutations | trunk | 3554 | 16 | 16828 | 44 |
DOCK2,THRB,CSF3R,SMPD4,RBM47,PLEK,ANKRD44,MYO1F,HCK,DPYD,ITGB2,ITGAX,SPOCK3,ADAM33,TNFAIP8L2,ABR |
1.460e-02 | -4.23 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 19 | 16828 | 44 |
CSF1R,SNX17,DPYD,RASGRP2,HCK,ANKRD44,ADAM33,PREX1,ITGAX,ITGB2,MLKL,MAP3K11,THRB,CPN1,DOCK2,VMP1,GAB1,MFNG,RAC2 |
1.460e-02 | -4.23 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 19 | 16828 | 44 |
MLKL,MAP3K11,CPN1,THRB,DOCK2,VMP1,RAC2,GAB1,MFNG,RASGRP2,HCK,DPYD,CSF1R,SNX17,ANKRD44,PREX1,ADAM33,ITGAX,ITGB2 |
1.467e-02 | -4.22 | mRNA editing complex | cellular component | GO:0045293 | 6 | 1 | 19108 | 47 |
RBM47 |
1.470e-02 | -4.22 | regulation of cellular component size | biological process | GO:0032535 | 352 | 4 | 18204 | 49 |
HCK,PREX1,CYFIP1,PLEK |
1.471e-02 | -4.22 | negative regulation of leukocyte activation | biological process | GO:0002695 | 191 | 3 | 18204 | 49 |
INPP5D,TNFAIP8L2,CD74 |
1.476e-02 | -4.22 | FAM234B (family with sequence similarity 234 member B) | protein interactions | 57613 | 72 | 2 | 19454 | 50 |
ITM2B,RAC2 |
1.476e-02 | -4.22 | ITGB2 (integrin subunit beta 2) | protein interactions | 3689 | 72 | 2 | 19454 | 50 |
ITGAX,ITGB2 |
1.476e-02 | -4.22 | PPARGC1A (PPARG coactivator 1 alpha) | protein interactions | 10891 | 72 | 2 | 19454 | 50 |
THRB,RXRA |
1.476e-02 | -4.22 | JMJD1C (jumonji domain containing 1C) | protein interactions | 221037 | 72 | 2 | 19454 | 50 |
RXRA,THRB |
1.511e-02 | -4.19 | Dedicator of cytokinesis N-terminal subdomain | gene3d domains | 1.20.1270.350 | 5 | 1 | 14470 | 44 |
DOCK2 |
1.512e-02 | -4.19 | positive regulation of hemopoiesis | biological process | GO:1903708 | 193 | 3 | 18204 | 49 |
ZFP36L1,CD74,INPP5D |
1.512e-02 | -4.19 | positive regulation of leukocyte differentiation | biological process | GO:1902107 | 193 | 3 | 18204 | 49 |
INPP5D,ZFP36L1,CD74 |
1.515e-02 | -4.19 | PANK4 (pantothenate kinase 4 (inactive)) | protein interactions | 55229 | 73 | 2 | 19454 | 50 |
UNC93B1,RMC1 |
1.515e-02 | -4.19 | TLR9 (toll like receptor 9) | protein interactions | 54106 | 73 | 2 | 19454 | 50 |
INPP5D,UNC93B1 |
1.515e-02 | -4.19 | DAB2IP (DAB2 interacting protein) | protein interactions | 153090 | 73 | 2 | 19454 | 50 |
RAC2,SNX17 |
1.526e-02 | -4.18 | antigen processing and presentation of peptide antigen | biological process | GO:0048002 | 70 | 2 | 18204 | 49 |
CD74,UNC93B1 |
1.530e-02 | -4.18 | CKAP4 (cytoskeleton associated protein 4) | protein interactions | 10970 | 571 | 5 | 19454 | 50 |
RAC2,SMPD4,P2RY6,VMP1,UNC93B1 |
1.531e-02 | -4.18 | CERS2 (ceramide synthase 2) | protein interactions | 29956 | 203 | 3 | 19454 | 50 |
UNC93B1,P2RY6,RAC2 |
1.532e-02 | -4.18 | SLC35E2A (solute carrier family 35 member E2A (pseudogene)) | protein interactions | 9906 | 6 | 1 | 19454 | 50 |
ADAM33 |
1.532e-02 | -4.18 | Ncoa2 (nuclear receptor coactivator 2) | protein interactions | 17978 | 6 | 1 | 19454 | 50 |
RXRA |
1.532e-02 | -4.18 | ITGAX (integrin subunit alpha X) | protein interactions | 3687 | 6 | 1 | 19454 | 50 |
ITGB2 |
1.532e-02 | -4.18 | CD300LF (CD300 molecule like family member f) | protein interactions | 146722 | 6 | 1 | 19454 | 50 |
INPP5D |
1.532e-02 | -4.18 | Bace1 (beta-site APP cleaving enzyme 1) | protein interactions | 23821 | 6 | 1 | 19454 | 50 |
PSAP |
1.533e-02 | -4.18 | regulation of response to cytokine stimulus | biological process | GO:0060759 | 194 | 3 | 18204 | 49 |
SH2B3,CD74,RBM47 |
1.535e-02 | -4.18 | DH-domain | interpro domains | IPR000219 | 70 | 2 | 18521 | 50 |
PREX1,ABR |
1.541e-02 | -4.17 | secretory vesicle | cellular component | GO:0099503 | 1076 | 7 | 19108 | 47 |
ITGAX,CYFIP1,PSAP,CD68,CMTM6,ITGB2,DOCK2 |
1.552e-02 | -4.17 | INPPL1 (inositol polyphosphate phosphatase like 1) | protein interactions | 3636 | 204 | 3 | 19454 | 50 |
CSF1R,INPP5D,GAB1 |
1.552e-02 | -4.17 | VAV1 (vav guanine nucleotide exchange factor 1) | protein interactions | 7409 | 204 | 3 | 19454 | 50 |
GAB1,DOCK2,HCK |
1.554e-02 | -4.16 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 36 | 16828 | 44 |
ITGAX,SH2B3,ELMO1,ADAM33,ENTPD1,ANKRD44,P2RY6,PLXND1,SNX17,MYO1F,DPYD,HCK,CD74,MARCO,CD68,MAP3K11,MLKL,CPN1,SLCO2B1,SPOCK3,RXRA,PREX1,CMTM6,PSAP,DAPP1,CSF1R,PLXNC1,GAB1,SMPD4,RAC2,PLEK,DOCK2,VMP1,NCAM2,THRB,CSF3R |
1.554e-02 | -4.16 | COG1 (component of oligomeric golgi complex 1) | protein interactions | 9382 | 74 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.554e-02 | -4.16 | KCNK1 (potassium two pore domain channel subfamily K member 1) | protein interactions | 3775 | 74 | 2 | 19454 | 50 |
CMTM6,UNC93B1 |
1.554e-02 | -4.16 | TEC (tec protein tyrosine kinase) | protein interactions | 7006 | 74 | 2 | 19454 | 50 |
GAB1,CYFIP1 |
1.554e-02 | -4.16 | CACNA2D1 (calcium voltage-gated channel auxiliary subunit alpha2delta 1) | protein interactions | 781 | 74 | 2 | 19454 | 50 |
VMP1,ITM2B |
1.554e-02 | -4.16 | COG7 (component of oligomeric golgi complex 7) | protein interactions | 91949 | 74 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.565e-02 | -4.16 | STROIDFINGER | prints domains | PR00047 | 46 | 2 | 5227 | 22 |
RXRA,THRB |
1.567e-02 | -4.16 | IL-3 Signaling Pathway | WikiPathways | WP286 | 49 | 2 | 5310 | 21 |
INPP5D,HCK |
1.576e-02 | -4.15 | DBL_dom_sf | interpro domains | IPR035899 | 71 | 2 | 18521 | 50 |
PREX1,ABR |
1.592e-02 | -4.14 | CDKAL1 (CDK5 regulatory subunit associated protein 1 like 1) | protein interactions | 54901 | 206 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
1.592e-02 | -4.14 | RhoGEF | pfam domains | PF00621 | 70 | 2 | 17795 | 49 |
ABR,PREX1 |
1.594e-02 | -4.14 | CHP1 (calcineurin like EF-hand protein 1) | protein interactions | 11261 | 75 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.594e-02 | -4.14 | SPTLC2 (serine palmitoyltransferase long chain base subunit 2) | protein interactions | 9517 | 75 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
1.599e-02 | -4.14 | positive regulation of cell projection organization | biological process | GO:0031346 | 361 | 4 | 18204 | 49 |
RAC2,CYFIP1,PLXNC1,PLXND1 |
1.604e-02 | -4.13 | positive regulation of prostaglandin biosynthetic process | biological process | GO:0031394 | 6 | 1 | 18204 | 49 |
CD74 |
1.604e-02 | -4.13 | regulation of translation at synapse, modulating synaptic transmission | biological process | GO:0099547 | 6 | 1 | 18204 | 49 |
CYFIP1 |
1.604e-02 | -4.13 | dCMP metabolic process | biological process | GO:0046063 | 6 | 1 | 18204 | 49 |
DPYD |
1.604e-02 | -4.13 | positive regulation of macrophage proliferation | biological process | GO:0120041 | 6 | 1 | 18204 | 49 |
CSF1R |
1.604e-02 | -4.13 | regulation of synapse pruning | biological process | GO:1905806 | 6 | 1 | 18204 | 49 |
PLXNC1 |
1.604e-02 | -4.13 | enucleate erythrocyte development | biological process | GO:0048822 | 6 | 1 | 18204 | 49 |
RAC2 |
1.604e-02 | -4.13 | membrane raft distribution | biological process | GO:0031580 | 6 | 1 | 18204 | 49 |
DOCK2 |
1.604e-02 | -4.13 | regulation of translation at postsynapse | biological process | GO:0140245 | 6 | 1 | 18204 | 49 |
CYFIP1 |
1.604e-02 | -4.13 | dUMP catabolic process | biological process | GO:0046079 | 6 | 1 | 18204 | 49 |
DPYD |
1.604e-02 | -4.13 | positive regulation of vitamin D receptor signaling pathway | biological process | GO:0070564 | 6 | 1 | 18204 | 49 |
RXRA |
1.604e-02 | -4.13 | negative regulation of amine metabolic process | biological process | GO:0033239 | 6 | 1 | 18204 | 49 |
ITGB2 |
1.604e-02 | -4.13 | regulation of endothelial tube morphogenesis | biological process | GO:1901509 | 6 | 1 | 18204 | 49 |
ITGAX |
1.604e-02 | -4.13 | deoxyribonucleoside catabolic process | biological process | GO:0046121 | 6 | 1 | 18204 | 49 |
DPYD |
1.604e-02 | -4.13 | dCMP catabolic process | biological process | GO:0006249 | 6 | 1 | 18204 | 49 |
DPYD |
1.604e-02 | -4.13 | sphingomyelin catabolic process | biological process | GO:0006685 | 6 | 1 | 18204 | 49 |
SMPD4 |
1.607e-02 | -4.13 | Host Interactions of HIV factors | REACTOME pathways | R-HSA-162909 | 134 | 3 | 10285 | 41 |
ELMO1,HCK,DOCK2 |
1.608e-02 | -4.13 | external side of plasma membrane | cellular component | GO:0009897 | 396 | 4 | 19108 | 47 |
ITGAX,CSF3R,ITGB2,CD74 |
1.609e-02 | -4.13 | ELMO_dom | interpro domains | IPR006816 | 6 | 1 | 18521 | 50 |
ELMO1 |
1.609e-02 | -4.13 | Integrin_bsu_cyt_dom | interpro domains | IPR014836 | 6 | 1 | 18521 | 50 |
ITGB2 |
1.609e-02 | -4.13 | Saposin-like | interpro domains | IPR011001 | 6 | 1 | 18521 | 50 |
PSAP |
1.609e-02 | -4.13 | positive regulation of chemokine production | biological process | GO:0032722 | 72 | 2 | 18204 | 49 |
CSF1R,CD74 |
1.613e-02 | -4.13 | OPALIN (oligodendrocytic myelin paranodal and inner loop protein) | protein interactions | 93377 | 207 | 3 | 19454 | 50 |
SMPD4,UNC93B1,CMTM6 |
1.614e-02 | -4.13 | thyroid hormone binding | molecular function | GO:0070324 | 6 | 1 | 18094 | 49 |
THRB |
1.614e-02 | -4.13 | CTPase activity | molecular function | GO:0043273 | 6 | 1 | 18094 | 49 |
ENTPD1 |
1.614e-02 | -4.13 | retinoic acid-responsive element binding | molecular function | GO:0044323 | 6 | 1 | 18094 | 49 |
RXRA |
1.614e-02 | -4.13 | ADP phosphatase activity | molecular function | GO:0043262 | 6 | 1 | 18094 | 49 |
ENTPD1 |
1.614e-02 | -4.13 | inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity | molecular function | GO:0052659 | 6 | 1 | 18094 | 49 |
INPP5D |
1.624e-02 | -4.12 | vesicle | cellular component | GO:0031982 | 4141 | 17 | 19108 | 47 |
SNX17,ITM2B,ITGAX,UNC93B1,DOCK2,MARCO,RAC2,RMC1,CD74,PSAP,HCK,CYFIP1,CSF3R,ITGB2,CD68,CMTM6,ENTPD1 |
1.630e-02 | -4.12 | STRDHORMONER | prints domains | PR00398 | 47 | 2 | 5227 | 22 |
RXRA,THRB |
1.633e-02 | -4.11 | PAK2 (p21 (RAC1) activated kinase 2) | protein interactions | 5062 | 208 | 3 | 19454 | 50 |
HCK,DOCK2,RAC2 |
1.635e-02 | -4.11 | PGM3 (phosphoglucomutase 3) | protein interactions | 5238 | 76 | 2 | 19454 | 50 |
P2RY6,SNX17 |
1.635e-02 | -4.11 | CD1B (CD1b molecule) | protein interactions | 910 | 76 | 2 | 19454 | 50 |
PSAP,ITM2B |
1.641e-02 | -4.11 | ELMO_CED12 | pfam domains | PF04727 | 6 | 1 | 17795 | 49 |
ELMO1 |
1.641e-02 | -4.11 | Integrin_B_tail | pfam domains | PF07965 | 6 | 1 | 17795 | 49 |
ITGB2 |
1.641e-02 | -4.11 | Integrin_b_cyt | pfam domains | PF08725 | 6 | 1 | 17795 | 49 |
ITGB2 |
1.652e-02 | -4.10 | endothelial cell migration | biological process | GO:0043542 | 73 | 2 | 18204 | 49 |
PLXND1,GAB1 |
1.654e-02 | -4.10 | ATP1B3 (ATPase Na+/K+ transporting subunit beta 3) | protein interactions | 483 | 209 | 3 | 19454 | 50 |
RAC2,P2RY6,UNC93B1 |
1.656e-02 | -4.10 | superpathway of pyrimidine ribonucleosides degradation | BIOCYC pathways | META_PWY-7209 | 5 | 1 | 902 | 3 |
DPYD |
1.660e-02 | -4.10 | ERBB2 (erb-b2 receptor tyrosine kinase 2) | protein interactions | 2064 | 583 | 5 | 19454 | 50 |
HCK,SH2B3,SMPD4,GAB1,PSAP |
1.671e-02 | -4.09 | cargo receptor activity | molecular function | GO:0038024 | 73 | 2 | 18094 | 49 |
MARCO,ITGB2 |
1.673e-02 | -4.09 | RETINOIDXR | prints domains | PR00545 | 4 | 1 | 5227 | 22 |
RXRA |
1.673e-02 | -4.09 | THYROIDHORMR | prints domains | PR00546 | 4 | 1 | 5227 | 22 |
THRB |
1.673e-02 | -4.09 | LYSASSOCTDMP | prints domains | PR00336 | 4 | 1 | 5227 | 22 |
CD68 |
1.676e-02 | -4.09 | TNS3 (tensin 3) | protein interactions | 64759 | 77 | 2 | 19454 | 50 |
RAC2,GAB1 |
1.676e-02 | -4.09 | ADGRL2 (adhesion G protein-coupled receptor L2) | protein interactions | 23266 | 77 | 2 | 19454 | 50 |
UNC93B1,RAC2 |
1.676e-02 | -4.09 | PALD1 (phosphatase domain containing paladin 1) | protein interactions | 27143 | 77 | 2 | 19454 | 50 |
RAC2,P2RY6 |
1.676e-02 | -4.09 | DYM (dymeclin) | protein interactions | 54808 | 77 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.680e-02 | -4.09 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 9 | 16828 | 44 |
ELMO1,PLEK,SMPD4,RAC2,CD74,DPYD,PLXNC1,NCAM2,DOCK2 |
1.684e-02 | -4.08 | leukocyte activation involved in immune response | biological process | GO:0002366 | 201 | 3 | 18204 | 49 |
MFNG,DOCK2,CD74 |
1.695e-02 | -4.08 | organelle localization by membrane tethering | biological process | GO:0140056 | 74 | 2 | 18204 | 49 |
PLEK,VMP1 |
1.696e-02 | -4.08 | EPHB2 (EPH receptor B2) | protein interactions | 2048 | 211 | 3 | 19454 | 50 |
GAB1,CYFIP1,CSF1R |
1.703e-02 | -4.07 | immune response-regulating signaling pathway | biological process | GO:0002764 | 368 | 4 | 18204 | 49 |
UNC93B1,HCK,INPP5D,FYB1 |
1.703e-02 | -4.07 | activation of immune response | biological process | GO:0002253 | 368 | 4 | 18204 | 49 |
FYB1,INPP5D,HCK,UNC93B1 |
1.705e-02 | -4.07 | cell junction | cellular component | GO:0030054 | 2224 | 11 | 19108 | 47 |
GAB1,RAC2,FYB1,ITGB2,RASGRP2,PLXNC1,HCK,CYFIP1,PLXND1,MLKL,ABR |
1.706e-02 | -4.07 | regulation of protein polymerization | biological process | GO:0032271 | 202 | 3 | 18204 | 49 |
PREX1,CYFIP1,HCK |
1.708e-02 | -4.07 | regulation of localization | biological process | GO:0032879 | 2028 | 11 | 18204 | 49 |
RXRA,CYFIP1,DOCK2,HCK,ITGB2,RAC2,P2RY6,ZFP36L1,CD74,VMP1,SNX17 |
1.709e-02 | -4.07 | human chr12q24.12 | chromosome location | human chr12q24.12 | 9 | 1 | 26134 | 50 |
SH2B3 |
1.709e-02 | -4.07 | cerebellar climbing fiber to Purkinje cell synapse | cellular component | GO:0150053 | 7 | 1 | 19108 | 47 |
PLXNC1 |
1.717e-02 | -4.06 | cytoplasm | cellular component | GO:0005737 | 12081 | 37 | 19108 | 47 |
FYB1,CSF3R,ITGB2,PLEK,MFNG,CD68,SMPD4,CMTM6,RMC1,ZFP36L1,PSAP,PREX1,HCK,MLKL,VMP1,RASGRP2,MARCO,RXRA,RBM47,ITGAX,GAB1,DPYD,TNFAIP8L2,CD74,CYFIP1,UNC93B1,MAP3K11,DAPP1,MYO1F,DOCK2,SH2B3,RAC2,INPP5D,ABR,SNX17,ELMO1,ITM2B |
1.728e-02 | -4.06 | negative regulation of cell-cell adhesion | biological process | GO:0022408 | 203 | 3 | 18204 | 49 |
TNFAIP8L2,CD74,SH2B3 |
1.737e-02 | -4.05 | Ras signaling pathway | KEGG pathways | hsa04014 | 226 | 4 | 7161 | 32 |
CSF1R,GAB1,RASGRP2,RAC2 |
1.738e-02 | -4.05 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | biological process | GO:0007193 | 75 | 2 | 18204 | 49 |
PSAP,MARCO |
1.738e-02 | -4.05 | regulation of calcium ion transmembrane transporter activity | biological process | GO:1901019 | 75 | 2 | 18204 | 49 |
P2RY6,VMP1 |
1.739e-02 | -4.05 | LMNB1 (lamin B1) | protein interactions | 4001 | 590 | 5 | 19454 | 50 |
VMP1,SMPD4,RAC2,MYO1F,RXRA |
1.739e-02 | -4.05 | PPP6C (protein phosphatase 6 catalytic subunit) | protein interactions | 5537 | 213 | 3 | 19454 | 50 |
UNC93B1,ANKRD44,P2RY6 |
1.748e-02 | -4.05 | Nuclear Receptor transcription pathway | REACTOME pathways | R-HSA-383280 | 51 | 2 | 10285 | 41 |
RXRA,THRB |
1.752e-02 | -4.04 | 4FE4S_FER_2 | prosite domains | PS51379 | 5 | 1 | 12186 | 43 |
DPYD |
1.759e-02 | -4.04 | CANT1 (calcium activated nucleotidase 1) | protein interactions | 124583 | 79 | 2 | 19454 | 50 |
MFNG,ITM2B |
1.759e-02 | -4.04 | ATAD1 (ATPase family AAA domain containing 1) | protein interactions | 84896 | 79 | 2 | 19454 | 50 |
UNC93B1,RAC2 |
1.759e-02 | -4.04 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 24 | 16828 | 44 |
RBM47,ITM2B,RAC2,SMPD4,SLCO2B1,MLKL,MAP3K11,NCAM2,DOCK2,PREX1,ELMO1,ABR,SPOCK3,ITGB2,SH2B3,ITGAX,HCK,DPYD,CSF1R,MYO1F,PLXND1,DAPP1,P2RY6,ANKRD44 |
1.759e-02 | -4.04 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 24 | 16828 | 44 |
ITM2B,SLCO2B1,MLKL,MAP3K11,ELMO1,SH2B3,ITGAX,DPYD,HCK,PLXND1,MYO1F,P2RY6,ANKRD44,RBM47,RAC2,SMPD4,NCAM2,DOCK2,PREX1,ABR,SPOCK3,ITGB2,DAPP1,CSF1R |
1.761e-02 | -4.04 | CA9 (carbonic anhydrase 9) | protein interactions | 768 | 214 | 3 | 19454 | 50 |
VMP1,SMPD4,ITM2B |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
GAB1,CYFIP1,INPP5D |
1.761e-02 | -4.04 | NCAPD2 (non-SMC condensin I complex subunit D2) | protein interactions | 9918 | 214 | 3 | 19454 | 50 |
UNC93B1,CD74,P2RY6 |
1.774e-02 | -4.03 | cell activation involved in immune response | biological process | GO:0002263 | 205 | 3 | 18204 | 49 |
MFNG,CD74,DOCK2 |
1.776e-02 | -4.03 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 47 |
ENTPD1,HCK |
1.786e-02 | -4.03 | TLR8 (toll like receptor 8) | protein interactions | 51311 | 7 | 1 | 19454 | 50 |
UNC93B1 |
1.786e-02 | -4.03 | ZCCHC24 (zinc finger CCHC-type containing 24) | protein interactions | 219654 | 7 | 1 | 19454 | 50 |
RBM47 |
1.786e-02 | -4.03 | Gadd45b (growth arrest and DNA-damage-inducible 45 beta) | protein interactions | 17873 | 7 | 1 | 19454 | 50 |
RXRA |
1.804e-02 | -4.01 | ATP2B1 (ATPase plasma membrane Ca2+ transporting 1) | protein interactions | 490 | 216 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
1.804e-02 | -4.01 | HACD3 (3-hydroxyacyl-CoA dehydratase 3) | protein interactions | 51495 | 216 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
1.811e-02 | -4.01 | - | gene3d domains | 2.40.160.110 | 6 | 1 | 14470 | 44 |
CD68 |
1.818e-02 | -4.01 | kinase binding | molecular function | GO:0019900 | 780 | 6 | 18094 | 49 |
SH2B3,PLEK,ITGB2,MLKL,MAP3K11,ITGAX |
1.824e-02 | -4.00 | transmembrane signaling receptor activity | molecular function | GO:0004888 | 1251 | 8 | 18094 | 49 |
PLXND1,ITGB2,CSF3R,CSF1R,PLXNC1,CD74,MARCO,P2RY6 |
1.827e-02 | -4.00 | endocytic recycling | biological process | GO:0032456 | 77 | 2 | 18204 | 49 |
CMTM6,SNX17 |
1.829e-02 | -4.00 | cellular process | biological process | GO:0009987 | 14996 | 46 | 18204 | 49 |
VMP1,ZFP36L1,GAB1,P2RY6,RASGRP2,ENTPD1,DOCK2,CD68,LRMDA,MLKL,PLXND1,ELMO1,RXRA,SLCO2B1,MFNG,FYB1,PREX1,MYO1F,CMTM6,SMPD4,CPN1,NCAM2,RBM47,CD74,CSF3R,HCK,UNC93B1,TNFAIP8L2,DPYD,DAPP1,MARCO,ITGAX,SNX17,ABR,PLEK,RMC1,THRB,RAC2,ITGB2,MAP3K11,SH2B3,PSAP,CYFIP1,CSF1R,INPP5D,PLXNC1 |
1.840e-02 | -4.00 | regulation of leukocyte activation | biological process | GO:0002694 | 572 | 5 | 18204 | 49 |
ZFP36L1,CD74,RAC2,INPP5D,TNFAIP8L2 |
1.843e-02 | -3.99 | KRTAP3-3 (keratin associated protein 3-3) | protein interactions | 85293 | 81 | 2 | 19454 | 50 |
P2RY6,DOCK2 |
1.843e-02 | -3.99 | FADS1 (fatty acid desaturase 1) | protein interactions | 3992 | 81 | 2 | 19454 | 50 |
VMP1,RAC2 |
1.843e-02 | -3.99 | THRB (thyroid hormone receptor beta) | protein interactions | 7068 | 81 | 2 | 19454 | 50 |
THRB,RXRA |
1.843e-02 | -3.99 | CAND2 (cullin associated and neddylation dissociated 2 (putative)) | protein interactions | 23066 | 81 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
1.849e-02 | -3.99 | KRTAP1-1 (keratin associated protein 1-1) | protein interactions | 81851 | 218 | 3 | 19454 | 50 |
DOCK2,P2RY6,HCK |
1.866e-02 | -3.98 | regulation of chemotaxis | biological process | GO:0050920 | 209 | 3 | 18204 | 49 |
RAC2,CD74,CSF1R |
1.869e-02 | -3.98 | response to interleukin-3 | biological process | GO:0036015 | 7 | 1 | 18204 | 49 |
SH2B3 |
1.869e-02 | -3.98 | membrane raft localization | biological process | GO:0051665 | 7 | 1 | 18204 | 49 |
DOCK2 |
1.869e-02 | -3.98 | dUMP metabolic process | biological process | GO:0046078 | 7 | 1 | 18204 | 49 |
DPYD |
1.869e-02 | -3.98 | macropinocytosis | biological process | GO:0044351 | 7 | 1 | 18204 | 49 |
DOCK2 |
1.869e-02 | -3.98 | bradykinin catabolic process | biological process | GO:0010815 | 7 | 1 | 18204 | 49 |
CPN1 |
1.869e-02 | -3.98 | positive regulation of isomerase activity | biological process | GO:0010912 | 7 | 1 | 18204 | 49 |
ITGB2 |
1.869e-02 | -3.98 | autophagosome membrane docking | biological process | GO:0016240 | 7 | 1 | 18204 | 49 |
VMP1 |
1.869e-02 | -3.98 | cellular response to interleukin-3 | biological process | GO:0036016 | 7 | 1 | 18204 | 49 |
SH2B3 |
1.869e-02 | -3.98 | regulation of macrophage proliferation | biological process | GO:0120040 | 7 | 1 | 18204 | 49 |
CSF1R |
1.869e-02 | -3.98 | mitochondrion-endoplasmic reticulum membrane tethering | biological process | GO:1990456 | 7 | 1 | 18204 | 49 |
VMP1 |
1.869e-02 | -3.98 | chorio-allantoic fusion | biological process | GO:0060710 | 7 | 1 | 18204 | 49 |
ZFP36L1 |
1.869e-02 | -3.98 | regulation of ATPase-coupled calcium transmembrane transporter activity | biological process | GO:1901894 | 7 | 1 | 18204 | 49 |
VMP1 |
1.869e-02 | -3.98 | retinal cell apoptotic process | biological process | GO:1990009 | 7 | 1 | 18204 | 49 |
THRB |
1.869e-02 | -3.98 | positive regulation of dendritic cell antigen processing and presentation | biological process | GO:0002606 | 7 | 1 | 18204 | 49 |
CD74 |
1.869e-02 | -3.98 | platelet degranulation | biological process | GO:0002576 | 7 | 1 | 18204 | 49 |
PLEK |
1.869e-02 | -3.98 | nuclear-transcribed mRNA catabolic process, deadenylation-independent decay | biological process | GO:0031086 | 7 | 1 | 18204 | 49 |
ZFP36L1 |
1.869e-02 | -3.98 | regulation of isomerase activity | biological process | GO:0010911 | 7 | 1 | 18204 | 49 |
ITGB2 |
1.869e-02 | -3.98 | regulation of mast cell proliferation | biological process | GO:0070666 | 7 | 1 | 18204 | 49 |
RAC2 |
1.874e-02 | -3.98 | Rho GTPase cycle | REACTOME pathways | R-HSA-194840 | 142 | 3 | 10285 | 41 |
RAC2,PREX1,ABR |
1.875e-02 | -3.98 | SaposinB_dom | interpro domains | IPR008139 | 7 | 1 | 18521 | 50 |
PSAP |
1.875e-02 | -3.98 | Integrin_bsu_tail_dom_sf | interpro domains | IPR036349 | 7 | 1 | 18521 | 50 |
ITGB2 |
1.875e-02 | -3.98 | Hematopoietin_rcpt_Gp130_CS | interpro domains | IPR003529 | 7 | 1 | 18521 | 50 |
CSF3R |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPOCK3 |
1.875e-02 | -3.98 | Integrin_bsu_tail | interpro domains | IPR012896 | 7 | 1 | 18521 | 50 |
ITGB2 |
1.875e-02 | -3.98 | MYSc_Myo1 | interpro domains | IPR036072 | 7 | 1 | 18521 | 50 |
MYO1F |
1.881e-02 | -3.97 | inositol-1,4,5-trisphosphate 5-phosphatase activity | molecular function | GO:0052658 | 7 | 1 | 18094 | 49 |
INPP5D |
1.881e-02 | -3.97 | LBD domain binding | molecular function | GO:0050693 | 7 | 1 | 18094 | 49 |
RXRA |
1.881e-02 | -3.97 | inositol-polyphosphate 5-phosphatase activity | molecular function | GO:0004445 | 7 | 1 | 18094 | 49 |
INPP5D |
1.881e-02 | -3.97 | phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity | molecular function | GO:0034485 | 7 | 1 | 18094 | 49 |
INPP5D |
1.881e-02 | -3.97 | sphingomyelin phosphodiesterase activity | molecular function | GO:0004767 | 7 | 1 | 18094 | 49 |
SMPD4 |
1.881e-02 | -3.97 | MHC class II protein binding | molecular function | GO:0042289 | 7 | 1 | 18094 | 49 |
CD74 |
1.893e-02 | -3.97 | SCFD1 (sec1 family domain containing 1) | protein interactions | 23256 | 220 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
1.912e-02 | -3.96 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 49 |
SPOCK3 |
1.912e-02 | -3.96 | KRTAP10-8 (keratin associated protein 10-8) | protein interactions | 386681 | 399 | 4 | 19454 | 50 |
HCK,ITGB2,P2RY6,DOCK2 |
1.913e-02 | -3.96 | positive regulation of GTPase activity | biological process | GO:0043547 | 211 | 3 | 18204 | 49 |
RASGRP2,PREX1,ABR |
1.917e-02 | -3.95 | myeloid cell development | biological process | GO:0061515 | 79 | 2 | 18204 | 49 |
RAC2,SH2B3 |
1.917e-02 | -3.95 | regulation of protein targeting | biological process | GO:1903533 | 79 | 2 | 18204 | 49 |
ITGB2,RAC2 |
1.932e-02 | -3.95 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 10 | 18204 | 49 |
RXRA,MAP3K11,RBM47,MARCO,CD74,CYFIP1,P2RY6,CSF1R,THRB,MFNG |
1.939e-02 | -3.94 | PDGFRB (platelet derived growth factor receptor beta) | protein interactions | 5159 | 222 | 3 | 19454 | 50 |
RAC2,GAB1,CSF1R |
1.946e-02 | -3.94 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 10 | 18204 | 49 |
RXRA,MAP3K11,MARCO,RBM47,CD74,P2RY6,CYFIP1,CSF1R,MFNG,THRB |
1.952e-02 | -3.94 | regulation of signaling | biological process | GO:0023051 | 3534 | 16 | 18204 | 49 |
INPP5D,CSF1R,CYFIP1,DOCK2,RBM47,MARCO,RXRA,MFNG,THRB,P2RY6,PLEK,ABR,CD74,SH2B3,MAP3K11,PREX1 |
1.966e-02 | -3.93 | Dbl homology (DH) domain | gene3d domains | 1.20.900.10 | 71 | 2 | 14470 | 44 |
PREX1,ABR |
1.974e-02 | -3.93 | KRTAP3-1 (keratin associated protein 3-1) | protein interactions | 83896 | 84 | 2 | 19454 | 50 |
DOCK2,HCK |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
HCK,CSF1R |
1.978e-02 | -3.92 | MET activates PTPN11 | REACTOME pathways | R-HSA-8865999 | 5 | 1 | 10285 | 41 |
GAB1 |
1.984e-02 | -3.92 | EPO signaling pathway | Pathway Interaction DB | epopathway | 33 | 2 | 2226 | 15 |
SH2B3,GAB1 |
1.985e-02 | -3.92 | pyrimidine ribonucleosides degradation | BIOCYC pathways | HUMAN_PWY-7209 | 6 | 1 | 902 | 3 |
DPYD |
1.985e-02 | -3.92 | MFSD4A (major facilitator superfamily domain containing 4A) | protein interactions | 148808 | 224 | 3 | 19454 | 50 |
UNC93B1,VMP1,SMPD4 |
1.987e-02 | -3.92 | regulation of cell communication | biological process | GO:0010646 | 3541 | 16 | 18204 | 49 |
CD74,P2RY6,ABR,PLEK,THRB,MFNG,PREX1,SH2B3,MAP3K11,DOCK2,CYFIP1,CSF1R,INPP5D,RXRA,RBM47,MARCO |
2.008e-02 | -3.91 | RINT1 (RAD50 interactor 1) | protein interactions | 60561 | 225 | 3 | 19454 | 50 |
UNC93B1,RAC2,P2RY6 |
2.018e-02 | -3.90 | ATP5ME (ATP synthase membrane subunit e) | protein interactions | 521 | 85 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.026e-02 | -3.90 | regulation of supramolecular fiber organization | biological process | GO:1902903 | 388 | 4 | 18204 | 49 |
PREX1,PLEK,CYFIP1,HCK |
2.028e-02 | -3.90 | biological process involved in interspecies interaction between organisms | biological process | GO:0044419 | 1540 | 9 | 18204 | 49 |
CD74,CD68,CSF1R,MLKL,UNC93B1,HCK,MARCO,TNFAIP8L2,ITGAX |
2.032e-02 | -3.90 | AUP1 (AUP1 lipid droplet regulating VLDL assembly factor) | protein interactions | 550 | 226 | 3 | 19454 | 50 |
P2RY6,RAC2,UNC93B1 |
2.034e-02 | -3.90 | regulation of lymphocyte differentiation | biological process | GO:0045619 | 216 | 3 | 18204 | 49 |
INPP5D,ZFP36L1,CD74 |
2.038e-02 | -3.89 | CHURC1-FNTB (CHURC1-FNTB readthrough) | protein interactions | 100529261 | 8 | 1 | 19454 | 50 |
CYFIP1 |
2.038e-02 | -3.89 | CD1D (CD1d molecule) | protein interactions | 912 | 8 | 1 | 19454 | 50 |
CD74 |
2.038e-02 | -3.89 | DISP3 (dispatched RND transporter family member 3) | protein interactions | 57540 | 8 | 1 | 19454 | 50 |
RASGRP2 |
2.049e-02 | -3.89 | human chr11q13.1 | chromosome location | human chr11q13.1 | 115 | 2 | 26134 | 50 |
MAP3K11,RASGRP2 |
2.056e-02 | -3.88 | endoderm development | biological process | GO:0007492 | 82 | 2 | 18204 | 49 |
ZFP36L1,ITGB2 |
2.057e-02 | -3.88 | ESYT1 (extended synaptotagmin 1) | protein interactions | 23344 | 408 | 4 | 19454 | 50 |
RAC2,VMP1,SMPD4,P2RY6 |
2.057e-02 | -3.88 | arm | COSMIC cancer mutations | arm | 1331 | 8 | 16828 | 44 |
ENTPD1,DPYD,RASGRP2,MYO1F,CSF1R,MLKL,MARCO,ADAM33 |
2.059e-02 | -3.88 | focal adhesion | cellular component | GO:0005925 | 427 | 4 | 19108 | 47 |
ITGB2,RAC2,CYFIP1,HCK |
2.063e-02 | -3.88 | HIBADH (3-hydroxyisobutyrate dehydrogenase) | protein interactions | 11112 | 86 | 2 | 19454 | 50 |
ADAM33,DAPP1 |
2.063e-02 | -3.88 | WAS (WASP actin nucleation promoting factor) | protein interactions | 7454 | 86 | 2 | 19454 | 50 |
FYB1,HCK |
2.073e-02 | -3.88 | haematopoietic_and_lymphoid_tissue-other-normal | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-other-normal | 8 | 1 | 16828 | 44 |
CSF1R |
2.079e-02 | -3.87 | TNPO3 (transportin 3) | protein interactions | 23534 | 228 | 3 | 19454 | 50 |
UNC93B1,MFNG,P2RY6 |
2.079e-02 | -3.87 | receptor tyrosine kinase binding | molecular function | GO:0030971 | 82 | 2 | 18094 | 49 |
SH2B3,ITGAX |
2.079e-02 | -3.87 | multicellular organismal process | biological process | GO:0032501 | 6177 | 24 | 18204 | 49 |
THRB,MFNG,ZFP36L1,PLEK,GAB1,SNX17,VMP1,CD74,TNFAIP8L2,PSAP,ENTPD1,ITM2B,SH2B3,RAC2,PREX1,ITGB2,PLXND1,INPP5D,CSF1R,CYFIP1,DOCK2,SLCO2B1,MARCO,NCAM2 |
2.082e-02 | -3.87 | SapB | smart domains | SM00741 | 6 | 1 | 9717 | 34 |
PSAP |
2.082e-02 | -3.87 | Integrin_b_cyt | smart domains | SM01241 | 6 | 1 | 9717 | 34 |
ITGB2 |
2.088e-02 | -3.87 | ADXRDTASE | prints domains | PR00419 | 5 | 1 | 5227 | 22 |
DPYD |
2.099e-02 | -3.86 | ELMO | prosite domains | PS51335 | 6 | 1 | 12186 | 43 |
ELMO1 |
2.103e-02 | -3.86 | positive regulation of ion transmembrane transporter activity | biological process | GO:0032414 | 83 | 2 | 18204 | 49 |
VMP1,P2RY6 |
2.103e-02 | -3.86 | positive regulation of B cell activation | biological process | GO:0050871 | 83 | 2 | 18204 | 49 |
CD74,INPP5D |
2.103e-02 | -3.86 | positive regulation of calcium ion transmembrane transport | biological process | GO:1904427 | 83 | 2 | 18204 | 49 |
P2RY6,VMP1 |
2.108e-02 | -3.86 | FGR (FGR proto-oncogene, Src family tyrosine kinase) | protein interactions | 2268 | 87 | 2 | 19454 | 50 |
HCK,INPP5D |
2.111e-02 | -3.86 | specific granule membrane | cellular component | GO:0035579 | 91 | 2 | 19108 | 47 |
ITGB2,CMTM6 |
2.121e-02 | -3.85 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 47 |
NCAM2,CYFIP1,PLXND1,PREX1,ABR |
2.122e-02 | -3.85 | macromolecule localization | biological process | GO:0033036 | 2376 | 12 | 18204 | 49 |
SLCO2B1,CMTM6,CD68,FYB1,ITGB2,UNC93B1,PSAP,VMP1,SNX17,CD74,PLEK,ZFP36L1 |
2.134e-02 | -3.85 | female mating behavior | biological process | GO:0060180 | 8 | 1 | 18204 | 49 |
THRB |
2.134e-02 | -3.85 | CMP metabolic process | biological process | GO:0046035 | 8 | 1 | 18204 | 49 |
DPYD |
2.134e-02 | -3.85 | negative regulation of monocyte differentiation | biological process | GO:0045656 | 8 | 1 | 18204 | 49 |
INPP5D |
2.134e-02 | -3.85 | regulation of keratinocyte apoptotic process | biological process | GO:1902172 | 8 | 1 | 18204 | 49 |
ZFP36L1 |
2.134e-02 | -3.85 | necroptotic signaling pathway | biological process | GO:0097527 | 8 | 1 | 18204 | 49 |
MLKL |
2.134e-02 | -3.85 | glycolipid transport | biological process | GO:0046836 | 8 | 1 | 18204 | 49 |
PSAP |
2.134e-02 | -3.85 | regulation of mast cell chemotaxis | biological process | GO:0060753 | 8 | 1 | 18204 | 49 |
RAC2 |
2.134e-02 | -3.85 | pyrimidine nucleobase catabolic process | biological process | GO:0006208 | 8 | 1 | 18204 | 49 |
DPYD |
2.134e-02 | -3.85 | regulation of female receptivity | biological process | GO:0045924 | 8 | 1 | 18204 | 49 |
THRB |
2.134e-02 | -3.85 | dichotomous subdivision of an epithelial terminal unit | biological process | GO:0060600 | 8 | 1 | 18204 | 49 |
PLXND1 |
2.134e-02 | -3.85 | cellular response to macrophage colony-stimulating factor stimulus | biological process | GO:0036006 | 8 | 1 | 18204 | 49 |
CSF1R |
2.134e-02 | -3.85 | positive regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:2000601 | 8 | 1 | 18204 | 49 |
CYFIP1 |
2.134e-02 | -3.85 | negative regulation of erythrocyte differentiation | biological process | GO:0045647 | 8 | 1 | 18204 | 49 |
ZFP36L1 |
2.134e-02 | -3.85 | negative regulation of granulocyte differentiation | biological process | GO:0030853 | 8 | 1 | 18204 | 49 |
INPP5D |
2.134e-02 | -3.85 | pyrimidine nucleoside monophosphate catabolic process | biological process | GO:0009131 | 8 | 1 | 18204 | 49 |
DPYD |
2.134e-02 | -3.85 | pyrimidine ribonucleotide catabolic process | biological process | GO:0009222 | 8 | 1 | 18204 | 49 |
DPYD |
2.134e-02 | -3.85 | type I pneumocyte differentiation | biological process | GO:0060509 | 8 | 1 | 18204 | 49 |
THRB |
2.134e-02 | -3.85 | positive regulation of unsaturated fatty acid biosynthetic process | biological process | GO:2001280 | 8 | 1 | 18204 | 49 |
CD74 |
2.134e-02 | -3.85 | regulation of neutrophil degranulation | biological process | GO:0043313 | 8 | 1 | 18204 | 49 |
ITGB2 |
2.134e-02 | -3.85 | pyrimidine deoxyribonucleoside monophosphate catabolic process | biological process | GO:0009178 | 8 | 1 | 18204 | 49 |
DPYD |
2.134e-02 | -3.85 | regulation of peptidyl-tyrosine phosphorylation | biological process | GO:0050730 | 220 | 3 | 18204 | 49 |
CSF1R,CD74,ITGB2 |
2.140e-02 | -3.84 | TIG1_plexin | interpro domains | IPR041019 | 8 | 1 | 18521 | 50 |
PLXND1 |
2.140e-02 | -3.84 | Integrin_bsu_VWA | interpro domains | IPR002369 | 8 | 1 | 18521 | 50 |
ITGB2 |
2.140e-02 | -3.84 | Tyr_kinase_rcpt_3_CS | interpro domains | IPR001824 | 8 | 1 | 18521 | 50 |
CSF1R |
2.140e-02 | -3.84 | GDA1_CD39_NTPase | interpro domains | IPR000407 | 8 | 1 | 18521 | 50 |
ENTPD1 |
2.140e-02 | -3.84 | Myosin_TH1 | interpro domains | IPR010926 | 8 | 1 | 18521 | 50 |
MYO1F |
2.140e-02 | -3.84 | Integrin_beta_N | interpro domains | IPR033760 | 8 | 1 | 18521 | 50 |
ITGB2 |
2.146e-02 | -3.84 | CD4 receptor binding | molecular function | GO:0042609 | 8 | 1 | 18094 | 49 |
CD74 |
2.146e-02 | -3.84 | inositol tetrakisphosphate phosphatase activity | molecular function | GO:0052743 | 8 | 1 | 18094 | 49 |
INPP5D |
2.151e-02 | -3.84 | membrane docking | biological process | GO:0022406 | 84 | 2 | 18204 | 49 |
PLEK,VMP1 |
2.153e-02 | -3.84 | TAP2 (transporter 2, ATP binding cassette subfamily B member) | protein interactions | 6891 | 88 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.159e-02 | -3.84 | response to insulin | biological process | GO:0032868 | 221 | 3 | 18204 | 49 |
ZFP36L1,CYFIP1,GAB1 |
2.159e-02 | -3.84 | leukocyte mediated immunity | biological process | GO:0002443 | 221 | 3 | 18204 | 49 |
CD74,INPP5D,UNC93B1 |
2.165e-02 | -3.83 | establishment of localization | biological process | GO:0051234 | 3887 | 17 | 18204 | 49 |
MYO1F,DOCK2,CMTM6,CD68,ELMO1,MARCO,SLCO2B1,CD74,SNX17,VMP1,P2RY6,ZFP36L1,PLEK,ITGB2,PSAP,UNC93B1,HCK |
2.182e-02 | -3.82 | Integrin_alpha | pfam domains | PF00357 | 8 | 1 | 17795 | 49 |
ITGAX |
2.182e-02 | -3.82 | Myosin_TH1 | pfam domains | PF06017 | 8 | 1 | 17795 | 49 |
MYO1F |
2.182e-02 | -3.82 | TIG_plexin | pfam domains | PF17960 | 8 | 1 | 17795 | 49 |
PLXND1 |
2.182e-02 | -3.82 | Integrin_beta | pfam domains | PF00362 | 8 | 1 | 17795 | 49 |
ITGB2 |
2.182e-02 | -3.82 | GDA1_CD39 | pfam domains | PF01150 | 8 | 1 | 17795 | 49 |
ENTPD1 |
2.182e-02 | -3.82 | PSI_integrin | pfam domains | PF17205 | 8 | 1 | 17795 | 49 |
ITGB2 |
2.190e-02 | -3.82 | regulation of cellular process | biological process | GO:0050794 | 11468 | 38 | 18204 | 49 |
HCK,UNC93B1,TNFAIP8L2,RASGRP2,ITM2B,VMP1,CD74,CSF3R,ZFP36L1,GAB1,P2RY6,MARCO,ITGAX,RXRA,ELMO1,PLXND1,MLKL,DAPP1,DOCK2,PSAP,FYB1,RAC2,ITGB2,PREX1,MAP3K11,SH2B3,MFNG,THRB,SNX17,PLEK,ABR,RMC1,SPOCK3,RBM47,PLXNC1,CSF1R,INPP5D,CYFIP1 |
2.193e-02 | -3.82 | unconventional myosin complex | cellular component | GO:0016461 | 9 | 1 | 19108 | 47 |
MYO1F |
2.193e-02 | -3.82 | dendritic growth cone | cellular component | GO:0044294 | 9 | 1 | 19108 | 47 |
CYFIP1 |
2.199e-02 | -3.82 | ACKR2 (atypical chemokine receptor 2) | protein interactions | 1238 | 89 | 2 | 19454 | 50 |
UNC93B1,CMTM6 |
2.199e-02 | -3.82 | PRMT2 (protein arginine methyltransferase 2) | protein interactions | 3275 | 89 | 2 | 19454 | 50 |
THRB,RXRA |
2.220e-02 | -3.81 | cell-substrate junction | cellular component | GO:0030055 | 437 | 4 | 19108 | 47 |
HCK,CYFIP1,RAC2,ITGB2 |
2.221e-02 | -3.81 | regulation of intracellular signal transduction | biological process | GO:1902531 | 1832 | 10 | 18204 | 49 |
PREX1,SH2B3,MAP3K11,MARCO,CD74,DOCK2,P2RY6,ABR,PLEK,CSF1R |
2.224e-02 | -3.81 | JAK1 (Janus kinase 1) | protein interactions | 3716 | 234 | 3 | 19454 | 50 |
INPP5D,GAB1,CSF3R |
2.227e-02 | -3.80 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 18 | 16828 | 44 |
MYO1F,SNX17,PLXND1,PSAP,DPYD,P2RY6,RXRA,ELMO1,PREX1,ITGB2,SH2B3,CPN1,MAP3K11,DOCK2,NCAM2,RBM47,MARCO,MFNG |
2.227e-02 | -3.80 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 18 | 16828 | 44 |
P2RY6,PLXND1,PSAP,MYO1F,SNX17,DPYD,SH2B3,ITGB2,ELMO1,RXRA,PREX1,DOCK2,NCAM2,MAP3K11,CPN1,MFNG,RBM47,MARCO |
2.242e-02 | -3.80 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | 413 | 4 | 16828 | 44 |
CSF1R,CSF3R,SH2B3,CD74 |
2.242e-02 | -3.80 | myelofibrosis | COSMIC cancer mutations | myelofibrosis | 413 | 4 | 16828 | 44 |
SH2B3,CD74,CSF1R,CSF3R |
2.244e-02 | -3.80 | anchoring junction | cellular component | GO:0070161 | 902 | 6 | 19108 | 47 |
RAC2,CYFIP1,HCK,GAB1,ITGB2,FYB1 |
2.290e-02 | -3.78 | HLA-DMA (major histocompatibility complex, class II, DM alpha) | protein interactions | 3108 | 9 | 1 | 19454 | 50 |
CD74 |
2.290e-02 | -3.78 | KIF17 (kinesin family member 17) | protein interactions | 57576 | 9 | 1 | 19454 | 50 |
MAP3K11 |
2.290e-02 | -3.78 | SEZ6 (seizure related 6 homolog) | protein interactions | 124925 | 9 | 1 | 19454 | 50 |
SNX17 |
2.290e-02 | -3.78 | RBM46 (RNA binding motif protein 46) | protein interactions | 166863 | 9 | 1 | 19454 | 50 |
RBM47 |
2.290e-02 | -3.78 | SCTR (secretin receptor) | protein interactions | 6344 | 9 | 1 | 19454 | 50 |
CYFIP1 |
2.290e-02 | -3.78 | SLN (sarcolipin) | protein interactions | 6588 | 9 | 1 | 19454 | 50 |
VMP1 |
2.290e-02 | -3.78 | MCTP2 (multiple C2 and transmembrane domain containing 2) | protein interactions | 55784 | 9 | 1 | 19454 | 50 |
RAC2 |
2.290e-02 | -3.78 | FHAD1 (forkhead associated phosphopeptide binding domain 1) | protein interactions | 114827 | 9 | 1 | 19454 | 50 |
RAC2 |
2.291e-02 | -3.78 | enzyme regulator activity | molecular function | GO:0030234 | 1305 | 8 | 18094 | 49 |
SPOCK3,ABR,RAC2,ELMO1,DOCK2,PSAP,PREX1,RASGRP2 |
2.292e-02 | -3.78 | KHDRBS3 (KH RNA binding domain containing, signal transduction associated 3) | protein interactions | 10656 | 91 | 2 | 19454 | 50 |
INPP5D,DOCK2 |
2.292e-02 | -3.78 | AMIGO1 (adhesion molecule with Ig like domain 1) | protein interactions | 57463 | 91 | 2 | 19454 | 50 |
ADAM33,ITM2B |
2.292e-02 | -3.78 | PTPRJ (protein tyrosine phosphatase receptor type J) | protein interactions | 5795 | 91 | 2 | 19454 | 50 |
RAC2,P2RY6 |
2.299e-02 | -3.77 | PPP6R3 (protein phosphatase 6 regulatory subunit 3) | protein interactions | 55291 | 237 | 3 | 19454 | 50 |
ANKRD44,CD74,P2RY6 |
2.303e-02 | -3.77 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 42 | 16828 | 44 |
THRB,CSF3R,DOCK2,VMP1,NCAM2,RBM47,PLEK,MFNG,GAB1,RAC2,SMPD4,CSF1R,PSAP,DAPP1,PLXNC1,RASGRP2,RXRA,TNFAIP8L2,ABR,PREX1,ITGB2,SPOCK3,CPN1,MAP3K11,MLKL,SLCO2B1,MARCO,ITM2B,CD68,CD74,SNX17,MYO1F,PLXND1,DPYD,HCK,ENTPD1,P2RY6,ANKRD44,ADAM33,ELMO1,SH2B3,ITGAX |
2.312e-02 | -3.77 | STX4 (syntaxin 4) | protein interactions | 6810 | 423 | 4 | 19454 | 50 |
ITM2B,SMPD4,GAB1,RAC2 |
2.339e-02 | -3.76 | WASF1 (WASP family member 1) | protein interactions | 8936 | 92 | 2 | 19454 | 50 |
RAC2,CYFIP1 |
2.339e-02 | -3.76 | MLEC (malectin) | protein interactions | 9761 | 92 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.340e-02 | -3.76 | Signaling events mediated by TCPTP | Pathway Interaction DB | tcptp_pathway | 36 | 2 | 2226 | 15 |
GAB1,CSF1R |
2.341e-02 | -3.75 | immune response-activating cell surface receptor signaling pathway | biological process | GO:0002429 | 228 | 3 | 18204 | 49 |
INPP5D,HCK,FYB1 |
2.344e-02 | -3.75 | RhoGEF | smart domains | SM00325 | 68 | 2 | 9717 | 34 |
ABR,PREX1 |
2.346e-02 | -3.75 | regulation of tissue remodeling | biological process | GO:0034103 | 88 | 2 | 18204 | 49 |
INPP5D,CSF1R |
2.350e-02 | -3.75 | KRTAP10-9 (keratin associated protein 10-9) | protein interactions | 386676 | 239 | 3 | 19454 | 50 |
DOCK2,INPP5D,HCK |
2.369e-02 | -3.74 | MET activates PI3K/AKT signaling | REACTOME pathways | R-HSA-8851907 | 6 | 1 | 10285 | 41 |
GAB1 |
2.372e-02 | -3.74 | monocarboxylic acid binding | molecular function | GO:0033293 | 88 | 2 | 18094 | 49 |
PSAP,RXRA |
2.372e-02 | -3.74 | NRAGE signals death through JNK | REACTOME pathways | R-HSA-193648 | 60 | 2 | 10285 | 41 |
ABR,PREX1 |
2.387e-02 | -3.74 | transport | biological process | GO:0006810 | 3615 | 16 | 18204 | 49 |
CMTM6,DOCK2,MYO1F,SLCO2B1,MARCO,ELMO1,PLEK,ZFP36L1,P2RY6,SNX17,VMP1,CD74,HCK,UNC93B1,PSAP,ITGB2 |
2.387e-02 | -3.74 | DAB1 (DAB adaptor protein 1) | protein interactions | 1600 | 93 | 2 | 19454 | 50 |
INPP5D,ITGB2 |
2.387e-02 | -3.74 | MAIP1 (matrix AAA peptidase interacting protein 1) | protein interactions | 79568 | 93 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.397e-02 | -3.73 | respiratory burst involved in defense response | biological process | GO:0002679 | 9 | 1 | 18204 | 49 |
HCK |
2.397e-02 | -3.73 | negative regulation of antigen processing and presentation | biological process | GO:0002578 | 9 | 1 | 18204 | 49 |
CD68 |
2.397e-02 | -3.73 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 49 |
CSF1R |
2.397e-02 | -3.73 | toll-like receptor 9 signaling pathway | biological process | GO:0034162 | 9 | 1 | 18204 | 49 |
UNC93B1 |
2.397e-02 | -3.73 | establishment of T cell polarity | biological process | GO:0001768 | 9 | 1 | 18204 | 49 |
DOCK2 |
2.397e-02 | -3.73 | regulation of translation at synapse | biological process | GO:0140243 | 9 | 1 | 18204 | 49 |
CYFIP1 |
2.397e-02 | -3.73 | peroxisome proliferator activated receptor signaling pathway | biological process | GO:0035357 | 9 | 1 | 18204 | 49 |
RXRA |
2.397e-02 | -3.73 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 49 |
SNX17 |
2.397e-02 | -3.73 | regulation of mRNA 3'-end processing | biological process | GO:0031440 | 9 | 1 | 18204 | 49 |
ZFP36L1 |
2.397e-02 | -3.73 | negative regulation of chemokine-mediated signaling pathway | biological process | GO:0070100 | 9 | 1 | 18204 | 49 |
SH2B3 |
2.397e-02 | -3.73 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 49 |
SNX17 |
2.397e-02 | -3.73 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 49 |
CSF1R |
2.397e-02 | -3.73 | positive regulation of antigen processing and presentation | biological process | GO:0002579 | 9 | 1 | 18204 | 49 |
CD74 |
2.397e-02 | -3.73 | transepithelial chloride transport | biological process | GO:0030321 | 9 | 1 | 18204 | 49 |
P2RY6 |
2.397e-02 | -3.73 | mesendoderm development | biological process | GO:0048382 | 9 | 1 | 18204 | 49 |
ZFP36L1 |
2.397e-02 | -3.73 | marginal zone B cell differentiation | biological process | GO:0002315 | 9 | 1 | 18204 | 49 |
MFNG |
2.402e-02 | -3.73 | CCDC47 (coiled-coil domain containing 47) | protein interactions | 57003 | 428 | 4 | 19454 | 50 |
RAC2,SMPD4,P2RY6,UNC93B1 |
2.404e-02 | -3.73 | BRICHOS_dom | interpro domains | IPR007084 | 9 | 1 | 18521 | 50 |
ITM2B |
2.404e-02 | -3.73 | Integrin_bsu | interpro domains | IPR015812 | 9 | 1 | 18521 | 50 |
ITGB2 |
2.407e-02 | -3.73 | Exopolyphosphatase. Domain 2 | gene3d domains | 3.30.420.150 | 8 | 1 | 14470 | 44 |
ENTPD1 |
2.412e-02 | -3.72 | UDP phosphatase activity | molecular function | GO:0045134 | 9 | 1 | 18094 | 49 |
ENTPD1 |
2.422e-02 | -3.72 | regulation of leukocyte migration | biological process | GO:0002685 | 231 | 3 | 18204 | 49 |
CD74,RAC2,CSF1R |
2.423e-02 | -3.72 | lysosomal lumen | cellular component | GO:0043202 | 98 | 2 | 19108 | 47 |
PSAP,CD74 |
2.424e-02 | -3.72 | Integrin_B_tail | smart domains | SM01242 | 7 | 1 | 9717 | 34 |
ITGB2 |
2.435e-02 | -3.72 | MPG (N-methylpurine DNA glycosylase) | protein interactions | 4350 | 94 | 2 | 19454 | 50 |
THRB,RXRA |
2.437e-02 | -3.71 | Insulin Signaling | WikiPathways | WP481 | 161 | 3 | 5310 | 21 |
GAB1,MAP3K11,RAC2 |
2.445e-02 | -3.71 | HEMATOPO_REC_L_F2 | prosite domains | PS01353 | 7 | 1 | 12186 | 43 |
CSF3R |
2.445e-02 | -3.71 | SAP_B | prosite domains | PS50015 | 7 | 1 | 12186 | 43 |
PSAP |
2.446e-02 | -3.71 | Regulation of actin dynamics for phagocytic cup formation | REACTOME pathways | R-HSA-2029482 | 61 | 2 | 10285 | 41 |
ELMO1,CYFIP1 |
2.452e-02 | -3.71 | PH_12 | pfam domains | PF16457 | 9 | 1 | 17795 | 49 |
ELMO1 |
2.452e-02 | -3.71 | BRICHOS | pfam domains | PF04089 | 9 | 1 | 17795 | 49 |
ITM2B |
2.455e-02 | -3.71 | central_nervous_system-brain-glioma | COSMIC cancer mutations | central_nervous_system-brain-glioma | 15470 | 44 | 16828 | 44 |
RAC2,SMPD4,MFNG,GAB1,RBM47,PLEK,NCAM2,DOCK2,VMP1,CSF3R,THRB,SPOCK3,ITGB2,PREX1,TNFAIP8L2,RXRA,ABR,CMTM6,PLXNC1,RASGRP2,CSF1R,PSAP,DAPP1,CD74,ZFP36L1,CD68,MARCO,ITM2B,SLCO2B1,CPN1,MAP3K11,MLKL,ITGAX,SH2B3,ADAM33,ELMO1,P2RY6,ANKRD44,ENTPD1,HCK,DPYD,SNX17,MYO1F,PLXND1 |
2.483e-02 | -3.70 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 40 | 16828 | 44 |
RBM47,PLEK,RAC2,SMPD4,MFNG,GAB1,CSF3R,THRB,NCAM2,DOCK2,VMP1,PREX1,RXRA,ABR,SPOCK3,ITGB2,PLXNC1,RASGRP2,CSF1R,PSAP,DAPP1,ZFP36L1,MARCO,CD74,SLCO2B1,CPN1,MLKL,MAP3K11,ADAM33,ELMO1,ITGAX,SH2B3,HCK,DPYD,SNX17,MYO1F,PLXND1,P2RY6,ANKRD44,ENTPD1 |
2.483e-02 | -3.70 | PCK2 (phosphoenolpyruvate carboxykinase 2, mitochondrial) | protein interactions | 5106 | 95 | 2 | 19454 | 50 |
RMC1,P2RY6 |
2.497e-02 | -3.69 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 17 | 16828 | 44 |
ELMO1,RXRA,PREX1,ITGAX,SPOCK3,MYO1F,P2RY6,ANKRD44,ITM2B,PLEK,MARCO,ZFP36L1,GAB1,SMPD4,MLKL,DOCK2,NCAM2 |
2.524e-02 | -3.68 | DH_2 | prosite domains | PS50010 | 70 | 2 | 12186 | 43 |
PREX1,ABR |
2.529e-02 | -3.68 | Platelet activation, signaling and aggregation | REACTOME pathways | R-HSA-76002 | 282 | 4 | 10285 | 41 |
PSAP,RASGRP2,RAC2,PLEK |
2.532e-02 | -3.68 | LMAN2 (lectin, mannose binding 2) | protein interactions | 10960 | 96 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.541e-02 | -3.67 | STOML3 (stomatin like 3) | protein interactions | 161003 | 10 | 1 | 19454 | 50 |
ADAM33 |
2.541e-02 | -3.67 | SEZ6L (seizure related 6 homolog like) | protein interactions | 23544 | 10 | 1 | 19454 | 50 |
SNX17 |
2.541e-02 | -3.67 | MYO18B (myosin XVIIIB) | protein interactions | 84700 | 10 | 1 | 19454 | 50 |
RAC2 |
2.541e-02 | -3.67 | PLA2G1B (phospholipase A2 group IB) | protein interactions | 5319 | 10 | 1 | 19454 | 50 |
CSF3R |
2.541e-02 | -3.67 | PGA4 (pepsinogen A4) | protein interactions | 643847 | 10 | 1 | 19454 | 50 |
CD74 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
ITGB2 |
2.547e-02 | -3.67 | ATG16L1 (autophagy related 16 like 1) | protein interactions | 55054 | 1138 | 7 | 19454 | 50 |
ANKRD44,PLEK,INPP5D,CYFIP1,DOCK2,ELMO1,SMPD4 |
2.553e-02 | -3.67 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 44 |
HCK,MAP3K11,MLKL,CSF1R |
2.553e-02 | -3.67 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 44 |
HCK,CSF1R,MAP3K11,MLKL |
2.555e-02 | -3.67 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 42 | 16828 | 44 |
NCAM2,DOCK2,VMP1,CSF3R,THRB,SMPD4,RAC2,MFNG,GAB1,RBM47,PLEK,PLXNC1,RASGRP2,CSF1R,PSAP,DAPP1,SPOCK3,ITGB2,PREX1,RXRA,TNFAIP8L2,ABR,SLCO2B1,CPN1,MAP3K11,MLKL,ZFP36L1,CD68,MARCO,ITM2B,ANKRD44,P2RY6,ENTPD1,DPYD,HCK,SNX17,MYO1F,PLXND1,ITGAX,SH2B3,ADAM33,ELMO1 |
2.558e-02 | -3.67 | PICALM (phosphatidylinositol binding clathrin assembly protein) | protein interactions | 8301 | 247 | 3 | 19454 | 50 |
RAC2,VMP1,RBM47 |
2.561e-02 | -3.66 | Golgi membrane | cellular component | GO:0000139 | 683 | 5 | 19108 | 47 |
CD74,MFNG,UNC93B1,SMPD4,ITM2B |
2.563e-02 | -3.66 | ruffle membrane | cellular component | GO:0032587 | 101 | 2 | 19108 | 47 |
PLEK,RASGRP2 |
2.581e-02 | -3.66 | ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase) | protein interactions | 27 | 97 | 2 | 19454 | 50 |
RAC2,HCK |
2.581e-02 | -3.66 | CLPTM1L (CLPTM1 like) | protein interactions | 81037 | 97 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.585e-02 | -3.66 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK_cell_leukaemia | 10 | 1 | 16828 | 44 |
CSF3R |
2.585e-02 | -3.66 | NK_cell_leukaemia | COSMIC cancer mutations | NK_cell_leukaemia | 10 | 1 | 16828 | 44 |
CSF3R |
2.587e-02 | -3.65 | regulation of lymphocyte proliferation | biological process | GO:0050670 | 237 | 3 | 18204 | 49 |
RAC2,CD74,INPP5D |
2.596e-02 | -3.65 | ovary-other-neoplasm | COSMIC cancer mutations | ovary-other-neoplasm | 12717 | 39 | 16828 | 44 |
CMTM6,RASGRP2,PLXNC1,PSAP,CSF1R,ITGB2,PREX1,ABR,RXRA,NCAM2,DOCK2,VMP1,CSF3R,THRB,RAC2,SMPD4,MFNG,GAB1,PLEK,RBM47,P2RY6,ANKRD44,HCK,DPYD,PLXND1,MYO1F,SNX17,SH2B3,ITGAX,ELMO1,ADAM33,SLCO2B1,MLKL,MAP3K11,CPN1,CD74,ZFP36L1,ITM2B,MARCO |
2.598e-02 | -3.65 | regulation of protein-containing complex assembly | biological process | GO:0043254 | 419 | 4 | 18204 | 49 |
PLEK,CYFIP1,PREX1,HCK |
2.602e-02 | -3.65 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 6 | 16828 | 44 |
DOCK2,DPYD,MAP3K11,CSF1R,ELMO1,ADAM33 |
2.605e-02 | -3.65 | SSR1 (signal sequence receptor subunit 1) | protein interactions | 6745 | 439 | 4 | 19454 | 50 |
PSAP,RAC2,SMPD4,VMP1 |
2.605e-02 | -3.65 | ATG9A (autophagy related 9A) | protein interactions | 79065 | 439 | 4 | 19454 | 50 |
SMPD4,MAP3K11,RMC1,SNX17 |
2.610e-02 | -3.65 | breast-carcinoma-ductal_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductal_carcinoma | 14824 | 43 | 16828 | 44 |
RAC2,SMPD4,GAB1,MFNG,PLEK,NCAM2,DOCK2,VMP1,CSF3R,THRB,SPOCK3,ITGB2,PREX1,ABR,RXRA,TNFAIP8L2,CMTM6,RASGRP2,PLXNC1,PSAP,DAPP1,CSF1R,CD74,CD68,ZFP36L1,ITM2B,MARCO,SLCO2B1,MAP3K11,MLKL,CPN1,SH2B3,ITGAX,ELMO1,ADAM33,P2RY6,ANKRD44,ENTPD1,DPYD,HCK,PLXND1,SNX17,MYO1F |
2.624e-02 | -3.64 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 26 | 16828 | 44 |
ABR,RXRA,PREX1,ITGB2,CSF1R,PLXNC1,CMTM6,PLEK,MFNG,GAB1,RAC2,THRB,VMP1,DOCK2,NCAM2,ELMO1,ITGAX,SH2B3,PLXND1,MYO1F,DPYD,ANKRD44,MARCO,ZFP36L1,CPN1,SLCO2B1 |
2.625e-02 | -3.64 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 44 |
HCK,MAP3K11,MLKL,ABR,CSF1R |
2.626e-02 | -3.64 | caecum | COSMIC cancer mutations | caecum | 14248 | 42 | 16828 | 44 |
DPYD,HCK,SNX17,MYO1F,PLXND1,ANKRD44,P2RY6,ENTPD1,ADAM33,ELMO1,ITGAX,SH2B3,SLCO2B1,CPN1,MAP3K11,MLKL,ZFP36L1,CD68,MARCO,ITM2B,PLXNC1,RASGRP2,CSF1R,PSAP,DAPP1,PREX1,RXRA,TNFAIP8L2,ABR,SPOCK3,ITGB2,CSF3R,THRB,NCAM2,DOCK2,VMP1,RBM47,PLEK,RAC2,SMPD4,MFNG,GAB1 |
2.631e-02 | -3.64 | PLEKHG3 (pleckstrin homology and RhoGEF domain containing G3) | protein interactions | 26030 | 98 | 2 | 19454 | 50 |
RAC2,VMP1 |
2.631e-02 | -3.64 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 2 | 19454 | 50 |
RAC2,GAB1 |
2.660e-02 | -3.63 | regulation of modification of postsynaptic structure | biological process | GO:0099159 | 10 | 1 | 18204 | 49 |
CYFIP1 |
2.660e-02 | -3.63 | regulation of vitamin D receptor signaling pathway | biological process | GO:0070562 | 10 | 1 | 18204 | 49 |
RXRA |
2.660e-02 | -3.63 | cellular response to salt stress | biological process | GO:0071472 | 10 | 1 | 18204 | 49 |
ZFP36L1 |
2.660e-02 | -3.63 | dendrite extension | biological process | GO:0097484 | 10 | 1 | 18204 | 49 |
CYFIP1 |
2.660e-02 | -3.63 | endothelial cell chemotaxis | biological process | GO:0035767 | 10 | 1 | 18204 | 49 |
GAB1 |
2.660e-02 | -3.63 | establishment of lymphocyte polarity | biological process | GO:0001767 | 10 | 1 | 18204 | 49 |
DOCK2 |
2.660e-02 | -3.63 | nucleobase catabolic process | biological process | GO:0046113 | 10 | 1 | 18204 | 49 |
DPYD |
2.660e-02 | -3.63 | thrombin-activated receptor signaling pathway | biological process | GO:0070493 | 10 | 1 | 18204 | 49 |
PLEK |
2.668e-02 | -3.62 | IPPc | interpro domains | IPR000300 | 10 | 1 | 18521 | 50 |
INPP5D |
2.676e-02 | -3.62 | glycosphingolipid binding | molecular function | GO:0043208 | 10 | 1 | 18094 | 49 |
PSAP |
2.676e-02 | -3.62 | phosphatidylinositol trisphosphate phosphatase activity | molecular function | GO:0034594 | 10 | 1 | 18094 | 49 |
INPP5D |
2.676e-02 | -3.62 | mitogen-activated protein kinase kinase binding | molecular function | GO:0031434 | 10 | 1 | 18094 | 49 |
MAP3K11 |
2.676e-02 | -3.62 | phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity | molecular function | GO:0004439 | 10 | 1 | 18094 | 49 |
INPP5D |
2.676e-02 | -3.62 | GDP phosphatase activity | molecular function | GO:0004382 | 10 | 1 | 18094 | 49 |
ENTPD1 |
2.680e-02 | -3.62 | PRPSAP1 (phosphoribosyl pyrophosphate synthetase associated protein 1) | protein interactions | 5635 | 99 | 2 | 19454 | 50 |
HCK,ANKRD44 |
2.680e-02 | -3.62 | XPO4 (exportin 4) | protein interactions | 64328 | 99 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.685e-02 | -3.62 | KRAS (KRAS proto-oncogene, GTPase) | protein interactions | 3845 | 2876 | 13 | 19454 | 50 |
GAB1,VMP1,PREX1,HCK,ITM2B,CYFIP1,RAC2,SMPD4,RXRA,RASGRP2,P2RY6,PLXNC1,SLCO2B1 |
2.693e-02 | -3.61 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 50 |
GAB1,CYFIP1,FYB1 |
2.704e-02 | -3.61 | negative regulation of myeloid cell differentiation | biological process | GO:0045638 | 95 | 2 | 18204 | 49 |
INPP5D,ZFP36L1 |
2.704e-02 | -3.61 | Saposin-like | gene3d domains | 1.10.225.10 | 9 | 1 | 14470 | 44 |
PSAP |
2.718e-02 | -3.61 | regulation of hemopoiesis | biological process | GO:1903706 | 425 | 4 | 18204 | 49 |
INPP5D,CSF3R,ZFP36L1,CD74 |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
CSF1R,HCK |
2.730e-02 | -3.60 | regulation of mononuclear cell proliferation | biological process | GO:0032944 | 242 | 3 | 18204 | 49 |
RAC2,CD74,INPP5D |
2.731e-02 | -3.60 | SYNGR1 (synaptogyrin 1) | protein interactions | 9145 | 100 | 2 | 19454 | 50 |
UNC93B1,CMTM6 |
2.731e-02 | -3.60 | TTC27 (tetratricopeptide repeat domain 27) | protein interactions | 55622 | 100 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.737e-02 | -3.60 | response to lipid | biological process | GO:0033993 | 862 | 6 | 18204 | 49 |
HCK,RXRA,CPN1,CD68,P2RY6,ZFP36L1 |
2.737e-02 | -3.60 | Viral myocarditis | KEGG pathways | hsa05416 | 58 | 2 | 7161 | 32 |
RAC2,ITGB2 |
2.756e-02 | -3.59 | immunoglobulin mediated immune response | biological process | GO:0016064 | 96 | 2 | 18204 | 49 |
INPP5D,CD74 |
2.763e-02 | -3.59 | RAC2 (Rac family small GTPase 2) | protein interactions | 5880 | 666 | 5 | 19454 | 50 |
MAP3K11,VMP1,SMPD4,CYFIP1,DOCK2 |
2.766e-02 | -3.59 | INB | smart domains | SM00187 | 8 | 1 | 9717 | 34 |
ITGB2 |
2.772e-02 | -3.59 | vWFA_dom_sf | interpro domains | IPR036465 | 96 | 2 | 18521 | 50 |
ITGB2,ITGAX |
2.776e-02 | -3.58 | MSH6 (mutS homolog 6) | protein interactions | 2956 | 255 | 3 | 19454 | 50 |
P2RY6,RMC1,UNC93B1 |
2.780e-02 | -3.58 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 4 | 18204 | 49 |
SH2B3,GAB1,CSF1R,HCK |
2.781e-02 | -3.58 | LRP5 (LDL receptor related protein 5) | protein interactions | 4041 | 101 | 2 | 19454 | 50 |
RAC2,ADAM33 |
2.781e-02 | -3.58 | NBAS (NBAS subunit of NRZ tethering complex) | protein interactions | 51594 | 101 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.781e-02 | -3.58 | FAR1 (fatty acyl-CoA reductase 1) | protein interactions | 84188 | 101 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.789e-02 | -3.58 | RECEPTOR_TYR_KIN_III | prosite domains | PS00240 | 8 | 1 | 12186 | 43 |
CSF1R |
2.789e-02 | -3.58 | TH1 | prosite domains | PS51757 | 8 | 1 | 12186 | 43 |
MYO1F |
2.789e-02 | -3.58 | GDA1_CD39_NTPASE | prosite domains | PS01238 | 8 | 1 | 12186 | 43 |
ENTPD1 |
2.792e-02 | -3.58 | GHSR (growth hormone secretagogue receptor) | protein interactions | 2693 | 11 | 1 | 19454 | 50 |
P2RY6 |
2.792e-02 | -3.58 | PLEK (pleckstrin) | protein interactions | 5341 | 11 | 1 | 19454 | 50 |
PLEK |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
CYFIP1 |
2.792e-02 | -3.58 | NYAP1 (neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1) | protein interactions | 222950 | 11 | 1 | 19454 | 50 |
CYFIP1 |
2.792e-02 | -3.58 | RBP7 (retinol binding protein 7) | protein interactions | 116362 | 11 | 1 | 19454 | 50 |
DAPP1 |
2.792e-02 | -3.58 | MS4A7 (membrane spanning 4-domains A7) | protein interactions | 58475 | 11 | 1 | 19454 | 50 |
ITGB2 |
2.792e-02 | -3.58 | LAT2 (linker for activation of T cells family member 2) | protein interactions | 7462 | 11 | 1 | 19454 | 50 |
GAB1 |
2.819e-02 | -3.57 | KRT31 (keratin 31) | protein interactions | 3881 | 450 | 4 | 19454 | 50 |
DOCK2,INPP5D,HCK,ITGB2 |
2.825e-02 | -3.57 | Cytokine Signaling in Immune system | REACTOME pathways | R-HSA-1280215 | 756 | 7 | 10285 | 41 |
ITGAX,HCK,ITGB2,INPP5D,MAP3K11,CSF1R,CSF3R |
2.832e-02 | -3.56 | human chr17q23.1 | chromosome location | human chr17q23.1 | 15 | 1 | 26134 | 50 |
VMP1 |
2.832e-02 | -3.56 | human chr3p24.2 | chromosome location | human chr3p24.2 | 15 | 1 | 26134 | 50 |
THRB |
2.832e-02 | -3.56 | DOCK5 (dedicator of cytokinesis 5) | protein interactions | 80005 | 102 | 2 | 19454 | 50 |
ELMO1,RAC2 |
2.832e-02 | -3.56 | GRAP2 (GRB2 related adaptor protein 2) | protein interactions | 9402 | 102 | 2 | 19454 | 50 |
GAB1,CSF1R |
2.832e-02 | -3.56 | FASLG (Fas ligand) | protein interactions | 356 | 102 | 2 | 19454 | 50 |
HCK,FYB1 |
2.832e-02 | -3.56 | TMX3 (thioredoxin related transmembrane protein 3) | protein interactions | 54495 | 102 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
2.837e-02 | -3.56 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 16 | 16828 | 44 |
SH2B3,ITGB2,ELMO1,CMTM6,ANKRD44,PLXND1,CSF1R,DPYD,GAB1,MARCO,DOCK2,NCAM2,MLKL,THRB,CSF3R,SLCO2B1 |
2.837e-02 | -3.56 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 16 | 16828 | 44 |
THRB,MLKL,CSF3R,SLCO2B1,DOCK2,NCAM2,MARCO,GAB1,CSF1R,PLXND1,DPYD,CMTM6,ANKRD44,ELMO1,ITGB2,SH2B3 |
2.841e-02 | -3.56 | cytokine receptor activity | molecular function | GO:0004896 | 97 | 2 | 18094 | 49 |
CSF3R,CD74 |
2.847e-02 | -3.56 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 49 |
PLXND1,PLXNC1,CYFIP1 |
2.893e-02 | -3.54 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 5 | 16828 | 44 |
HCK,CSF1R,MLKL,MAP3K11,ITGB2 |
2.902e-02 | -3.54 | Joubert Syndrome | SMPDB pathways | SMP0000582 | 20 | 1 | 1369 | 2 |
INPP5D |
2.902e-02 | -3.54 | Phosphatidylinositol Phosphate Metabolism | SMPDB pathways | SMP0000463 | 20 | 1 | 1369 | 2 |
INPP5D |
2.913e-02 | -3.54 | SCAR complex | cellular component | GO:0031209 | 12 | 1 | 19108 | 47 |
CYFIP1 |
2.922e-02 | -3.53 | prostate gland growth | biological process | GO:0060736 | 11 | 1 | 18204 | 49 |
PSAP |
2.922e-02 | -3.53 | pyrimidine deoxyribonucleoside monophosphate metabolic process | biological process | GO:0009176 | 11 | 1 | 18204 | 49 |
DPYD |
2.922e-02 | -3.53 | regulation of neurotrophin TRK receptor signaling pathway | biological process | GO:0051386 | 11 | 1 | 18204 | 49 |
CYFIP1 |
2.922e-02 | -3.53 | retinal cone cell development | biological process | GO:0046549 | 11 | 1 | 18204 | 49 |
THRB |
2.922e-02 | -3.53 | deoxyribonucleoside metabolic process | biological process | GO:0009120 | 11 | 1 | 18204 | 49 |
DPYD |
2.922e-02 | -3.53 | heme catabolic process | biological process | GO:0042167 | 11 | 1 | 18204 | 49 |
SLCO2B1 |
2.922e-02 | -3.53 | leukocyte aggregation | biological process | GO:0070486 | 11 | 1 | 18204 | 49 |
RAC2 |
2.922e-02 | -3.53 | positive regulation of chemokine (C-X-C motif) ligand 2 production | biological process | GO:2000343 | 11 | 1 | 18204 | 49 |
CD74 |
2.922e-02 | -3.53 | epithelial cell differentiation involved in prostate gland development | biological process | GO:0060742 | 11 | 1 | 18204 | 49 |
PSAP |
2.922e-02 | -3.53 | positive regulation of integrin activation | biological process | GO:0033625 | 11 | 1 | 18204 | 49 |
PLEK |
2.922e-02 | -3.53 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 49 |
SH2B3 |
2.922e-02 | -3.53 | pigment catabolic process | biological process | GO:0046149 | 11 | 1 | 18204 | 49 |
SLCO2B1 |
2.922e-02 | -3.53 | pinocytosis | biological process | GO:0006907 | 11 | 1 | 18204 | 49 |
DOCK2 |
2.928e-02 | -3.53 | Pathways in cancer | KEGG pathways | hsa05200 | 395 | 5 | 7161 | 32 |
RASGRP2,CSF1R,RAC2,CSF3R,RXRA |
2.931e-02 | -3.53 | DOCK_C_lobe_C | interpro domains | IPR043162 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | DOCKER_Lobe_B | interpro domains | IPR046770 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | C2_DOCK-type_domain | interpro domains | IPR027007 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | DOCK | interpro domains | IPR026791 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | DOCKER_Lobe_A | interpro domains | IPR046769 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | DOCK_C_lobe_A | interpro domains | IPR043161 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | OATP | interpro domains | IPR004156 | 11 | 1 | 18521 | 50 |
SLCO2B1 |
2.931e-02 | -3.53 | DOCKER_dom | interpro domains | IPR027357 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.931e-02 | -3.53 | DOCKER_Lobe_C | interpro domains | IPR046773 | 11 | 1 | 18521 | 50 |
DOCK2 |
2.936e-02 | -3.53 | LRRFIP2 (LRR binding FLII interacting protein 2) | protein interactions | 9209 | 104 | 2 | 19454 | 50 |
RXRA,VMP1 |
2.936e-02 | -3.53 | CTDSP1 (CTD small phosphatase 1) | protein interactions | 58190 | 104 | 2 | 19454 | 50 |
CSF1R,RAC2 |
2.940e-02 | -3.53 | complement component C3b binding | molecular function | GO:0001851 | 11 | 1 | 18094 | 49 |
ITGB2 |
2.940e-02 | -3.53 | nitric-oxide synthase binding | molecular function | GO:0050998 | 11 | 1 | 18094 | 49 |
CD74 |
2.940e-02 | -3.53 | JUN kinase kinase kinase activity | molecular function | GO:0004706 | 11 | 1 | 18094 | 49 |
MAP3K11 |
2.940e-02 | -3.53 | T cell receptor binding | molecular function | GO:0042608 | 11 | 1 | 18094 | 49 |
DOCK2 |
2.951e-02 | -3.52 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 20 | 16828 | 44 |
MFNG,GAB1,RAC2,VMP1,MLKL,MAP3K11,THRB,CPN1,ITGAX,ITGB2,ABR,ADAM33,PREX1,ANKRD44,PLXND1,CSF1R,SNX17,HCK,RASGRP2,DPYD |
2.951e-02 | -3.52 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 20 | 16828 | 44 |
SNX17,CSF1R,PLXND1,RASGRP2,HCK,DPYD,ANKRD44,ADAM33,ABR,PREX1,ITGB2,ITGAX,CPN1,THRB,MAP3K11,MLKL,VMP1,MFNG,GAB1,RAC2 |
2.956e-02 | -3.52 | positive regulation of cellular component organization | biological process | GO:0051130 | 1122 | 7 | 18204 | 49 |
PLXNC1,HCK,RAC2,PLXND1,PLEK,CYFIP1,DOCK2 |
2.959e-02 | -3.52 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 5 | 16828 | 44 |
HCK,MAP3K11,MLKL,CSF1R,ITGB2 |
2.961e-02 | -3.52 | NUP155 (nucleoporin 155) | protein interactions | 9631 | 457 | 4 | 19454 | 50 |
SMPD4,VMP1,P2RY6,RAC2 |
2.967e-02 | -3.52 | cellular response to peptide hormone stimulus | biological process | GO:0071375 | 250 | 3 | 18204 | 49 |
GAB1,CYFIP1,ZFP36L1 |
2.972e-02 | -3.52 | positive regulation of interleukin-6 production | biological process | GO:0032755 | 100 | 2 | 18204 | 49 |
UNC93B1,CD74 |
2.972e-02 | -3.52 | regulation of dendrite development | biological process | GO:0050773 | 100 | 2 | 18204 | 49 |
PREX1,CYFIP1 |
2.988e-02 | -3.51 | BZW2 (basic leucine zipper and W2 domains 2) | protein interactions | 28969 | 105 | 2 | 19454 | 50 |
CD68,CYFIP1 |
2.988e-02 | -3.51 | CIAO2B (cytosolic iron-sulfur assembly component 2B) | protein interactions | 51647 | 105 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.988e-02 | -3.51 | SLC27A4 (solute carrier family 27 member 4) | protein interactions | 10999 | 105 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
2.988e-02 | -3.51 | DOCK-C2 | pfam domains | PF14429 | 11 | 1 | 17795 | 49 |
DOCK2 |
2.988e-02 | -3.51 | DHR-2_Lobe_C | pfam domains | PF20421 | 11 | 1 | 17795 | 49 |
DOCK2 |
2.988e-02 | -3.51 | DHR-2_Lobe_A | pfam domains | PF06920 | 11 | 1 | 17795 | 49 |
DOCK2 |
2.988e-02 | -3.51 | OATP | pfam domains | PF03137 | 11 | 1 | 17795 | 49 |
SLCO2B1 |
2.988e-02 | -3.51 | DHR-2_Lobe_B | pfam domains | PF20422 | 11 | 1 | 17795 | 49 |
DOCK2 |
2.993e-02 | -3.51 | Integrin cell surface interactions | REACTOME pathways | R-HSA-216083 | 68 | 2 | 10285 | 41 |
ITGAX,ITGB2 |
3.000e-02 | -3.51 | Cytochrome c1, transmembrane anchor, C-terminal | gene3d domains | 1.20.5.100 | 10 | 1 | 14470 | 44 |
ITGB2 |
3.027e-02 | -3.50 | B cell mediated immunity | biological process | GO:0019724 | 101 | 2 | 18204 | 49 |
INPP5D,CD74 |
3.027e-02 | -3.50 | platelet activation | biological process | GO:0030168 | 101 | 2 | 18204 | 49 |
PLEK,ENTPD1 |
3.027e-02 | -3.50 | regulation of carbohydrate biosynthetic process | biological process | GO:0043255 | 101 | 2 | 18204 | 49 |
PLEK,P2RY6 |
3.040e-02 | -3.49 | side of membrane | cellular component | GO:0098552 | 715 | 5 | 19108 | 47 |
HCK,ITGAX,CD74,CSF3R,ITGB2 |
3.040e-02 | -3.49 | NSD1 (nuclear receptor binding SET domain protein 1) | protein interactions | 64324 | 106 | 2 | 19454 | 50 |
THRB,RXRA |
3.042e-02 | -3.49 | SELP (selectin P) | protein interactions | 6403 | 12 | 1 | 19454 | 50 |
SNX17 |
3.042e-02 | -3.49 | CCZ1B (CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated) | protein interactions | 221960 | 12 | 1 | 19454 | 50 |
RMC1 |
3.042e-02 | -3.49 | PDC (phosducin) | protein interactions | 5132 | 12 | 1 | 19454 | 50 |
PLXNC1 |
3.042e-02 | -3.49 | TENM4 (teneurin transmembrane protein 4) | protein interactions | 26011 | 12 | 1 | 19454 | 50 |
DOCK2 |
3.042e-02 | -3.49 | FUT4 (fucosyltransferase 4) | protein interactions | 2526 | 12 | 1 | 19454 | 50 |
ITGB2 |
3.042e-02 | -3.49 | ROPN1L (rhophilin associated tail protein 1 like) | protein interactions | 83853 | 12 | 1 | 19454 | 50 |
CD74 |
3.042e-02 | -3.49 | PNMT (phenylethanolamine N-methyltransferase) | protein interactions | 5409 | 12 | 1 | 19454 | 50 |
HCK |
3.042e-02 | -3.49 | AMPD3 (adenosine monophosphate deaminase 3) | protein interactions | 272 | 12 | 1 | 19454 | 50 |
ITGB2 |
3.042e-02 | -3.49 | ADGRB3 (adhesion G protein-coupled receptor B3) | protein interactions | 577 | 12 | 1 | 19454 | 50 |
ELMO1 |
3.058e-02 | -3.49 | regulation of transporter activity | biological process | GO:0032409 | 253 | 3 | 18204 | 49 |
P2RY6,RXRA,VMP1 |
3.078e-02 | -3.48 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 44 |
MLKL,MAP3K11,CSF1R,HCK |
3.081e-02 | -3.48 | stomach | COSMIC cancer mutations | stomach | 15550 | 44 | 16828 | 44 |
GAB1,MFNG,RAC2,SMPD4,RBM47,PLEK,VMP1,DOCK2,NCAM2,THRB,CSF3R,ITGB2,SPOCK3,RXRA,TNFAIP8L2,ABR,PREX1,CMTM6,CSF1R,DAPP1,PSAP,PLXNC1,RASGRP2,CD74,MARCO,ITM2B,ZFP36L1,CD68,CPN1,MAP3K11,MLKL,SLCO2B1,SH2B3,ITGAX,ADAM33,ELMO1,ENTPD1,P2RY6,ANKRD44,MYO1F,SNX17,PLXND1,DPYD,HCK |
3.082e-02 | -3.48 | artery development | biological process | GO:0060840 | 102 | 2 | 18204 | 49 |
PLXND1,SNX17 |
3.082e-02 | -3.48 | regulation of phagocytosis | biological process | GO:0050764 | 102 | 2 | 18204 | 49 |
DOCK2,HCK |
3.092e-02 | -3.48 | GEMIN4 (gem nuclear organelle associated protein 4) | protein interactions | 50628 | 266 | 3 | 19454 | 50 |
UNC93B1,P2RY6,CD74 |
3.092e-02 | -3.48 | TRIP13 (thyroid hormone receptor interactor 13) | protein interactions | 9319 | 266 | 3 | 19454 | 50 |
UNC93B1,THRB,P2RY6 |
3.092e-02 | -3.48 | COPB1 (COPI coat complex subunit beta 1) | protein interactions | 1315 | 266 | 3 | 19454 | 50 |
CD74,P2RY6,UNC93B1 |
3.093e-02 | -3.48 | VMA21 (vacuolar ATPase assembly factor VMA21) | protein interactions | 203547 | 107 | 2 | 19454 | 50 |
RAC2,ADAM33 |
3.093e-02 | -3.48 | IQGAP2 (IQ motif containing GTPase activating protein 2) | protein interactions | 10788 | 107 | 2 | 19454 | 50 |
UNC93B1,CD74 |
3.093e-02 | -3.48 | TPP2 (tripeptidyl peptidase 2) | protein interactions | 7174 | 107 | 2 | 19454 | 50 |
P2RY6,CD74 |
3.093e-02 | -3.48 | RPL39 (ribosomal protein L39) | protein interactions | 6170 | 107 | 2 | 19454 | 50 |
P2RY6,VMP1 |
3.094e-02 | -3.48 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | 12 | 1 | 16828 | 44 |
CSF1R |
3.100e-02 | -3.47 | RHOA (ras homolog family member A) | protein interactions | 387 | 1186 | 7 | 19454 | 50 |
GAB1,RAC2,VMP1,SMPD4,CYFIP1,PREX1,ABR |
3.101e-02 | -3.47 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 4 | 18204 | 49 |
PLXNC1,PLXND1,CYFIP1,PREX1 |
3.107e-02 | -3.47 | MCAM (melanoma cell adhesion molecule) | protein interactions | 4162 | 464 | 4 | 19454 | 50 |
CYFIP1,GAB1,RAC2,LRMDA |
3.107e-02 | -3.47 | BRICHOS | smart domains | SM01039 | 9 | 1 | 9717 | 34 |
ITM2B |
3.121e-02 | -3.47 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 44 |
HCK,CSF1R,MAP3K11,MLKL |
3.125e-02 | -3.47 | regulation of biological process | biological process | GO:0050789 | 12079 | 39 | 18204 | 49 |
GAB1,P2RY6,CSF3R,ZFP36L1,CD74,VMP1,TNFAIP8L2,HCK,UNC93B1,ITM2B,RASGRP2,PLXND1,DAPP1,MLKL,CD68,DOCK2,ITGAX,MARCO,RXRA,ELMO1,MFNG,THRB,RMC1,ABR,PLEK,SNX17,PSAP,SH2B3,MAP3K11,PREX1,ITGB2,FYB1,RAC2,INPP5D,CSF1R,CYFIP1,PLXNC1,SPOCK3,RBM47 |
3.132e-02 | -3.46 | BRICHOS | prosite domains | PS50869 | 9 | 1 | 12186 | 43 |
ITM2B |
3.132e-02 | -3.46 | INTEGRIN_BETA | prosite domains | PS00243 | 9 | 1 | 12186 | 43 |
ITGB2 |
3.138e-02 | -3.46 | erythrocyte differentiation | biological process | GO:0030218 | 103 | 2 | 18204 | 49 |
RAC2,SH2B3 |
3.142e-02 | -3.46 | ion binding | molecular function | GO:0043167 | 6007 | 23 | 18094 | 49 |
ENTPD1,THRB,MLKL,RASGRP2,ITM2B,ZFP36L1,ITGB2,ADAM33,RXRA,MYO1F,SPOCK3,PLEK,MFNG,CSF1R,CPN1,SMPD4,ITGAX,PSAP,MAP3K11,DPYD,RAC2,HCK,DAPP1 |
3.146e-02 | -3.46 | Phosphate bond hydrolysis by NTPDase proteins | REACTOME pathways | R-HSA-8850843 | 8 | 1 | 10285 | 41 |
ENTPD1 |
3.146e-02 | -3.46 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 8 | 16828 | 44 |
PLXNC1,HCK,ENTPD1,RXRA,ELMO1,PLEK,SMPD4,SPOCK3 |
3.147e-02 | -3.46 | TYW1 (tRNA-yW synthesizing protein 1 homolog) | protein interactions | 55253 | 108 | 2 | 19454 | 50 |
RAC2,ADAM33 |
3.152e-02 | -3.46 | dendrite terminus | cellular component | GO:0044292 | 13 | 1 | 19108 | 47 |
CYFIP1 |
3.152e-02 | -3.46 | early phagosome | cellular component | GO:0032009 | 13 | 1 | 19108 | 47 |
UNC93B1 |
3.168e-02 | -3.45 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 34 |
HCK,CSF1R |
3.181e-02 | -3.45 | SRPRA (SRP receptor subunit alpha) | protein interactions | 6734 | 269 | 3 | 19454 | 50 |
RMC1,P2RY6,RAC2 |
3.184e-02 | -3.45 | response to macrophage colony-stimulating factor | biological process | GO:0036005 | 12 | 1 | 18204 | 49 |
CSF1R |
3.184e-02 | -3.45 | cytidine to uridine editing | biological process | GO:0016554 | 12 | 1 | 18204 | 49 |
RBM47 |
3.184e-02 | -3.45 | regulation of chemokine-mediated signaling pathway | biological process | GO:0070099 | 12 | 1 | 18204 | 49 |
SH2B3 |
3.184e-02 | -3.45 | cellular response to thyroid hormone stimulus | biological process | GO:0097067 | 12 | 1 | 18204 | 49 |
THRB |
3.184e-02 | -3.45 | regulation of prostaglandin biosynthetic process | biological process | GO:0031392 | 12 | 1 | 18204 | 49 |
CD74 |
3.193e-02 | -3.44 | FAD/NAD-binding_dom | interpro domains | IPR023753 | 12 | 1 | 18521 | 50 |
DPYD |
3.194e-02 | -3.44 | regulation of chemokine production | biological process | GO:0032642 | 104 | 2 | 18204 | 49 |
CSF1R,CD74 |
3.194e-02 | -3.44 | epithelial cell migration | biological process | GO:0010631 | 104 | 2 | 18204 | 49 |
GAB1,PLXND1 |
3.200e-02 | -3.44 | NHSL3 (NHS like 3) | protein interactions | 57648 | 109 | 2 | 19454 | 50 |
RAC2,CYFIP1 |
3.200e-02 | -3.44 | COQ8B (coenzyme Q8B) | protein interactions | 79934 | 109 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
3.200e-02 | -3.44 | TMEM109 (transmembrane protein 109) | protein interactions | 79073 | 109 | 2 | 19454 | 50 |
RAC2,UNC93B1 |
3.200e-02 | -3.44 | B4GAT1 (beta-1,4-glucuronyltransferase 1) | protein interactions | 11041 | 109 | 2 | 19454 | 50 |
CMTM6,UNC93B1 |
3.203e-02 | -3.44 | prostaglandin transmembrane transporter activity | molecular function | GO:0015132 | 12 | 1 | 18094 | 49 |
SLCO2B1 |
3.203e-02 | -3.44 | phosphatidylinositol-4,5-bisphosphate phosphatase activity | molecular function | GO:0106019 | 12 | 1 | 18094 | 49 |
INPP5D |
3.251e-02 | -3.43 | response to type II interferon | biological process | GO:0034341 | 105 | 2 | 18204 | 49 |
HCK,CD74 |
3.251e-02 | -3.43 | antigen processing and presentation | biological process | GO:0019882 | 105 | 2 | 18204 | 49 |
UNC93B1,CD74 |
3.251e-02 | -3.43 | gland morphogenesis | biological process | GO:0022612 | 105 | 2 | 18204 | 49 |
CSF1R,PLXND1 |
3.252e-02 | -3.43 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 44 |
HCK,MAP3K11,MLKL,CSF1R |
3.254e-02 | -3.43 | PLXNA1 (plexin A1) | protein interactions | 5361 | 110 | 2 | 19454 | 50 |
RAC2,PLXND1 |
3.254e-02 | -3.43 | SLC27A2 (solute carrier family 27 member 2) | protein interactions | 11001 | 110 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
3.254e-02 | -3.43 | NOTCH3 (notch receptor 3) | protein interactions | 4854 | 110 | 2 | 19454 | 50 |
ANKRD44,ADAM33 |
3.254e-02 | -3.43 | ARHGAP39 (Rho GTPase activating protein 39) | protein interactions | 80728 | 110 | 2 | 19454 | 50 |
NCAM2,RAC2 |
3.256e-02 | -3.42 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 49 |
CPN1 |
3.256e-02 | -3.42 | Pyr_redox_2 | pfam domains | PF07992 | 12 | 1 | 17795 | 49 |
DPYD |
3.275e-02 | -3.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 49 |
PLXNC1,PLXND1,CYFIP1,PREX1,RAC2 |
3.291e-02 | -3.41 | KCNQ4 (potassium voltage-gated channel subfamily Q member 4) | protein interactions | 9132 | 13 | 1 | 19454 | 50 |
CSF1R |
3.291e-02 | -3.41 | MRNIP (MRN complex interacting protein) | protein interactions | 51149 | 13 | 1 | 19454 | 50 |
ANKRD44 |
3.291e-02 | -3.41 | CLYBL (citramalyl-CoA lyase) | protein interactions | 171425 | 13 | 1 | 19454 | 50 |
INPP5D |
3.291e-02 | -3.41 | PRSS56 (serine protease 56) | protein interactions | 646960 | 13 | 1 | 19454 | 50 |
RMC1 |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
CYFIP1 |
3.291e-02 | -3.41 | SEMA4A (semaphorin 4A) | protein interactions | 64218 | 13 | 1 | 19454 | 50 |
PLXND1 |
3.291e-02 | -3.41 | C1orf74 (chromosome 1 open reading frame 74) | protein interactions | 148304 | 13 | 1 | 19454 | 50 |
HCK |
3.291e-02 | -3.41 | SCG3 (secretogranin III) | protein interactions | 29106 | 13 | 1 | 19454 | 50 |
NCAM2 |
3.291e-02 | -3.41 | GGT6 (gamma-glutamyltransferase 6) | protein interactions | 124975 | 13 | 1 | 19454 | 50 |
ADAM33 |
3.296e-02 | -3.41 | - | gene3d domains | 1.20.58.740 | 11 | 1 | 14470 | 44 |
DOCK2 |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPN1 |
3.296e-02 | -3.41 | - | gene3d domains | 1.25.40.410 | 11 | 1 | 14470 | 44 |
DOCK2 |
3.306e-02 | -3.41 | angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | angioimmunoblastic_T_cell_lymphoma | 269 | 3 | 16828 | 44 |
SH2B3,CSF1R,HCK |
3.320e-02 | -3.41 | INTEGRINB | prints domains | PR01186 | 8 | 1 | 5227 | 22 |
ITGB2 |
3.333e-02 | -3.40 | PANX1 (pannexin 1) | protein interactions | 24145 | 274 | 3 | 19454 | 50 |
VMP1,SMPD4,RAC2 |
3.333e-02 | -3.40 | MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy) | SMPDB pathways | SMP0000202 | 23 | 1 | 1369 | 2 |
DPYD |
3.333e-02 | -3.40 | Pyrimidine Metabolism | SMPDB pathways | SMP0000046 | 23 | 1 | 1369 | 2 |
DPYD |
3.333e-02 | -3.40 | UMP Synthase Deficiency (Orotic Aciduria) | SMPDB pathways | SMP0000219 | 23 | 1 | 1369 | 2 |
DPYD |
3.333e-02 | -3.40 | beta-Ureidopropionase Deficiency | SMPDB pathways | SMP0000172 | 23 | 1 | 1369 | 2 |
DPYD |
3.333e-02 | -3.40 | Dihydropyrimidinase Deficiency | SMPDB pathways | SMP0000178 | 23 | 1 | 1369 | 2 |
DPYD |
3.341e-02 | -3.40 | immune response-regulating cell surface receptor signaling pathway | biological process | GO:0002768 | 262 | 3 | 18204 | 49 |
FYB1,INPP5D,HCK |
3.346e-02 | -3.40 | pleura | COSMIC cancer mutations | pleura | 4914 | 19 | 16828 | 44 |
PREX1,ADAM33,SH2B3,ITGAX,ITGB2,DPYD,HCK,RASGRP2,CSF1R,SNX17,ANKRD44,RAC2,MFNG,GAB1,MAP3K11,MLKL,CPN1,THRB,VMP1 |
3.349e-02 | -3.40 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 9 | 18204 | 49 |
SMPD4,DAPP1,INPP5D,CSF1R,DPYD,PLEK,ENTPD1,HCK,MAP3K11 |
3.363e-02 | -3.39 | GLG1 (golgi glycoprotein 1) | protein interactions | 2734 | 112 | 2 | 19454 | 50 |
MLKL,ITM2B |
3.363e-02 | -3.39 | SIGLECL1 (SIGLEC family like 1) | protein interactions | 284369 | 112 | 2 | 19454 | 50 |
CMTM6,ITM2B |
3.365e-02 | -3.39 | T cell receptor signaling pathway | biological process | GO:0050852 | 107 | 2 | 18204 | 49 |
FYB1,INPP5D |
3.365e-02 | -3.39 | epithelium migration | biological process | GO:0090132 | 107 | 2 | 18204 | 49 |
PLXND1,GAB1 |
3.374e-02 | -3.39 | regulation of phosphate metabolic process | biological process | GO:0019220 | 1154 | 7 | 18204 | 49 |
CD74,P2RY6,PLEK,CSF1R,ITGB2,MAP3K11,MARCO |
3.379e-02 | -3.39 | positive regulation of cell differentiation | biological process | GO:0045597 | 906 | 6 | 18204 | 49 |
ZFP36L1,CYFIP1,CD74,INPP5D,PLXND1,PLXNC1 |
3.388e-02 | -3.38 | regulation of phosphorus metabolic process | biological process | GO:0051174 | 1155 | 7 | 18204 | 49 |
CSF1R,CD74,P2RY6,PLEK,MARCO,ITGB2,MAP3K11 |
3.396e-02 | -3.38 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 49 |
PLXNC1,PLXND1,ITGAX,CYFIP1 |
3.418e-02 | -3.38 | DOK2 (docking protein 2) | protein interactions | 9046 | 113 | 2 | 19454 | 50 |
HCK,INPP5D |
3.420e-02 | -3.38 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 30 | 16828 | 44 |
ELMO1,ITGAX,MYO1F,PLXND1,DPYD,HCK,ENTPD1,P2RY6,ANKRD44,MARCO,ZFP36L1,MAP3K11,SLCO2B1,RXRA,ABR,PREX1,SPOCK3,CSF1R,PSAP,PLXNC1,RBM47,GAB1,MFNG,SMPD4,RAC2,THRB,CSF3R,DOCK2,VMP1,NCAM2 |
3.422e-02 | -3.37 | cardiac septum development | biological process | GO:0003279 | 108 | 2 | 18204 | 49 |
PLXND1,SNX17 |
3.444e-02 | -3.37 | enucleate erythrocyte differentiation | biological process | GO:0043353 | 13 | 1 | 18204 | 49 |
RAC2 |
3.444e-02 | -3.37 | positive regulation of inositol phosphate biosynthetic process | biological process | GO:0060732 | 13 | 1 | 18204 | 49 |
P2RY6 |
3.444e-02 | -3.37 | type II interferon-mediated signaling pathway | biological process | GO:0060333 | 13 | 1 | 18204 | 49 |
HCK |
3.444e-02 | -3.37 | G protein-coupled purinergic nucleotide receptor signaling pathway | biological process | GO:0035589 | 13 | 1 | 18204 | 49 |
P2RY6 |
3.444e-02 | -3.37 | positive regulation of actin filament depolymerization | biological process | GO:0030836 | 13 | 1 | 18204 | 49 |
PLEK |
3.444e-02 | -3.37 | positive regulation of platelet activation | biological process | GO:0010572 | 13 | 1 | 18204 | 49 |
PLEK |
3.444e-02 | -3.37 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 49 |
SH2B3 |
3.444e-02 | -3.37 | retinal cone cell differentiation | biological process | GO:0042670 | 13 | 1 | 18204 | 49 |
THRB |
3.444e-02 | -3.37 | porphyrin-containing compound catabolic process | biological process | GO:0006787 | 13 | 1 | 18204 | 49 |
SLCO2B1 |
3.444e-02 | -3.37 | tetrapyrrole catabolic process | biological process | GO:0033015 | 13 | 1 | 18204 | 49 |
SLCO2B1 |
3.446e-02 | -3.37 | IPPc | smart domains | SM00128 | 10 | 1 | 9717 | 34 |
INPP5D |
3.447e-02 | -3.37 | SH3_1 | pfam domains | PF00018 | 106 | 2 | 17795 | 49 |
HCK,MYO1F |
3.465e-02 | -3.36 | G protein-coupled purinergic nucleotide receptor activity | molecular function | GO:0045028 | 13 | 1 | 18094 | 49 |
P2RY6 |
3.465e-02 | -3.36 | phosphatidylinositol phosphate 5-phosphatase activity | molecular function | GO:0034595 | 13 | 1 | 18094 | 49 |
INPP5D |
3.465e-02 | -3.36 | diacylglycerol binding | molecular function | GO:0019992 | 13 | 1 | 18094 | 49 |
RASGRP2 |
3.465e-02 | -3.36 | inositol trisphosphate phosphatase activity | molecular function | GO:0046030 | 13 | 1 | 18094 | 49 |
INPP5D |
3.465e-02 | -3.36 | icosanoid transmembrane transporter activity | molecular function | GO:0071714 | 13 | 1 | 18094 | 49 |
SLCO2B1 |
3.465e-02 | -3.36 | RNA 7-methylguanosine cap binding | molecular function | GO:0000340 | 13 | 1 | 18094 | 49 |
CYFIP1 |
3.474e-02 | -3.36 | ATP5MF (ATP synthase membrane subunit f) | protein interactions | 9551 | 114 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
3.500e-02 | -3.35 | seminoma | COSMIC cancer mutations | seminoma | 700 | 5 | 16828 | 44 |
HCK,MLKL,MAP3K11,ABR,CSF1R |
3.519e-02 | -3.35 | actin filament | cellular component | GO:0005884 | 120 | 2 | 19108 | 47 |
HCK,RAC2 |
3.520e-02 | -3.35 | SNRPE (small nuclear ribonucleoprotein polypeptide E) | protein interactions | 6635 | 280 | 3 | 19454 | 50 |
UNC93B1,CD74,P2RY6 |
3.520e-02 | -3.35 | TSG101 (tumor susceptibility 101) | protein interactions | 7251 | 280 | 3 | 19454 | 50 |
THRB,HCK,MLKL |
3.522e-02 | -3.35 | response to organonitrogen compound | biological process | GO:0010243 | 915 | 6 | 18204 | 49 |
ITGB2,ZFP36L1,CYFIP1,GAB1,P2RY6,CD68 |
3.523e-02 | -3.35 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 4 | 16828 | 44 |
DOCK2,NCAM2,SPOCK3,DPYD |
3.525e-02 | -3.35 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 34 | 16828 | 44 |
SLCO2B1,MAP3K11,MLKL,CPN1,ITM2B,MARCO,ANKRD44,DPYD,HCK,PLXND1,MYO1F,SH2B3,ITGAX,ELMO1,ADAM33,NCAM2,DOCK2,VMP1,CSF3R,THRB,SMPD4,RAC2,GAB1,MFNG,PLEK,RASGRP2,PLXNC1,PSAP,CSF1R,SPOCK3,ITGB2,PREX1,ABR,RXRA |
3.539e-02 | -3.34 | negative regulation of leukocyte differentiation | biological process | GO:1902106 | 110 | 2 | 18204 | 49 |
CD74,INPP5D |
3.539e-02 | -3.34 | HRAS (HRas proto-oncogene, GTPase) | protein interactions | 3265 | 712 | 5 | 19454 | 50 |
SNX17,ABR,ITM2B,CYFIP1,GAB1 |
3.540e-02 | -3.34 | CPN1 (carboxypeptidase N subunit 1) | protein interactions | 1369 | 14 | 1 | 19454 | 50 |
CPN1 |
3.540e-02 | -3.34 | FFAR3 (free fatty acid receptor 3) | protein interactions | 2865 | 14 | 1 | 19454 | 50 |
UNC93B1 |
3.540e-02 | -3.34 | HHLA2 (HHLA2 member of B7 family) | protein interactions | 11148 | 14 | 1 | 19454 | 50 |
UNC93B1 |
3.540e-02 | -3.34 | SCGB3A1 (secretoglobin family 3A member 1) | protein interactions | 92304 | 14 | 1 | 19454 | 50 |
MARCO |
3.540e-02 | -3.34 | MON1A (MON1 homolog A, secretory trafficking associated) | protein interactions | 84315 | 14 | 1 | 19454 | 50 |
RMC1 |
3.540e-02 | -3.34 | TPSAB1 (tryptase alpha/beta 1) | protein interactions | 7177 | 14 | 1 | 19454 | 50 |
P2RY6 |
3.540e-02 | -3.34 | ITGAL (integrin subunit alpha L) | protein interactions | 3683 | 14 | 1 | 19454 | 50 |
ITGB2 |
3.540e-02 | -3.34 | COPZ2 (COPI coat complex subunit zeta 2) | protein interactions | 51226 | 14 | 1 | 19454 | 50 |
SNX17 |
3.540e-02 | -3.34 | CYP1B1 (cytochrome P450 family 1 subfamily B member 1) | protein interactions | 1545 | 14 | 1 | 19454 | 50 |
RAC2 |
3.540e-02 | -3.34 | PARM1 (prostate androgen-regulated mucin-like protein 1) | protein interactions | 25849 | 14 | 1 | 19454 | 50 |
SNX17 |
3.540e-02 | -3.34 | CSF3 (colony stimulating factor 3) | protein interactions | 1440 | 14 | 1 | 19454 | 50 |
CSF3R |
3.551e-02 | -3.34 | EPHA7 (EPH receptor A7) | protein interactions | 2045 | 281 | 3 | 19454 | 50 |
CSF1R,CYFIP1,RAC2 |
3.572e-02 | -3.33 | Fc epsilon RI signaling pathway | KEGG pathways | ko04664 | 67 | 2 | 7161 | 32 |
INPP5D,RAC2 |
3.572e-02 | -3.33 | Fc epsilon RI signaling pathway | KEGG pathways | hsa04664 | 67 | 2 | 7161 | 32 |
INPP5D,RAC2 |
3.593e-02 | -3.33 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 49 |
PREX1,RAC2,CYFIP1,PLXNC1,PLXND1 |
3.615e-02 | -3.32 | HLA-A (major histocompatibility complex, class I, A) | protein interactions | 3105 | 283 | 3 | 19454 | 50 |
RAC2,ADAM33,ITM2B |
3.615e-02 | -3.32 | SOAT1 (sterol O-acyltransferase 1) | protein interactions | 6646 | 283 | 3 | 19454 | 50 |
RAC2,VMP1,ADAM33 |
3.642e-02 | -3.31 | EMC3 (ER membrane protein complex subunit 3) | protein interactions | 55831 | 117 | 2 | 19454 | 50 |
RAC2,P2RY6 |
3.647e-02 | -3.31 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 9 | 18204 | 49 |
PLEK,DPYD,CSF1R,INPP5D,SMPD4,DAPP1,MAP3K11,ENTPD1,HCK |
3.657e-02 | -3.31 | erythrocyte homeostasis | biological process | GO:0034101 | 112 | 2 | 18204 | 49 |
SH2B3,RAC2 |
3.670e-02 | -3.30 | Cell death signalling via NRAGE, NRIF and NADE | REACTOME pathways | R-HSA-204998 | 76 | 2 | 10285 | 41 |
PREX1,ABR |
3.680e-02 | -3.30 | CIAO1 (cytosolic iron-sulfur assembly component 1) | protein interactions | 9391 | 285 | 3 | 19454 | 50 |
SMPD4,P2RY6,UNC93B1 |
3.704e-02 | -3.30 | positive regulation of actin nucleation | biological process | GO:0051127 | 14 | 1 | 18204 | 49 |
CYFIP1 |
3.704e-02 | -3.30 | alpha-beta T cell proliferation | biological process | GO:0046633 | 14 | 1 | 18204 | 49 |
DOCK2 |
3.704e-02 | -3.30 | toll-like receptor 3 signaling pathway | biological process | GO:0034138 | 14 | 1 | 18204 | 49 |
UNC93B1 |
3.704e-02 | -3.30 | regulation of podosome assembly | biological process | GO:0071801 | 14 | 1 | 18204 | 49 |
HCK |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
P2RY6 |
3.704e-02 | -3.30 | deoxyribonucleoside monophosphate catabolic process | biological process | GO:0009159 | 14 | 1 | 18204 | 49 |
DPYD |
3.704e-02 | -3.30 | regulation of unsaturated fatty acid biosynthetic process | biological process | GO:2001279 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | regulation of modification of synaptic structure | biological process | GO:1905244 | 14 | 1 | 18204 | 49 |
CYFIP1 |
3.704e-02 | -3.30 | positive regulation by symbiont of entry into host | biological process | GO:0075294 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | positive regulation of viral entry into host cell | biological process | GO:0046598 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | cellular response to oxidised low-density lipoprotein particle stimulus | biological process | GO:0140052 | 14 | 1 | 18204 | 49 |
CD68 |
3.704e-02 | -3.30 | immunological synapse formation | biological process | GO:0001771 | 14 | 1 | 18204 | 49 |
DOCK2 |
3.713e-02 | -3.29 | G protein-coupled receptor signaling pathway | biological process | GO:0007186 | 1178 | 7 | 18204 | 49 |
MARCO,PSAP,PREX1,RAC2,P2RY6,SH2B3,PLEK |
3.717e-02 | -3.29 | positive regulation of plasma membrane bounded cell projection assembly | biological process | GO:0120034 | 113 | 2 | 18204 | 49 |
RAC2,CYFIP1 |
3.717e-02 | -3.29 | regulation of regulated secretory pathway | biological process | GO:1903305 | 113 | 2 | 18204 | 49 |
ITGB2,RAC2 |
3.717e-02 | -3.29 | tissue migration | biological process | GO:0090130 | 113 | 2 | 18204 | 49 |
PLXND1,GAB1 |
3.727e-02 | -3.29 | metalloendopeptidase inhibitor activity | molecular function | GO:0008191 | 14 | 1 | 18094 | 49 |
SPOCK3 |
3.727e-02 | -3.29 | Toll-like receptor binding | molecular function | GO:0035325 | 14 | 1 | 18094 | 49 |
UNC93B1 |
3.756e-02 | -3.28 | NOP9 (NOP9 nucleolar protein) | protein interactions | 161424 | 119 | 2 | 19454 | 50 |
P2RY6,RBM47 |
3.756e-02 | -3.28 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 50 |
CD74,PLXNC1 |
3.758e-02 | -3.28 | signaling adaptor activity | molecular function | GO:0035591 | 113 | 2 | 18094 | 49 |
GAB1,SH2B3 |
3.759e-02 | -3.28 | human chr3p22.3 | chromosome location | human chr3p22.3 | 20 | 1 | 26134 | 50 |
CMTM6 |
3.762e-02 | -3.28 | GTPase activator activity | molecular function | GO:0005096 | 273 | 3 | 18094 | 49 |
ABR,DOCK2,PREX1 |
3.774e-02 | -3.28 | defense response to virus | biological process | GO:0051607 | 275 | 3 | 18204 | 49 |
UNC93B1,MLKL,ITGAX |
3.779e-02 | -3.28 | VDAC1 (voltage dependent anion channel 1) | protein interactions | 7416 | 494 | 4 | 19454 | 50 |
UNC93B1,RMC1,P2RY6,CD74 |
3.783e-02 | -3.27 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 4 | 16828 | 44 |
CSF1R,MLKL,MAP3K11,HCK |
3.788e-02 | -3.27 | GLIPR1 (GLI pathogenesis related 1) | protein interactions | 11010 | 15 | 1 | 19454 | 50 |
CMTM6 |
3.788e-02 | -3.27 | PTPRCAP (protein tyrosine phosphatase receptor type C associated protein) | protein interactions | 5790 | 15 | 1 | 19454 | 50 |
CMTM6 |
3.788e-02 | -3.27 | GALNT3 (polypeptide N-acetylgalactosaminyltransferase 3) | protein interactions | 2591 | 15 | 1 | 19454 | 50 |
UNC93B1 |
3.788e-02 | -3.27 | GCK (glucokinase) | protein interactions | 2645 | 15 | 1 | 19454 | 50 |
CSF3R |
3.788e-02 | -3.27 | SPATA6 (spermatogenesis associated 6) | protein interactions | 54558 | 15 | 1 | 19454 | 50 |
SNX17 |
3.788e-02 | -3.27 | UCP3 (uncoupling protein 3) | protein interactions | 7352 | 15 | 1 | 19454 | 50 |
RBM47 |
3.788e-02 | -3.27 | CASTOR1 (cytosolic arginine sensor for mTORC1 subunit 1) | protein interactions | 652968 | 15 | 1 | 19454 | 50 |
RXRA |
3.788e-02 | -3.27 | AANAT (aralkylamine N-acetyltransferase) | protein interactions | 15 | 15 | 1 | 19454 | 50 |
P2RY6 |
3.788e-02 | -3.27 | NYAP2 (neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2) | protein interactions | 57624 | 15 | 1 | 19454 | 50 |
CYFIP1 |
3.788e-02 | -3.27 | NCKAP1L (NCK associated protein 1 like) | protein interactions | 3071 | 15 | 1 | 19454 | 50 |
CYFIP1 |
3.788e-02 | -3.27 | ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) | protein interactions | 953 | 15 | 1 | 19454 | 50 |
ANKRD44 |
3.814e-02 | -3.27 | CLPTM1 (CLPTM1 regulator of GABA type A receptor forward trafficking) | protein interactions | 1209 | 120 | 2 | 19454 | 50 |
MFNG,UNC93B1 |
3.814e-02 | -3.27 | ANKRD13A (ankyrin repeat domain 13A) | protein interactions | 88455 | 120 | 2 | 19454 | 50 |
P2RY6,UNC93B1 |
3.814e-02 | -3.27 | PJA1 (praja ring finger ubiquitin ligase 1) | protein interactions | 64219 | 120 | 2 | 19454 | 50 |
ABR,ENTPD1 |
3.815e-02 | -3.27 | DOCKER | prosite domains | PS51651 | 11 | 1 | 12186 | 43 |
DOCK2 |
3.815e-02 | -3.27 | C2_DOCK | prosite domains | PS51650 | 11 | 1 | 12186 | 43 |
DOCK2 |
3.818e-02 | -3.27 | transcription coregulator binding | molecular function | GO:0001221 | 114 | 2 | 18094 | 49 |
THRB,RXRA |
3.853e-02 | -3.26 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 4 | 19108 | 47 |
FYB1,MYO1F,HCK,RAC2 |
3.865e-02 | -3.25 | asymmetric, glutamatergic, excitatory synapse | cellular component | GO:0098985 | 16 | 1 | 19108 | 47 |
PLXNC1 |
3.872e-02 | -3.25 | EIF3J (eukaryotic translation initiation factor 3 subunit J) | protein interactions | 8669 | 121 | 2 | 19454 | 50 |
CD74,P2RY6 |
3.876e-02 | -3.25 | CSE1L (chromosome segregation 1 like) | protein interactions | 1434 | 291 | 3 | 19454 | 50 |
UNC93B1,RMC1,P2RY6 |
3.876e-02 | -3.25 | GOPC (golgi associated PDZ and coiled-coil motif containing) | protein interactions | 57120 | 291 | 3 | 19454 | 50 |
HCK,DPYD,CSF1R |
3.887e-02 | -3.25 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 21 | 16828 | 44 |
PSAP,PLXND1,DAPP1,MYO1F,CSF1R,RASGRP2,DPYD,PLXNC1,ANKRD44,P2RY6,ELMO1,ADAM33,PREX1,ITGAX,DOCK2,PLEK,MARCO,ZFP36L1,GAB1,MFNG,SMPD4 |
3.887e-02 | -3.25 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 21 | 16828 | 44 |
PLEK,MARCO,ZFP36L1,MFNG,GAB1,SMPD4,DOCK2,ELMO1,ADAM33,PREX1,ITGAX,PSAP,DAPP1,PLXND1,MYO1F,CSF1R,RASGRP2,DPYD,PLXNC1,ANKRD44,P2RY6 |
3.888e-02 | -3.25 | Liver X Receptor Pathway | WikiPathways | WP2874 | 10 | 1 | 5310 | 21 |
RXRA |
3.888e-02 | -3.25 | Vitamin D Metabolism | WikiPathways | WP1531 | 10 | 1 | 5310 | 21 |
RXRA |
3.888e-02 | -3.25 | Steroid Biosynthesis | WikiPathways | WP496 | 10 | 1 | 5310 | 21 |
CPN1 |
3.894e-02 | -3.25 | localization | biological process | GO:0051179 | 4474 | 18 | 18204 | 49 |
HCK,PSAP,UNC93B1,FYB1,ITGB2,ZFP36L1,PLEK,P2RY6,SNX17,VMP1,CD74,SLCO2B1,MARCO,ELMO1,CD68,CMTM6,MYO1F,DOCK2 |
3.905e-02 | -3.24 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 4 | 16828 | 44 |
HCK,MAP3K11,MLKL,CSF1R |
3.911e-02 | -3.24 | Adaptive Immune System | REACTOME pathways | R-HSA-1280218 | 810 | 7 | 10285 | 41 |
DAPP1,FYB1,INPP5D,GAB1,ITGB2,CD74,RASGRP2 |
3.917e-02 | -3.24 | MET receptor recycling | REACTOME pathways | R-HSA-8875656 | 10 | 1 | 10285 | 41 |
GAB1 |
3.917e-02 | -3.24 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 41 |
GAB1 |
3.929e-02 | -3.24 | skin-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma | 493 | 4 | 16828 | 44 |
SH2B3,CSF1R,ZFP36L1,DPYD |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
CYFIP1,RAC2 |
3.938e-02 | -3.23 | PI Metabolism | REACTOME pathways | R-HSA-1483255 | 79 | 2 | 10285 | 41 |
TNFAIP8L2,INPP5D |
3.943e-02 | -3.23 | KRTAP10-3 (keratin associated protein 10-3) | protein interactions | 386682 | 293 | 3 | 19454 | 50 |
P2RY6,INPP5D,DOCK2 |
3.943e-02 | -3.23 | human chr2q14.2 | chromosome location | human chr2q14.2 | 21 | 1 | 26134 | 50 |
MARCO |
3.943e-02 | -3.23 | human chr21q21.1 | chromosome location | human chr21q21.1 | 21 | 1 | 26134 | 50 |
NCAM2 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
SPOCK3 |
3.959e-02 | -3.23 | negative regulation of hemopoiesis | biological process | GO:1903707 | 117 | 2 | 18204 | 49 |
CD74,INPP5D |
3.964e-02 | -3.23 | sodium-independent organic anion transport | biological process | GO:0043252 | 15 | 1 | 18204 | 49 |
SLCO2B1 |
3.964e-02 | -3.23 | UMP metabolic process | biological process | GO:0046049 | 15 | 1 | 18204 | 49 |
DPYD |
3.964e-02 | -3.23 | positive regulation of ruffle assembly | biological process | GO:1900029 | 15 | 1 | 18204 | 49 |
CYFIP1 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
MLKL |
3.964e-02 | -3.23 | negative regulation of DNA damage response, signal transduction by p53 class mediator | biological process | GO:0043518 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | negative regulation of B cell apoptotic process | biological process | GO:0002903 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | p38MAPK cascade | biological process | GO:0038066 | 15 | 1 | 18204 | 49 |
ZFP36L1 |
3.964e-02 | -3.23 | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | biological process | GO:1900153 | 15 | 1 | 18204 | 49 |
ZFP36L1 |
3.964e-02 | -3.23 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | biological process | GO:1902166 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | ribonucleoside monophosphate catabolic process | biological process | GO:0009158 | 15 | 1 | 18204 | 49 |
DPYD |
3.988e-02 | -3.22 | nuclear vitamin D receptor binding | molecular function | GO:0042809 | 15 | 1 | 18094 | 49 |
RXRA |
3.988e-02 | -3.22 | phospholipid scramblase activity | molecular function | GO:0017128 | 15 | 1 | 18094 | 49 |
VMP1 |
3.988e-02 | -3.22 | ITPR1 (inositol 1,4,5-trisphosphate receptor type 1) | protein interactions | 3708 | 123 | 2 | 19454 | 50 |
VMP1,RAC2 |
3.999e-02 | -3.22 | amb2 Integrin signaling | Pathway Interaction DB | amb2_neutrophils_pathway | 48 | 2 | 2226 | 15 |
ITGB2,HCK |
4.020e-02 | -3.21 | positive regulation of calcium ion transport | biological process | GO:0051928 | 118 | 2 | 18204 | 49 |
P2RY6,VMP1 |
4.023e-02 | -3.21 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 4 | 18521 | 50 |
MAP3K11,MLKL,CSF1R,HCK |
4.035e-02 | -3.21 | APOA5 (apolipoprotein A5) | protein interactions | 116519 | 16 | 1 | 19454 | 50 |
CMTM6 |
4.035e-02 | -3.21 | CASTOR2 (cytosolic arginine sensor for mTORC1 subunit 2) | protein interactions | 729438 | 16 | 1 | 19454 | 50 |
RXRA |
4.035e-02 | -3.21 | ESM1 (endothelial cell specific molecule 1) | protein interactions | 11082 | 16 | 1 | 19454 | 50 |
ITGB2 |
4.035e-02 | -3.21 | IL1RL2 (interleukin 1 receptor like 2) | protein interactions | 8808 | 16 | 1 | 19454 | 50 |
MYO1F |
4.035e-02 | -3.21 | GMPR2 (guanosine monophosphate reductase 2) | protein interactions | 51292 | 16 | 1 | 19454 | 50 |
SNX17 |
4.035e-02 | -3.21 | ZSCAN4 (zinc finger and SCAN domain containing 4) | protein interactions | 201516 | 16 | 1 | 19454 | 50 |
HCK |
4.035e-02 | -3.21 | BEST2 (bestrophin 2) | protein interactions | 54831 | 16 | 1 | 19454 | 50 |
UNC93B1 |
4.035e-02 | -3.21 | SLCO3A1 (solute carrier organic anion transporter family member 3A1) | protein interactions | 28232 | 16 | 1 | 19454 | 50 |
RAC2 |
4.047e-02 | -3.21 | DAB2 (DAB adaptor protein 2) | protein interactions | 1601 | 124 | 2 | 19454 | 50 |
INPP5D,RAC2 |
4.047e-02 | -3.21 | ERLEC1 (endoplasmic reticulum lectin 1) | protein interactions | 27248 | 124 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
4.102e-02 | -3.19 | MHC class II protein complex | cellular component | GO:0042613 | 17 | 1 | 19108 | 47 |
CD74 |
4.104e-02 | -3.19 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 44 |
CSF1R |
4.113e-02 | -3.19 | UBR4 (ubiquitin protein ligase E3 component n-recognin 4) | protein interactions | 23352 | 298 | 3 | 19454 | 50 |
P2RY6,CD74,UNC93B1 |
4.113e-02 | -3.19 | GPR45 (G protein-coupled receptor 45) | protein interactions | 11250 | 298 | 3 | 19454 | 50 |
SMPD4,VMP1,CMTM6 |
4.113e-02 | -3.19 | ALDH3A2 (aldehyde dehydrogenase 3 family member A2) | protein interactions | 224 | 298 | 3 | 19454 | 50 |
RAC2,P2RY6,UNC93B1 |
4.115e-02 | -3.19 | small GTPase binding | molecular function | GO:0031267 | 283 | 3 | 18094 | 49 |
MAP3K11,DOCK2,CYFIP1 |
4.119e-02 | -3.19 | CYSRT1 (cysteine rich tail 1) | protein interactions | 375791 | 508 | 4 | 19454 | 50 |
ITGB2,HCK,DOCK2,INPP5D |
4.126e-02 | -3.19 | response to steroid hormone | biological process | GO:0048545 | 285 | 3 | 18204 | 49 |
CPN1,ZFP36L1,RXRA |
4.127e-02 | -3.19 | human chr4q23 | chromosome location | human chr4q23 | 22 | 1 | 26134 | 50 |
DAPP1 |
4.140e-02 | -3.18 | testis | COSMIC cancer mutations | testis | 733 | 5 | 16828 | 44 |
HCK,ABR,MAP3K11,MLKL,CSF1R |
4.144e-02 | -3.18 | RHOH (ras homolog family member H) | protein interactions | 399 | 509 | 4 | 19454 | 50 |
SMPD4,PREX1,ITM2B,CYFIP1 |
4.155e-02 | -3.18 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 4 | 16828 | 44 |
HCK,MLKL,MAP3K11,CSF1R |
4.194e-02 | -3.17 | IFITM3 (interferon induced transmembrane protein 3) | protein interactions | 10410 | 511 | 4 | 19454 | 50 |
ITM2B,CD74,SNX17,RMC1 |
4.223e-02 | -3.16 | cellular response to prostaglandin E stimulus | biological process | GO:0071380 | 16 | 1 | 18204 | 49 |
P2RY6 |
4.223e-02 | -3.16 | negative regulation of B cell proliferation | biological process | GO:0030889 | 16 | 1 | 18204 | 49 |
INPP5D |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
DPYD |
4.223e-02 | -3.16 | pyrimidine ribonucleoside monophosphate metabolic process | biological process | GO:0009173 | 16 | 1 | 18204 | 49 |
DPYD |
4.223e-02 | -3.16 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 49 |
NCAM2 |
4.223e-02 | -3.16 | modification of synaptic structure | biological process | GO:0099563 | 16 | 1 | 18204 | 49 |
CYFIP1 |
4.223e-02 | -3.16 | negative regulation of bone resorption | biological process | GO:0045779 | 16 | 1 | 18204 | 49 |
INPP5D |
4.223e-02 | -3.16 | prostaglandin transport | biological process | GO:0015732 | 16 | 1 | 18204 | 49 |
SLCO2B1 |
4.223e-02 | -3.16 | positive regulation of B cell differentiation | biological process | GO:0045579 | 16 | 1 | 18204 | 49 |
INPP5D |
4.223e-02 | -3.16 | regulation of granulocyte differentiation | biological process | GO:0030852 | 16 | 1 | 18204 | 49 |
INPP5D |
4.223e-02 | -3.16 | neutrophil homeostasis | biological process | GO:0001780 | 16 | 1 | 18204 | 49 |
SH2B3 |
4.223e-02 | -3.16 | positive regulation of dendrite development | biological process | GO:1900006 | 16 | 1 | 18204 | 49 |
CYFIP1 |
4.223e-02 | -3.16 | branching involved in salivary gland morphogenesis | biological process | GO:0060445 | 16 | 1 | 18204 | 49 |
PLXND1 |
4.226e-02 | -3.16 | CSNK1G3 (casein kinase 1 gamma 3) | protein interactions | 1456 | 127 | 2 | 19454 | 50 |
RAC2,CYFIP1 |
4.226e-02 | -3.16 | GOLPH3 (golgi phosphoprotein 3) | protein interactions | 64083 | 127 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
4.234e-02 | -3.16 | positive regulation of innate immune response | biological process | GO:0045089 | 288 | 3 | 18204 | 49 |
UNC93B1,HCK,RBM47 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPN1 |
4.235e-02 | -3.16 | Disintegrin_CS | interpro domains | IPR018358 | 16 | 1 | 18521 | 50 |
ADAM33 |
4.235e-02 | -3.16 | Integrin_alpha_C_CS | interpro domains | IPR018184 | 16 | 1 | 18521 | 50 |
ITGAX |
4.235e-02 | -3.16 | Integrin_alpha_Ig-like_1 | interpro domains | IPR013649 | 16 | 1 | 18521 | 50 |
ITGAX |
4.248e-02 | -3.16 | mitogen-activated protein kinase kinase kinase binding | molecular function | GO:0031435 | 16 | 1 | 18094 | 49 |
MAP3K11 |
4.248e-02 | -3.16 | sodium-independent organic anion transmembrane transporter activity | molecular function | GO:0015347 | 16 | 1 | 18094 | 49 |
SLCO2B1 |
4.269e-02 | -3.15 | Nucleotide GPCRs | WikiPathways | WP80 | 11 | 1 | 5310 | 21 |
P2RY6 |
4.275e-02 | -3.15 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 27 | 16828 | 44 |
ITGAX,SH2B3,ELMO1,P2RY6,ANKRD44,PLXND1,MYO1F,DPYD,ITM2B,MARCO,MLKL,CPN1,SLCO2B1,ITGB2,SPOCK3,RXRA,TNFAIP8L2,PREX1,DAPP1,CSF1R,PLXNC1,RAC2,DOCK2,VMP1,NCAM2,THRB,CSF3R |
4.282e-02 | -3.15 | PSD4 (pleckstrin and Sec7 domain containing 4) | protein interactions | 23550 | 17 | 1 | 19454 | 50 |
SNX17 |
4.282e-02 | -3.15 | FAM163B (family with sequence similarity 163 member B) | protein interactions | 642968 | 17 | 1 | 19454 | 50 |
PLXNC1 |
4.282e-02 | -3.15 | TMEM95 (transmembrane protein 95) | protein interactions | 339168 | 17 | 1 | 19454 | 50 |
CMTM6 |
4.282e-02 | -3.15 | ARL4A (ADP ribosylation factor like GTPase 4A) | protein interactions | 10124 | 17 | 1 | 19454 | 50 |
ELMO1 |
4.282e-02 | -3.15 | CGB2 (chorionic gonadotropin subunit beta 2) | protein interactions | 114336 | 17 | 1 | 19454 | 50 |
CYFIP1 |
4.282e-02 | -3.15 | SYNDIG1 (synapse differentiation inducing 1) | protein interactions | 79953 | 17 | 1 | 19454 | 50 |
UNC93B1 |
4.282e-02 | -3.15 | SMIM11 (small integral membrane protein 11) | protein interactions | 54065 | 17 | 1 | 19454 | 50 |
UNC93B1 |
4.286e-02 | -3.15 | FARP1 (FERM, ARH/RhoGEF and pleckstrin domain protein 1) | protein interactions | 10160 | 128 | 2 | 19454 | 50 |
RAC2,RBM47 |
4.286e-02 | -3.15 | MAP4K1 (mitogen-activated protein kinase kinase kinase kinase 1) | protein interactions | 11184 | 128 | 2 | 19454 | 50 |
MAP3K11,DAPP1 |
4.286e-02 | -3.15 | GAB2 (GRB2 associated binding protein 2) | protein interactions | 9846 | 128 | 2 | 19454 | 50 |
GAB1,INPP5D |
4.286e-02 | -3.15 | ASPH (aspartate beta-hydroxylase) | protein interactions | 444 | 303 | 3 | 19454 | 50 |
CMTM6,UNC93B1,P2RY6 |
4.296e-02 | -3.15 | phospholipid binding | molecular function | GO:0005543 | 489 | 4 | 18094 | 49 |
SNX17,DAPP1,PREX1,PSAP |
4.297e-02 | -3.15 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 6 | 19454 | 50 |
GAB1,RAC2,CYFIP1,DOCK2,MAP3K11,PREX1 |
4.301e-02 | -3.15 | MET activates RAP1 and RAC1 | REACTOME pathways | R-HSA-8875555 | 11 | 1 | 10285 | 41 |
GAB1 |
4.301e-02 | -3.15 | Signaling by FGFR4 in disease | REACTOME pathways | R-HSA-5655291 | 11 | 1 | 10285 | 41 |
GAB1 |
4.301e-02 | -3.15 | Import of palmitoyl-CoA into the mitochondrial matrix | REACTOME pathways | R-HSA-200425 | 11 | 1 | 10285 | 41 |
RXRA |
4.309e-02 | -3.14 | lung-carcinoid-endocrine_tumour-atypical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-atypical | 508 | 4 | 16828 | 44 |
MLKL,MAP3K11,CSF1R,HCK |
4.309e-02 | -3.14 | Signaling events mediated by PTP1B | Pathway Interaction DB | ptp1bpathway | 50 | 2 | 2226 | 15 |
HCK,CSF1R |
4.311e-02 | -3.14 | human chr14q24.1 | chromosome location | human chr14q24.1 | 23 | 1 | 26134 | 50 |
ZFP36L1 |
4.313e-02 | -3.14 | protein homodimerization activity | molecular function | GO:0042803 | 714 | 5 | 18094 | 49 |
MAP3K11,PLEK,DPYD,PSAP,CSF1R |
4.317e-02 | -3.14 | SH3 domain binding | molecular function | GO:0017124 | 122 | 2 | 18094 | 49 |
ELMO1,INPP5D |
4.318e-02 | -3.14 | Integrin_A_Ig_1 | pfam domains | PF08441 | 16 | 1 | 17795 | 49 |
ITGAX |
4.333e-02 | -3.14 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 43 |
HCK,CSF1R |
4.338e-02 | -3.14 | NADPH oxidase complex | cellular component | GO:0043020 | 18 | 1 | 19108 | 47 |
RAC2 |
4.355e-02 | -3.13 | chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | COSMIC cancer mutations | chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | 17 | 1 | 16828 | 44 |
SH2B3 |
4.355e-02 | -3.13 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | 17 | 1 | 16828 | 44 |
SH2B3 |
4.367e-02 | -3.13 | anatomical structure formation involved in morphogenesis | biological process | GO:0048646 | 964 | 6 | 18204 | 49 |
MFNG,PLXND1,ITGB2,DOCK2,GAB1,CSF3R |
4.380e-02 | -3.13 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 3 | 16828 | 44 |
VMP1,DOCK2,DPYD |
4.381e-02 | -3.13 | glycerophospholipid metabolic process | biological process | GO:0006650 | 292 | 3 | 18204 | 49 |
PLEK,INPP5D,SMPD4 |
4.407e-02 | -3.12 | ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) | protein interactions | 4363 | 130 | 2 | 19454 | 50 |
RAC2,UNC93B1 |
4.407e-02 | -3.12 | ARHGEF1 (Rho guanine nucleotide exchange factor 1) | protein interactions | 9138 | 130 | 2 | 19454 | 50 |
CYFIP1,PLEK |
4.409e-02 | -3.12 | CDC42 (cell division cycle 42) | protein interactions | 998 | 1280 | 7 | 19454 | 50 |
SNX17,CYFIP1,SMPD4,RAC2,CPN1,PREX1,MAP3K11 |
4.421e-02 | -3.12 | Tuberculosis | KEGG pathways | ko05152 | 178 | 3 | 7161 | 32 |
CD74,ITGAX,ITGB2 |
4.421e-02 | -3.12 | Tuberculosis | KEGG pathways | hsa05152 | 178 | 3 | 7161 | 32 |
CD74,ITGB2,ITGAX |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
NCAM2,PLXND1,PLXNC1,CSF3R,CSF1R |
4.429e-02 | -3.12 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 12 | 16828 | 44 |
ANKRD44,NCAM2,DOCK2,DPYD,RASGRP2,MYO1F,SPOCK3,GAB1,PREX1,ELMO1,ABR,PLEK |
4.446e-02 | -3.11 | endometrium-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-endometrioid_carcinoma | 15680 | 44 | 16828 | 44 |
CD68,ITM2B,CD74,SLCO2B1,CPN1,MLKL,ADAM33,ELMO1,DPYD,HCK,P2RY6,ENTPD1,RAC2,THRB,VMP1,PREX1,ITGB2,PLXNC1,RASGRP2,CSF1R,DAPP1,CMTM6,ZFP36L1,MARCO,MAP3K11,SH2B3,ITGAX,MYO1F,SNX17,PLXND1,ANKRD44,RBM47,PLEK,SMPD4,GAB1,MFNG,CSF3R,NCAM2,DOCK2,RXRA,TNFAIP8L2,ABR,SPOCK3,PSAP |
4.456e-02 | -3.11 | small molecule binding | molecular function | GO:0036094 | 6197 | 23 | 18094 | 49 |
RASGRP2,ITM2B,MLKL,ENTPD1,THRB,ITGB2,ADAM33,RXRA,ZFP36L1,SMPD4,ITGAX,PSAP,MAP3K11,DPYD,CSF1R,CPN1,MYO1F,SPOCK3,PLEK,MFNG,HCK,DAPP1,RAC2 |
4.459e-02 | -3.11 | regulation of anatomical structure size | biological process | GO:0090066 | 498 | 4 | 18204 | 49 |
PREX1,PLEK,CYFIP1,HCK |
4.468e-02 | -3.11 | ATP6V1H (ATPase H+ transporting V1 subunit H) | protein interactions | 51606 | 131 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
4.468e-02 | -3.11 | EIF2B1 (eukaryotic translation initiation factor 2B subunit alpha) | protein interactions | 1967 | 131 | 2 | 19454 | 50 |
UNC93B1,RBM47 |
4.468e-02 | -3.11 | LGALS7 (galectin 7) | protein interactions | 3963 | 131 | 2 | 19454 | 50 |
GAB1,RMC1 |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
RXRA,THRB |
4.481e-02 | -3.11 | regulation of integrin activation | biological process | GO:0033623 | 17 | 1 | 18204 | 49 |
PLEK |
4.481e-02 | -3.11 | protein kinase C signaling | biological process | GO:0070528 | 17 | 1 | 18204 | 49 |
PLEK |
4.481e-02 | -3.11 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | biological process | GO:1902165 | 17 | 1 | 18204 | 49 |
CD74 |
4.481e-02 | -3.11 | pyrimidine nucleoside catabolic process | biological process | GO:0046135 | 17 | 1 | 18204 | 49 |
DPYD |
4.481e-02 | -3.11 | regulation of respiratory burst | biological process | GO:0060263 | 17 | 1 | 18204 | 49 |
RAC2 |
4.481e-02 | -3.11 | monocyte differentiation | biological process | GO:0030224 | 17 | 1 | 18204 | 49 |
CSF1R |
4.481e-02 | -3.11 | response to hepatocyte growth factor | biological process | GO:0035728 | 17 | 1 | 18204 | 49 |
GAB1 |
4.492e-02 | -3.10 | Bacterial invasion of epithelial cells | KEGG pathways | ko05100 | 76 | 2 | 7161 | 32 |
ELMO1,GAB1 |
4.492e-02 | -3.10 | Bacterial invasion of epithelial cells | KEGG pathways | hsa05100 | 76 | 2 | 7161 | 32 |
GAB1,ELMO1 |
4.493e-02 | -3.10 | regulation of endocytosis | biological process | GO:0030100 | 295 | 3 | 18204 | 49 |
HCK,DOCK2,SNX17 |
4.493e-02 | -3.10 | myeloid cell differentiation | biological process | GO:0030099 | 295 | 3 | 18204 | 49 |
CSF1R,SH2B3,RAC2 |
4.493e-02 | -3.10 | atypical | COSMIC cancer mutations | atypical | 515 | 4 | 16828 | 44 |
HCK,MLKL,MAP3K11,CSF1R |
4.494e-02 | -3.10 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 43 |
CPN1 |
4.494e-02 | -3.10 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 43 |
CPN1 |
4.507e-02 | -3.10 | transmembrane receptor protein tyrosine kinase adaptor activity | molecular function | GO:0005068 | 17 | 1 | 18094 | 49 |
SH2B3 |
4.507e-02 | -3.10 | nucleoside diphosphate phosphatase activity | molecular function | GO:0017110 | 17 | 1 | 18094 | 49 |
ENTPD1 |
4.509e-02 | -3.10 | protein tyrosine kinase binding | molecular function | GO:1990782 | 125 | 2 | 18094 | 49 |
SH2B3,ITGAX |
4.514e-02 | -3.10 | positive regulation of cytokine production | biological process | GO:0001819 | 500 | 4 | 18204 | 49 |
RBM47,CSF1R,UNC93B1,CD74 |
4.514e-02 | -3.10 | regulation of cell-cell adhesion | biological process | GO:0022407 | 500 | 4 | 18204 | 49 |
TNFAIP8L2,CD74,ITGB2,SH2B3 |
4.524e-02 | -3.10 | RPN2 (ribophorin II) | protein interactions | 6185 | 762 | 5 | 19454 | 50 |
VMP1,SMPD4,P2RY6,RAC2,UNC93B1 |
4.529e-02 | -3.09 | SLC2A14 (solute carrier family 2 member 14) | protein interactions | 144195 | 18 | 1 | 19454 | 50 |
RAC2 |
4.529e-02 | -3.09 | PDE8A (phosphodiesterase 8A) | protein interactions | 5151 | 18 | 1 | 19454 | 50 |
RAC2 |
4.529e-02 | -3.09 | TM4SF20 (transmembrane 4 L six family member 20) | protein interactions | 79853 | 18 | 1 | 19454 | 50 |
CD74 |
4.529e-02 | -3.09 | NAALADL2 (N-acetylated alpha-linked acidic dipeptidase like 2) | protein interactions | 254827 | 18 | 1 | 19454 | 50 |
ITM2B |
4.529e-02 | -3.09 | MVB12B (multivesicular body subunit 12B) | protein interactions | 89853 | 18 | 1 | 19454 | 50 |
MLKL |
4.529e-02 | -3.09 | DCAF17 (DDB1 and CUL4 associated factor 17) | protein interactions | 80067 | 18 | 1 | 19454 | 50 |
PREX1 |
4.529e-02 | -3.09 | PMF1-BGLAP (PMF1-BGLAP readthrough) | protein interactions | 100527963 | 18 | 1 | 19454 | 50 |
CMTM6 |
4.529e-02 | -3.09 | FKBP8 (FKBP prolyl isomerase 8) | protein interactions | 23770 | 524 | 4 | 19454 | 50 |
RAC2,SMPD4,CD74,P2RY6 |
4.530e-02 | -3.09 | SPECC1 (sperm antigen with calponin homology and coiled-coil domains 1) | protein interactions | 92521 | 132 | 2 | 19454 | 50 |
RAC2,VMP1 |
4.530e-02 | -3.09 | TXNDC12 (thioredoxin domain containing 12) | protein interactions | 51060 | 132 | 2 | 19454 | 50 |
HCK,PSAP |
4.531e-02 | -3.09 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 3 | 18204 | 49 |
PLXND1,PLXNC1,CYFIP1 |
4.535e-02 | -3.09 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 3 | 19454 | 50 |
CYFIP1,GAB1,RMC1 |
4.573e-02 | -3.08 | endometrioid_carcinoma | COSMIC cancer mutations | endometrioid_carcinoma | 15690 | 44 | 16828 | 44 |
ITGB2,SPOCK3,TNFAIP8L2,RXRA,ABR,PREX1,CMTM6,CSF1R,PSAP,DAPP1,PLXNC1,RASGRP2,GAB1,MFNG,RAC2,SMPD4,RBM47,PLEK,VMP1,DOCK2,NCAM2,THRB,CSF3R,ITGAX,SH2B3,ADAM33,ELMO1,ENTPD1,ANKRD44,P2RY6,MYO1F,SNX17,PLXND1,DPYD,HCK,CD74,MARCO,ITM2B,ZFP36L1,CD68,CPN1,MAP3K11,MLKL,SLCO2B1 |
4.574e-02 | -3.08 | filopodium tip | cellular component | GO:0032433 | 19 | 1 | 19108 | 47 |
CYFIP1 |
4.591e-02 | -3.08 | PIGS (phosphatidylinositol glycan anchor biosynthesis class S) | protein interactions | 94005 | 133 | 2 | 19454 | 50 |
RAC2,UNC93B1 |
4.599e-02 | -3.08 | endometrium | COSMIC cancer mutations | endometrium | 15692 | 44 | 16828 | 44 |
MAP3K11,MARCO,ZFP36L1,ANKRD44,SNX17,MYO1F,PLXND1,ITGAX,SH2B3,DOCK2,NCAM2,CSF3R,GAB1,MFNG,SMPD4,RBM47,PLEK,PSAP,SPOCK3,TNFAIP8L2,RXRA,ABR,CPN1,MLKL,SLCO2B1,CD74,ITM2B,CD68,ENTPD1,P2RY6,DPYD,HCK,ADAM33,ELMO1,VMP1,THRB,RAC2,CMTM6,CSF1R,DAPP1,PLXNC1,RASGRP2,ITGB2,PREX1 |
4.607e-02 | -3.08 | ILK (integrin linked kinase) | protein interactions | 3611 | 312 | 3 | 19454 | 50 |
SH2B3,ITGB2,RMC1 |
4.616e-02 | -3.08 | cellular localization | biological process | GO:0051641 | 2660 | 12 | 18204 | 49 |
PLEK,CD74,VMP1,SNX17,UNC93B1,HCK,PSAP,ITGB2,FYB1,CD68,CMTM6,DOCK2 |
4.619e-02 | -3.07 | protein-containing complex binding | molecular function | GO:0044877 | 1772 | 9 | 18094 | 49 |
ITGB2,FYB1,MYO1F,THRB,MLKL,CYFIP1,ITGAX,DOCK2,CD74 |
4.629e-02 | -3.07 | Signaling events mediated by Stem cell factor receptor (c-Kit) | Pathway Interaction DB | kitpathway | 52 | 2 | 2226 | 15 |
SH2B3,GAB1 |
4.649e-02 | -3.07 | RalA downstream regulated genes | WikiPathways | WP2290 | 12 | 1 | 5310 | 21 |
RAC2 |
4.652e-02 | -3.07 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 49 |
GAB1,P2RY6,ZFP36L1,CYFIP1 |
4.653e-02 | -3.07 | FDFT1 (farnesyl-diphosphate farnesyltransferase 1) | protein interactions | 2222 | 134 | 2 | 19454 | 50 |
UNC93B1,CD74 |
4.654e-02 | -3.07 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 8 | 18204 | 49 |
UNC93B1,PSAP,CD74,SNX17,VMP1,CMTM6,PLEK,ZFP36L1 |
4.674e-02 | -3.06 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 5 | 19454 | 50 |
CSF3R,SH2B3,GAB1,INPP5D,CSF1R |
4.680e-02 | -3.06 | ATP5PO (ATP synthase peripheral stalk subunit OSCP) | protein interactions | 539 | 314 | 3 | 19454 | 50 |
P2RY6,PREX1,UNC93B1 |
4.683e-02 | -3.06 | P2Y receptors | REACTOME pathways | R-HSA-417957 | 12 | 1 | 10285 | 41 |
P2RY6 |
4.683e-02 | -3.06 | Transport of organic anions | REACTOME pathways | R-HSA-879518 | 12 | 1 | 10285 | 41 |
SLCO2B1 |
4.683e-02 | -3.06 | Pyrimidine catabolism | REACTOME pathways | R-HSA-73621 | 12 | 1 | 10285 | 41 |
DPYD |
4.683e-02 | -3.06 | PECAM1 interactions | REACTOME pathways | R-HSA-210990 | 12 | 1 | 10285 | 41 |
INPP5D |
4.709e-02 | -3.06 | phagocytic vesicle | cellular component | GO:0045335 | 141 | 2 | 19108 | 47 |
RAC2,UNC93B1 |
4.716e-02 | -3.05 | SEL1L (SEL1L adaptor subunit of SYVN1 ubiquitin ligase) | protein interactions | 6400 | 135 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
4.720e-02 | -3.05 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 49 |
ZFP36L1,P2RY6 |
4.721e-02 | -3.05 | regulation of cell population proliferation | biological process | GO:0042127 | 1790 | 9 | 18204 | 49 |
CD74,ZFP36L1,P2RY6,CSF1R,INPP5D,RAC2,SH2B3,HCK,ITGAX |
4.738e-02 | -3.05 | cell-cell junction maintenance | biological process | GO:0045217 | 18 | 1 | 18204 | 49 |
CSF1R |
4.738e-02 | -3.05 | positive regulation of type 2 immune response | biological process | GO:0002830 | 18 | 1 | 18204 | 49 |
CD74 |
4.738e-02 | -3.05 | regulation of dopamine metabolic process | biological process | GO:0042053 | 18 | 1 | 18204 | 49 |
ITGB2 |
4.738e-02 | -3.05 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 49 |
ITGAX |
4.738e-02 | -3.05 | regulation of hydrogen peroxide metabolic process | biological process | GO:0010310 | 18 | 1 | 18204 | 49 |
RAC2 |
4.738e-02 | -3.05 | ceramide transport | biological process | GO:0035627 | 18 | 1 | 18204 | 49 |
PSAP |
4.738e-02 | -3.05 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 49 |
SH2B3 |
4.738e-02 | -3.05 | pyrimidine deoxyribonucleotide catabolic process | biological process | GO:0009223 | 18 | 1 | 18204 | 49 |
DPYD |
4.738e-02 | -3.05 | positive regulation of superoxide anion generation | biological process | GO:0032930 | 18 | 1 | 18204 | 49 |
ITGB2 |
4.738e-02 | -3.05 | negative regulation of bone remodeling | biological process | GO:0046851 | 18 | 1 | 18204 | 49 |
INPP5D |
4.738e-02 | -3.05 | regulation of catecholamine metabolic process | biological process | GO:0042069 | 18 | 1 | 18204 | 49 |
ITGB2 |
4.752e-02 | -3.05 | Integrin_alpha | interpro domains | IPR000413 | 18 | 1 | 18521 | 50 |
ITGAX |
4.752e-02 | -3.05 | Integrin_alpha_Ig-like_2 | interpro domains | IPR048285 | 18 | 1 | 18521 | 50 |
ITGAX |
4.760e-02 | -3.04 | positive regulation of kinase activity | biological process | GO:0033674 | 302 | 3 | 18204 | 49 |
MAP3K11,CD74,CSF1R |
4.774e-02 | -3.04 | SP6 (Sp6 transcription factor) | protein interactions | 80320 | 19 | 1 | 19454 | 50 |
RMC1 |
4.774e-02 | -3.04 | SPOCK2 (SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2) | protein interactions | 9806 | 19 | 1 | 19454 | 50 |
SPOCK3 |
4.774e-02 | -3.04 | CSF1 (colony stimulating factor 1) | protein interactions | 1435 | 19 | 1 | 19454 | 50 |
CSF1R |
4.774e-02 | -3.04 | CHAC2 (ChaC glutathione specific gamma-glutamylcyclotransferase 2) | protein interactions | 494143 | 19 | 1 | 19454 | 50 |
DPYD |
4.779e-02 | -3.04 | ITGB5 (integrin subunit beta 5) | protein interactions | 3693 | 136 | 2 | 19454 | 50 |
ADAM33,RAC2 |
4.779e-02 | -3.04 | FPR2 (formyl peptide receptor 2) | protein interactions | 2358 | 136 | 2 | 19454 | 50 |
UNC93B1,VMP1 |
4.786e-02 | -3.04 | negative regulation of T cell activation | biological process | GO:0050868 | 130 | 2 | 18204 | 49 |
TNFAIP8L2,CD74 |
4.816e-02 | -3.03 | Complement and coagulation cascades | KEGG pathways | hsa04610 | 79 | 2 | 7161 | 32 |
ITGAX,ITGB2 |
4.816e-02 | -3.03 | Complement and coagulation cascades | KEGG pathways | ko04610 | 79 | 2 | 7161 | 32 |
ITGB2,ITGAX |
4.824e-02 | -3.03 | regulation of apoptotic process | biological process | GO:0042981 | 1518 | 8 | 18204 | 49 |
MAP3K11,TNFAIP8L2,HCK,ZFP36L1,CD74,INPP5D,PLXND1,CSF1R |
4.828e-02 | -3.03 | RHOT2 (ras homolog family member T2) | protein interactions | 89941 | 318 | 3 | 19454 | 50 |
CD74,P2RY6,SMPD4 |
4.842e-02 | -3.03 | NCOA6 (nuclear receptor coactivator 6) | protein interactions | 23054 | 137 | 2 | 19454 | 50 |
RXRA,THRB |
4.844e-02 | -3.03 | ADAM_CR | pfam domains | PF08516 | 18 | 1 | 17795 | 49 |
ADAM33 |
4.844e-02 | -3.03 | SRCR | pfam domains | PF00530 | 18 | 1 | 17795 | 49 |
MARCO |
4.844e-02 | -3.03 | Integrin_A_Ig_2 | pfam domains | PF20805 | 18 | 1 | 17795 | 49 |
ITGAX |
4.852e-02 | -3.03 | mesoderm development | biological process | GO:0007498 | 131 | 2 | 18204 | 49 |
ZFP36L1,HCK |
4.855e-02 | -3.03 | skin-face-other-keratoacanthoma | COSMIC cancer mutations | skin-face-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-back-other-keratoacanthoma | COSMIC cancer mutations | skin-back-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-lower_leg-other-keratoacanthoma | COSMIC cancer mutations | skin-lower_leg-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-upper_leg-other-keratoacanthoma | COSMIC cancer mutations | skin-upper_leg-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | genital | COSMIC cancer mutations | genital | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-chest-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-chest-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-arm-other-keratoacanthoma | COSMIC cancer mutations | skin-arm-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-leg-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-leg-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-lip-other-keratoacanthoma | COSMIC cancer mutations | skin-lip-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-genital-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-genital-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-upper_arm-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-upper_arm-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.855e-02 | -3.03 | skin-chest-other-keratoacanthoma | COSMIC cancer mutations | skin-chest-other-keratoacanthoma | 19 | 1 | 16828 | 44 |
CSF1R |
4.903e-02 | -3.02 | positive regulation of cell population proliferation | biological process | GO:0008284 | 992 | 6 | 18204 | 49 |
ITGAX,CSF1R,HCK,P2RY6,CD74,RAC2 |
4.905e-02 | -3.01 | ZW10 (zw10 kinetochore protein) | protein interactions | 9183 | 138 | 2 | 19454 | 50 |
RAC2,UNC93B1 |
4.905e-02 | -3.01 | AKAP12 (A-kinase anchoring protein 12) | protein interactions | 9590 | 138 | 2 | 19454 | 50 |
HCK,RAC2 |
4.905e-02 | -3.01 | PFN2 (profilin 2) | protein interactions | 5217 | 138 | 2 | 19454 | 50 |
RAC2,CYFIP1 |
4.905e-02 | -3.01 | NCOA1 (nuclear receptor coactivator 1) | protein interactions | 8648 | 138 | 2 | 19454 | 50 |
THRB,RXRA |
4.907e-02 | -3.01 | Fc Epsilon Receptor I Signaling in Mast Cells | SMPDB pathways | SMP0000358 | 34 | 1 | 1369 | 2 |
INPP5D |
4.912e-02 | -3.01 | 1D-myo-inositol hexakisphosphate biosynthesis II (mammalian) | BIOCYC pathways | HUMAN_PWY-6362 | 15 | 1 | 902 | 3 |
INPP5D |
4.912e-02 | -3.01 | 1D-myo-inositol hexakisphosphate biosynthesis II (mammalian) | BIOCYC pathways | META_PWY-6362 | 15 | 1 | 902 | 3 |
INPP5D |
4.912e-02 | -3.01 | D-myo-inositol (1,3,4)-trisphosphate biosynthesis | BIOCYC pathways | META_PWY-6364 | 15 | 1 | 902 | 3 |
INPP5D |
4.912e-02 | -3.01 | D-myo-inositol (1,3,4)-trisphosphate biosynthesis | BIOCYC pathways | HUMAN_PWY-6364 | 15 | 1 | 902 | 3 |
INPP5D |
4.916e-02 | -3.01 | regulation of small GTPase mediated signal transduction | biological process | GO:0051056 | 306 | 3 | 18204 | 49 |
PREX1,DOCK2,ABR |
4.918e-02 | -3.01 | regulation of mRNA processing | biological process | GO:0050684 | 132 | 2 | 18204 | 49 |
ZFP36L1,RBM47 |
4.937e-02 | -3.01 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 4 | 18204 | 49 |
PLEK,CYFIP1,RAC2,HCK |
4.940e-02 | -3.01 | T-Cell antigen Receptor (TCR) Signaling Pathway | WikiPathways | WP69 | 91 | 2 | 5310 | 21 |
SH2B3,FYB1 |
4.957e-02 | -3.00 | PDGFR-beta signaling pathway | Pathway Interaction DB | pdgfrbpathway | 54 | 2 | 2226 | 15 |
HCK,GAB1 |
4.968e-02 | -3.00 | MON2 (MON2 homolog, regulator of endosome-to-Golgi trafficking) | protein interactions | 23041 | 139 | 2 | 19454 | 50 |
UNC93B1,P2RY6 |
4.968e-02 | -3.00 | PTPRA (protein tyrosine phosphatase receptor type A) | protein interactions | 5786 | 139 | 2 | 19454 | 50 |
GAB1,CYFIP1 |
4.968e-02 | -3.00 | STX18 (syntaxin 18) | protein interactions | 53407 | 139 | 2 | 19454 | 50 |
RAC2,DPYD |
4.968e-02 | -3.00 | TMEM131 (transmembrane protein 131) | protein interactions | 23505 | 139 | 2 | 19454 | 50 |
ADAM33,RAC2 |
4.982e-02 | -3.00 | Sphingolipid metabolism | REACTOME pathways | R-HSA-428157 | 90 | 2 | 10285 | 41 |
SMPD4,PSAP |
4.985e-02 | -3.00 | nucleoside phosphate catabolic process | biological process | GO:1901292 | 133 | 2 | 18204 | 49 |
DPYD,ENTPD1 |
4.995e-02 | -3.00 | 3'-UTR-mediated mRNA destabilization | biological process | GO:0061158 | 19 | 1 | 18204 | 49 |
ZFP36L1 |
4.995e-02 | -3.00 | lipoprotein transport | biological process | GO:0042953 | 19 | 1 | 18204 | 49 |
VMP1 |
4.995e-02 | -3.00 | regulation of B cell apoptotic process | biological process | GO:0002902 | 19 | 1 | 18204 | 49 |
CD74 |
4.995e-02 | -3.00 | negative regulation of amyloid precursor protein biosynthetic process | biological process | GO:0042985 | 19 | 1 | 18204 | 49 |
ITM2B |
4.995e-02 | -3.00 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 49 |
PLEK |
4.995e-02 | -3.00 | sphingomyelin metabolic process | biological process | GO:0006684 | 19 | 1 | 18204 | 49 |
SMPD4 |
4.995e-02 | -3.00 | base conversion or substitution editing | biological process | GO:0016553 | 19 | 1 | 18204 | 49 |
RBM47 |
4.995e-02 | -3.00 | positive regulation of macrophage chemotaxis | biological process | GO:0010759 | 19 | 1 | 18204 | 49 |
CSF1R |
4.995e-02 | -3.00 | positive regulation of protein depolymerization | biological process | GO:1901881 | 19 | 1 | 18204 | 49 |
PLEK |
4.995e-02 | -3.00 | nucleoside monophosphate catabolic process | biological process | GO:0009125 | 19 | 1 | 18204 | 49 |
DPYD |